Document:

Supply, Distribution & Marketing Agreement

 Exhibit 10.1 
 SUPPLY, DISTRIBUTION AND MARKETING AGREEMENT 
 THIS SUPPLY, DISTRIBUTION AND MARKETING
AGREEMENT (this “Agreement”) is made effective as of August 9, 2006 (the “Effective Date”) by and among Oscient Pharmaceuticals Corporation, a Massachusetts corporation with a principal place of business at 1000 Winter
Street, Suite 2200, Waltham, Massachusetts (“Supplier”), Abbott International, LLC, a U.S. limited liability company with a place of business at 200 Abbott Park Road, Dept 64E, AP34-1, Abbott Park, IL 60064-6194 (“Purchaser”)
and, solely for the purposes of Sections 1.1, 2.3, 2.5, 3.2(b), 3.3(c), 7, 8.2, 8.4, 9.4, 11, 13.3, 16, 18 and 19 herein, Abbott Laboratories, Ltd., a Canadian corporation with a place of business at 8401, Autoroute Trans Canada, Saint-Laurent,
Québec (“Abbott Canada”) and solely for the purposes of Section 20, Abbott Laboratories, an Illinois corporation with a place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064. Supplier, Purchaser and Abbott
Canada are each hereafter referred to individually as a “Party” and together as the “Parties”. 
 WHEREAS,
Supplier has the capability to manufacture the Products (as defined below); and 
 WHEREAS, the Parties desire that Supplier supply
Purchaser with the Products under this Agreement on the terms and subject to the conditions set forth below. 
 NOW THEREFORE, in
consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	DEFINITIONS AND INTERPRETATION 

 1.1 Definitions.
Whenever used in the Agreement with an initial capital letter, the terms defined in this Article 1 shall have the meanings specified. 
  

	 	(a)	“ABS” shall mean acute bacterial sinusitis. 

  

	 	(b)	“Actual Selling Price” shall be equal to the aggregate Net Sales for all Product in the applicable month divided by the number of tablets sold by Purchaser
and Abbott Canada to wholesalers, pharmacies or hospitals in such applicable month. 

  

	 	(c)	“Actual Transfer Price” shall have the meaning ascribed thereto in Section 10.2(b). 

  

	 	(d)	“AECB” shall mean acute bacterial exacerbations of chronic bronchitis. 

  

	 	(e)	 “Affiliate” shall mean in respect of any Party any corporation, firm, limited liability company, partnership or other entity
which directly Controls or is Controlled by or is under common Control with such Party. For purposes of this definition only, “control” means ownership, directly or indirectly through one or more Affiliates, of fifty percent (50%) or
more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent 

  

 -1- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	 
(50%) or more of the equity interests in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement
whereby a party controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity. 

  

	 	(f)	“Adverse Event” shall mean a noxious and unintended response in a patient (human or animal) being administered a drug, whether or not such
response is related to the drug, which occurs at doses normally used or tested for the diagnosis, treatment or prevention of a disease or the modification of an organic function. 

  

	 	(g)	“Applicable Percentage” shall equal (i) [*]% for the period prior to Purchaser’s achievement of Product Net Sales of $[*] Million (calculated in
Canadian dollars); (ii) thereafter, [*]% until Purchaser’s achievement of Product Net Sales of $[*] Million (calculated in Canadian dollars); and (iii) [*]% for any period thereafter. 

  

	 	(h)	“Business Day” any day which is not a Saturday, Sunday or day observed as a holiday under the laws of the Province of Quebec or the federal laws of
Canada applicable therein or under the laws of Massachusetts or the federal laws of the United States of America applicable therein. 

  

	 	(i)	“Call” shall mean a personal visit by a Sales Representative to a member of the Target Audience in the Territory during which such Sales
Representative Details a Product. 

  

	 	(j)	“CAP” shall mean community-acquired pneumonia of mild-to-moderate severity. 

  

	 	(k)	“Certificate of Analysis and Compliance” means a written certification, substantially in the form attached as Exhibit A, delivered by Supplier to
Purchaser with each shipment of Finished Products that (i) sets forth the analytical test results for said shipment of Finished Product, and (ii) states that the said shipment of Finished Product was manufactured in compliance with the
Specifications and the GMP. 

  

	 	(l)	“Commercialize” and “Commercialization” shall mean, with respect to the Product, all activities relating to the marketing, promotion,
handling, distribution, storage, sale, shipping, offer for sale and importation for sale of the Product in the Territory. 

  

	 	(m)	“Compound” shall mean the form of gemifloxacin mesylate having the molecular formula [*]. 

  

	 	(n)	 “Contract Year” shall mean for the purpose of this Agreement, a period consisting of twelve (12) consecutive calendar
months commencing on the first day of December in each calendar year, provided, however that the first and last Contract Year for the purpose of this Agreement may be shorter than twelve (12) months whereby (i) the first Contract Year
thereof shall commence on the 

  

 -2- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	 
Effective Date and terminate on the earlier to occur of November 30 following the Effective date or the commencement of Manufacture of the Product by
the Purchaser pursuant to the Purchaser’s exercise of its Manufacturing option set forth in Section 5 below, and (ii) the last Contract Year thereof shall terminate on the earlier to occur of the last day of the Term or the
commencement of the Manufacture of the Product by the Purchaser pursuant to the Purchaser’s exercise of its Manufacturing option set forth in Section 5 below. 

  

	 	(o)	“Copyrights” shall mean all copyright works including literary and artistic works utilized in the Commercialization of the Products.

  

	 	(p)	“Confidential Information” shall mean with respect to a Party (the “Receiving Party”), all information which is disclosed by another Party
(the “Disclosing Party”) to the Receiving Party hereunder or to any of its employees, consultants, Affiliates, licensees or Sub-Distributors, except to the extent that the Receiving Party can demonstrate by written record or other suitable
physical evidence that such information, (a) as of the date of disclosure is demonstrably known to the Receiving Party or its Affiliates other than by virtue of a prior confidential disclosure to the Receiving Party or its Affiliates by the
Disclosing Party; (b) as of the date of disclosure is in, or subsequently enters, the public domain, through no fault or omission of the Receiving Party; (c) is obtained from a third party having a lawful right to make such disclosure free
from any obligation of confidentiality to the Disclosing Party; or (d) is independently developed by or for the Receiving Party without reference to or reliance upon any Confidential Information of the Disclosing Party.

  

	 	(q)	“Detail” or “Detailing” shall mean, with respect to the Product, the communication by a Sales Representative during a Call to a
member of the Target Audience (i) involving face-to-face contact, (ii) describing in a fair and balanced manner the approved indicated uses and other relevant characteristics of such Product, (iii) using marketing, promotional and
educational materials in an effort to increase the Target Audience prescribing and/or hospital ordering preferences of a Product for its approved indicated uses, and (iv) made at the Target Audience member’s office, in a hospital, at
marketing meetings sponsored by the Purchaser or Abbott Canada for the Products or other appropriate venues conducive to pharmaceutical product informational communication where the principal objective is to place an emphasis, either primary,
secondary or tertiary, on a Product and not simply to discuss a Product with a member of the Target Audience. 

  

	 	(r)	“Develop” shall mean, with respect to any Product, all activities relating to seeking, obtaining and/or maintaining Regulatory Approvals and public and
private formulary listings, regulatory affairs, statistical analysis and report writing and the preparation, submission, review and development of data related thereto and all other pre-approval activities, but excluding (i) the Manufacture of
the Product; or (ii) clinical or non-clinical research and drug development activities of the Product. 

  

 -3- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	(s)	“Diligent Efforts” means using reasonable efforts, consistent with prudent business judgment, including the carrying out of obligations or
tasks consistent with the standard of practice in the pharmaceutical industry in the Territory for the Commercialization of a pharmaceutical product having similar market potential, profit potential or strategic value as the Product, based on
conditions then prevailing, including, without limitation, the maturity of the Product and the intellectual property protection surrounding the Product and furthermore requires that each of Supplier, Purchaser or Abbott Canada, at a minimum,
provided that such actions are commercially reasonable: (i) determine the general industry practices with respect to the applicable activities; (ii) reasonably promptly assign responsibility for such obligations to specific employee(s) who
are held accountable for progress, and monitor such progress on an on-going basis; (iii) set and consistently seek to achieve specific and meaningful objectives for carrying out such obligations; and (iv) make and implement decisions and
allocate resources designed to advance progress with respect to such objectives. 

  

	 	(t)	“Estimated Exchange Rate” means the rate of exchange of Canadian dollars to U.S. dollars as determined by Purchaser, in good faith, for each
applicable Contract Year using historic exchange rate information from nationally published sources for the preceding year. Each Estimated Exchange Rate will be established by Purchaser at least thirty (30) days prior to the applicable Contract
Year. 

  

	 	(u)	“Estimated Transfer Price means the aggregate Net Sales for the Product during the three (3) month period ending August 31 immediately preceding
the new Contract Year divided by the number of Product tablets sold during such three month period, multiplied by the Applicable Percentage (as calculated based on Net Sales commencing from the First Commercial Sale through and including the period
covered by such new Contract Year), multiplied by the Estimated Exchange Rate; provided that, the Estimated Transfer Price may be revised to reflect any adjustments to Actual Selling Price resulting from new competition or material changes in the
market dynamics. 

  

	 	(v)	“Excess Run Quantities” shall mean the amount of Product remaining and held by Supplier after processing the Minimum Run Quantities pursuant to a Purchaser
Order after subtracting the amount of Product actually Purchased by Purchaser and the amount of Product designated from such Minimum Run Quantities to Safety Stock Inventory. 

  

	 	(w)	“Exhibits” means the exhibits to this Agreement, unless otherwise specified, and the following are the Exhibits attached to and incorporated in this
Agreement by reference and deemed to be part hereof: 

  

			
	Exhibit	  	 Description

	A	  	Certificate of Analysis and Compliance
		
	B	  	Form of Purchase Order

  

 -4- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	(x)	“First Commercial Sale” shall mean the date of the first arm’s length sale of the Product by or on behalf of Purchaser or Abbott Canada in
the Territory, other than sales by Purchaser to Abbott Canada. 

  

	 	(y)	“Final Packaging” means the labeling and packaging of Processed Product in accordance with Laws, including the package inserts and other components
reasonably necessary for the sale or distribution of the Product to wholesalers, pharmacies and physicians in the Territory. 

  

	 	(z)	“Finished Product” shall mean a Product in its finished form in Final Packaging, ready for sale to the market or distribution as Professional Samples.

  

	 	(aa)	“Generic” shall mean a pharmaceutical product that has the same active ingredient as the Product (gemifloxacin), has the same route of
administration, is bioequivalent to the Product and is approved for the same indications by the relevant Canadian governmental authority (other than the Product sold by Purchaser). 

  

	 	(bb)	“Good Manufacturing Practices” or “GMP” shall mean the good manufacturing practices and standards as set
forth in Division 2 of the Food and Drug Regulations and the GMP Guidelines and as otherwise established or required by applicable Regulatory Authorities in effect at the time and place for activities relating to the Product, and subject to any
arrangements, additions or clarifications agreed from time to time between the Supplier and Purchaser. 

  

	 	(cc)	“HC” shall mean Health Canada, Health Products and Food Branch, Therapeutic Products Directorate, or any replacement or successor authority
with jurisdiction over the sale of the Product in Canada. 

  

	 	(dd)	“Improvements” shall mean any and all changes to the Product, including, without limitation, any technical improvement, modification, invention
or discovery, whether patented or unpatented, including without limitation, methods, formulae and processes made, discovered, conceived, developed or acquired by either Party or their Affiliates, sublicensees, subcontractors or employees thereof,
constituting additions and/or betterments to the Product. 

  

	 	(ee)	“Intellectual Property” shall mean the Patent Rights, Trademarks and Copyrights. 

  

	 	(ff)	“Laws” shall mean all applicable statutes and regulations in Canada as well as all applicable standards, policies, guidelines or codes of conduct issued by
Regulatory Authorities, including Good Manufacturing Practices. 

  

	 	(gg)	“Manufacture” shall mean, with respect to any Product, all activities relating to synthesis, manufacture or otherwise making or having made any
Product, the Compound, or any component or formulation thereof (including, without limitation, process development work). 

  

 -5- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	(hh)	“Minimum Run Quantities” shall mean a standard lot size of Product typically run by Supplier in its usual course of business; provided that, the Supplier and
Purchaser agree that the actual amount of tablets delivered by Supplier may vary from lot to lot due to final yield variations, but in any case may never be more than [*] to [*] tablets. 

  

	 	(ii)	“Monthly Average Exchange Rate” shall mean the quotient determined by dividing (i) the sum of the conversion rate existing in the United States (as
reported in The Wall Street Journal) on the last business day preceding the applicable month immediately preceding the date upon which the Estimated Transfer Price or Actual Transfer Price, as the case may be, is to be calculated, and the
last business day of such applicable month, by (ii) two. If The Wall Street Journal ceases to be published, then the rate of exchange to be used shall be that reported in such other business publication of national circulation in the
United States as the Supplier and Purchaser reasonably agree. 

  

	 	(jj)	“Monthly Sales Report” means a report signed and certified as correct by a duly authorized senior officer of Abbott Canada containing with respect to each
applicable month: (i) all gross to Net Sales figures of the Product and the number of units of the Product sold; (ii) inventory status of the Product; (iii) a computation of the Actual Transfer Price for such month; and (iv) such
other information required to confirm the correctness and accuracy of any payment made hereunder. 

  

	 	(kk)	“Net Sales” shall mean the gross invoiced sales price for all Products sold by Purchaser or Abbott Canada to third parties throughout the
Territory, less the following amounts incurred or paid by Purchaser or Abbott Canada to third parties with respect to sales of Products regardless of the calendar quarter in which such sales were made: 

  

	 	(i)	trade, cash and quantity discounts or rebates, including, price reductions, distribution services agreement fees, cash sales incentives, cash discounts, government mandated rebates
and similar types of rebates, actually allowed or taken, where permitted by law; 

  

	 	(ii)	credits or allowances actually given or made for rejection of Products; 

  

	 	(iii)	third party freight, transport and delivery charges indicated separately directly related to sales of Product by Purchaser to wholesalers; 

  

	 	(iv)	any tax, tariff, duty or governmental charge levied on the sales, transfer, transportation or delivery of a Product to a third party, other than franchise or income tax of any kind
whatsoever, to the extent included in the gross invoiced sales price; and 

  

	 	(v)	uncollectible amounts on return of previously sold Products and returned Products. 

  

 -6- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Deductions due to (i), (ii), (iii) and (v) above shall not exceed a total of [*] percent ([*]%)
of the gross invoiced sales. “Net Sales” shall not include Professional Samples or sales or transfers between Purchaser and Abbott Canada and their respective Affiliates, unless the Product is consumed by such Affiliate. 
  

	 	(ll)	“Patent Rights” shall mean any of the patents and patent applications issued or pending in the Territory during the Term related to the
Products, including those listed in Schedule C hereto, and all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals related thereto and all re-issues, re-examinations and extensions thereof to
the extent these are or become available under the patent Laws of the Territory. 

  

	 	(mm)	“PDE” shall mean either (i) one (1) Primary Detail or (ii) two (2) Secondary Details or (iii) six (6) Tertiary Details
conducted by Purchaser. 

  

	 	(nn)	“Person” or “person” means any individual, firm, corporation, partnership, limited or unlimited liability company, trust, joint venture,
governmental entity, or other entity or organization. 

  

	 	(oo)	“Primary Detail” shall mean a Detail in the first mention position and consuming at least 60% of the time spent during a Call.

  

	 	(pp)	“Printed Materials” means printed packaging materials relating to any Processed Product and product labels, printed packaging materials or packaging inserts
relating to any Finished Product. 

  

	 	(qq)	“Processing Activities” means activities relating to production of the Products, including purchasing raw materials, manufacturing, processing, quality
control, filling, labeling, packaging, finishing, release and storage and other activities required to be undertaken by Supplier or its suppliers and its subcontractors in order to produce Finished Product, and the tests and analyses conducted in
connection therewith. 

  

	 	(rr)	“Processed Product” means a Product that has undergone the Processing Activities, prior to being in, and as released for, Final Packaging.

  

	 	(ss)	“Professional Samples” means Processed Product in Final Packaging intended for distribution as professional samples. 

  

	 	(tt)	“Product” or “Products” shall mean all oral human pharmaceutical tableted products containing the Compound (commonly distributed
under the trademark “Factive”), but specifically excluding any single enantiomer-based product or non-oral formulations, including all different dosages, strengths, presentations, and indications thereof . 

  

	 	(uu)	 “Regulatory Approval” shall mean any and all approvals, product and establishment licenses, registrations or authorizations of
any kind of any Regulatory Authority necessary for the Development or Commercialization of a 

  

 -7- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	 
Product, including, without limiting the generality of the foregoing, the notice of compliance issued by HC and the drug identification number assigned by
HC. 

  

	 	(vv)	“Regulatory Authorities” shall mean any applicable Canadian federal, provincial or local regulatory agency, department, bureau or other governmental entity
of any jurisdiction or any non-governmental regulator having responsibility in Canada for any Regulatory Approvals of any kind or the regulation of any aspect of the Commercialization of pharmaceuticals and any successor agency or authority thereto.
For greater certainty, this includes without limitation, HC, provincial Ministries of Health, the Patented Medicine Prices Review Board (“PMPRB”), Pharmaceutical Advertising Advisory Board (“PAAB”), Advertising Standards Canada
(“ASC”), Rx&D and Canadian Agencies for Drugs and Technologies in Health (formerly Canadian Coordinating Office for Health Technology Assessment). 

  

	 	(ww)	“Sale” by Purchaser or Abbott Canada shall be deemed to occur at the earliest of a Product being (i) shipped by Purchaser or Abbott
Canada, (ii) invoiced by Purchaser or Abbott Canada, or (iii) paid for by or on behalf of Purchaser’s or Abbott Canada’s customer. 

  

	 	(xx)	“Sales Representative” shall mean a professional pharmaceutical sales representative engaged or employed by Purchaser or Abbott Canada to conduct, among
other sales responsibilities, Detailing and other promotional efforts with respect to the Products. 

  

	 	(yy)	“Schedules” means the schedules to this Agreement, unless otherwise specified, and the following are the Schedules attached to and incorporated in this
Agreement by reference and deemed to be part hereof: 

  

			
	Schedule	  	 Description

	A	  	Specifications
		
	B	  	Trademarks
		
	C	  	Patents
		
	D	  	Next Year Estimated Transfer Price Determination
		
	E	  	Actual Transfer Price Quarterly Reconciliation

  

	 	(zz)	“Secondary Detail” shall mean a Detail in the second mention position and consuming at least 30% of time spent during a Call. 

  

	 	(aaa)	“Specifications” means, for each Product, such specifications as set forth in Schedule A, as such specifications may be supplemented or
modified from time to time hereafter in accordance with the provisions of this Agreement. 

  

	 	(bbb)	“Steering Committee” shall have the meaning ascribed thereto in Section 8.3. 

  

 -8- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	(ccc)	“Sub-Distributor” shall mean Abbott Canada or any Person to whom Purchaser has granted the right to distribute Products under the Trademarks in
the Territory pursuant to the terms of this Agreement. 

  

	 	(ddd)	“Target Audience” shall mean, for the Product, a licensed medical physician, authorized to write prescriptions for the Product pursuant to provincial
statutes who prescribes pharmaceutical products or issues hospital orders for pharmaceutical products in the Territory as identified in the Marketing Plan for the Product. 

  

	 	(eee)	“Trademarks” shall mean the trademarks described in Schedule B attached hereto. 

  

	 	(fff)	“Term” shall have the meaning ascribed thereto in Section 16 hereof. 

  

	 	(ggg)	“Tertiary Detail” shall mean a Detail in the third mention position and consuming at least ten percent (10%) of the time spent during a Call.

  

	 	(hhh)	“Territory” shall mean Canada. 

  

	 	(iii)	“Valid Claim” shall mean a claim in any unexpired and issued Patent Right that has not been disclaimed, revoked or held invalid by a final
unappealable decision of a court or government agency of competent jurisdiction. 

  

	1.2	Interpretation 

 In this Agreement a
reference to: 
  

	 	(1)	Article and Section numbers refer to Articles and Sections of this Agreement, and all references to Schedules and Exhibits refer to the Schedules and Exhibits attached hereto;

  

	 	(2)	the singular shall include the plural and vice versa and a reference to any gender shall include all genders; 

  

	 	(3)	a statutory provision includes a reference to the statutory provision as modified or re-enacted or both from time to time before or after the date of this Agreement and any
subordinate legislation made under the statutory provision (as so modified or re-enacted) before or after the date of this Agreement; 

  

	 	(4)	a document (or section thereof) is a reference to that document as modified, amended, restated or replaced from time to time; 

  

	 	(5)	a “month” is a reference to a calendar month; 

  

	 	(6)	“herein”, “hereof”, “hereunder”, “hereafter”, and words of similar import refer to this Agreement as a whole and not to any particular
Article or Section hereof; 

  

 -9- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	(7)	money herein or “$” are references to United States Dollars unless otherwise specifically noted and 

  

	 	(8)	“include”, “includes”, “including” and “such as” are to be construed as if they were immediately followed by the words “without
limitation”. 

 1.3 If any payment is required to be made or other action required to be taken pursuant to this Agreement on a day
which is not a Business Day, then such payment or action shall be made or taken on the next Business Day. 
 1.4 In calculating interest payable under
this Agreement for any period of time, the first day of such period shall be included and the last day of such period shall be excluded. 
 1.5 The
table of contents hereto and the headings of any Article, Section or part thereof are inserted for purposes of convenience only and do not form part of this Agreement. 
  

	2.	DISTRIBUTOR RIGHTS 

 2.1 Appointment and Acceptance.
Subject to the terms and conditions of this Agreement, in connection with the distribution, marketing and Sale of the Products, Supplier hereby appoints Purchaser as its distributor with the exclusive right to Commercialize the Products in the
Territory, and Purchaser hereby accepts such appointment. Supplier hereby grants to Purchaser, and Purchaser hereby accepts, a non-royalty bearing license to use the Trademarks and Copyrights solely in connection with the Commercialization of the
Products in the Territory.  
 2.2 Right to Appoint Sub-Distributor. Purchaser may appoint a Sub-Distributor;
provided, however, that (a) Supplier shall be notified of and shall have consented to such grant, which consent not to be unreasonably withheld or delayed; provided, however, Supplier confirms its consent to the appointment of
Abbott Canada as the Sub-Distributor, (b) the terms of the agreement with the Sub-Distributor shall be equivalent to the terms and conditions of this Agreement, except for the financial terms and except that Sub-Distributor shall have no right
to further appoint a Sub-Distributor, nor to assign or delegate all or any part of its rights, (c) Purchaser shall remain obligated for the payment to Supplier of all of its payment obligations hereunder, (d) Purchaser shall make its best
efforts to require Sub-Distributor to fulfill all of its obligations as described in this Agreement; (e) except as Supplier may in its discretion agree in writing, any agreement with the Sub-Distributor shall provide for termination upon
termination of this Agreement, and (f) Purchaser shall provide Supplier with a copy of each such agreement within thirty (30) days of execution. If Sub-Distributor is any person other than Abbott Canada, then such person shall replace
Abbott Canada as a Party to this Agreement and all references hereunder to Abbott Canada shall be deemed to be a reference to Sub-Distributor. 
 2.3
Retained Rights. Subject to the other terms of this Agreement, Supplier retains all rights not expressly granted under this Agreement, including the right to use and exploit the Trademarks and Copyrights for (i) uses in the
Territory relating to governmental obligations or requirements and investor promotions (i.e., Supplier exhibit booths or magazine publications discussing Supplier’s business), and (ii) any and all uses outside of the Territory. All rights
not expressly granted under this Agreement to Purchaser or Abbott Canada are reserved to Supplier. 
  

 -10- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 2.4 Modification of Product. 
 Supplier reserves the right to make Improvements during the Term and shall give prior notice to the Purchaser of any Improvement, which could require approval by Regulatory Authorities under applicable Laws. For
greater certainty, prior notice to the Purchaser is required for Improvements that are considered a “Level 1 Change” (i.e. change requiring a Supplement to a New Drug Submission), a “Level 2 Change” (i.e. Notifiable Change) or a
“Level 3 Change” (i.e. Notice of Change) under HC’s Changes to Marketed New Drug Products Policy. For a “Level 4 Change” as described in HC’s Changes to Marketed New Drug Policy, Supplier will provide to Purchaser a
copy of revised batch documents for Canadian GMP Product release purposes as and when they are revised. For a “Level 1 Change” and a “Level 2 Change”, Supplier and Purchaser shall agree upon the procedure and a reasonable period
of time for the implementation of the Improvements, including, without limitation, for obtaining any necessary Regulatory Approvals with regard to any such Improvement pursuant to Section 7 hereof and the launch thereof. In the event that
material changes are made to HC’s Changes to Marketed New Drug Products Policy, then the following applies: For any Improvement that requires prior notice to HC or approval from HC prior to implementation, the Parties shall agree in advance
upon the procedure and a reasonable period of time for the implementation of the Improvements. For all other Improvements, Oscient shall provide Abbott Canada with regular updates and documentation of any Improvements made, including whenever
requested by Abbott Canada due to an upcoming or actual inspection by HC or a request by HC. 
 2.5 Grant of Rights to Supplier. Each of
Purchaser and Abbott Canada hereby grant to Supplier a non-exclusive, perpetual, fully paid-up, irrevocable, fully sub-licensable, worldwide (not including the Territory during the Term) license to use the information, materials, data, documents and
plans relating to Products, including regulatory applications and Regulatory Approvals and, pursuant to Purchaser’s election under Section 3.2(d) herein, packaging documents, data and plans (“Purchaser Information”), which come
into the possession or under the control of Purchaser and/or Abbott Canada in the course of and as a result of (i) Purchaser’s participation in the Development and Commercialization of the Product pursuant to Purchaser’s rights under
this Agreement, and (ii) Abbott Canada’s participation in the Development and Commercialization of the Product pursuant to Abbott’s Canada’s rights under this Agreement. 
  

	3.	SUPPLY OF PRODUCT. 

 3.1 Supply Terms. Until
expiration of the Term, Supplier will use commercially reasonable efforts to supply to Purchaser, and Purchaser will exclusively purchase, all of Purchaser’s requirements for Finished Product pursuant to purchase orders delivered from time to
time by Purchaser to Supplier in accordance with Section 4.2. During the Term, neither Supplier nor any of its Affiliates shall have the right to manufacture or supply any Product for or to any other Person in the Territory. Unless otherwise
specified herein or expressly consented to in writing by Purchaser and Supplier, as between Purchaser and Supplier, Supplier shall have control of and discretion over performance of all activities necessary to supply Purchaser with Finished Product
as contemplated hereunder, in each case which shall be exercised in Supplier’s reasonable judgment in the ordinary course of business. Unless provided otherwise and only as and if permitted herein, a Party’s sublicensing, subcontracting or
delegating activities to be performed under this Agreement to an Affiliate or third party shall not release such Party from the performance of any of its responsibilities hereunder. 
  

 -11- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 3.2 Packaging. 
 (a) Packaging Layout. Supplier shall package the Products with the Trademarks and the trademarks of Purchaser’s Affiliate in accordance with the applicable Law, and such packaging shall indicate that
Supplier, or its applicable Affiliate, is the fabricator thereof. The packaging and any other Printed Materials shall bear notices bearing trademark ownership. Supplier shall provide Purchaser with information regarding the dimensions and parameters
of the Printed Materials. At least one hundred and fifty (150) days prior to the Required Delivery Date (as defined below), Purchaser shall provide Supplier with all artwork, copy or other material developed or produced by Purchaser or Abbott
Canada for the Printed Materials. Supplier will review such suggested layout and make any reasonable objections or comments that it may have to such layout in writing no more than ten (10) Business Days after receipt. Notwithstanding this,
Purchaser is responsible for ensuring Printed Material complies with Laws. The Supplier and Purchaser will then discuss the merits of such objections or comments and use their respective commercially reasonable efforts to mutually agree upon any
disputed items with respect to the final layout and content of the Printed Materials. Supplier shall, at Purchaser’s sole cost and expense, provide Purchaser with proofs or samples of the Printed Materials to be used with Product for
Purchaser’s prior review and approval; provided that, Purchaser shall prepare or arrange for the production of camera-ready artwork for the agreed Printed Materials. 
 (b) Changes to Packaging. Purchaser may from time to time request changes to the Printed Materials, which request shall be handled in accordance with Section 3.2(a). In addition, pursuant to the provisions
of Section 7.1 below, Abbott Canada shall submit for approval changes to the approved labeling (including package inserts and primary packages) for the Product with the Regulatory Authority, to the extent approval is required, at
Purchaser’s sole cost and expense. 
 (c) Obsolete Packaging. Supplier shall promptly implement any agreed change or approved
change, as the case may be, to the Printed Materials pursuant to Section 3.2(b), or on such other specific timeframe as agreed by the Supplier and Purchaser on a case-by-case basis. In the event that Abbott Canada requests or is required by an
applicable Law or Regulatory Authority to make changes in the Printed Materials for the Product, and Supplier has components for such Printed Materials in stock that it has purchased specifically for such Product, Purchaser shall have the obligation
to purchase, at Supplier’s cost, the lesser of (a) six months’ supply of such components based on forecasts made by Purchaser for the Product with respect to the next six months, and (b) all of the Supplier stock of such
components; provided that, the Parties agree, within 90 days of the date hereof, to re-negotiate this provision in good faith, so that, upon a change to Printed Materials, Purchaser bears the economic burden of components purchased on the basis of
Purchaser’s Forecast in a minimum order quantity and which can only be used by Supplier to manufacture Product in the Territory (i.e., foil, cartons and product inserts). 
  

 -12- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (d) Option to Package Finished Product. Supplier hereby grants to Purchaser the option to acquire
the right to package Products, including an option to acquire a sublicense to the necessary Trademarks to complete packaging. Purchaser shall notify Supplier in writing of its decision to exercise its rights under this Section 3.2(d), and the
Purchaser and Supplier (i) shall thereby enter into good faith negotiations regarding the terms and conditions of such sublicense and (ii) agree to negotiate revisions to the Initial Transfer Price or the Actual Transfer Price (each as
defined in Section 10 below), as the case may be, that are fair and reasonable given the reduction in packaging services provided by Supplier. 
 3.3
Quality Agreement. The Supplier and Purchaser shall negotiate and agree within sixty (60) days following the date hereof a quality agreement (the “Quality Agreement”), which shall (a) be on terms consistent with
applicable Law and those terms standard in the industry for transactions similar to this Agreement and (b) become effective as of the Effective Date. Each Party agrees to comply with the procedures set forth in the Quality Agreement regarding
quality and GMP related responsibilities and complaints. To the extent there are any inconsistencies or conflicts between this Agreement and the Quality Agreement, the terms and conditions of this Agreement shall control unless otherwise agreed to
in writing by Supplier and Purchaser in the form of an amendment to this Agreement. In the event that the Quality Agreement contains material provisions that differ from applicable Law, the applicable Law shall control. 
 3.4 Documentation, Monitoring and Recordkeeping. To the extent responsible for any Processing Activities hereunder, the Supplier, Purchaser and/or
Abbott Canada shall maintain complete and accurate documentation of all validation data, stability testing data, batch records, quality control and laboratory testing, as applicable, and any other data required under applicable Law and other
requirements of any relevant Regulatory Authority in connection with the performance of any Processing Activities hereunder. Throughout the term of this Agreement, and for so long thereafter as is required by applicable Law, Supplier shall monitor
and maintain reasonable records respecting its compliance with GMP, including through the establishment and implementation of such operating procedures as are reasonably necessary to assure such compliance. 
  

	4.	FORECASTING, ORDERING AND SHIPPING 

 4.1 Rolling
Forecasts. Throughout the Term of this Agreement, Purchaser shall provide Supplier, at the beginning of each month, with a non-binding rolling forecast (“Forecast”) prepared in good faith by Purchaser projecting
Purchaser’s requirements of Finished Product, for the [*] ([*]) month period commencing on the first day of the aforementioned month, specifically indicating such projected requirements for each month during such [*] ([*]) month period

 4.2 Submission of Purchase Orders. Purchaser acknowledges that Supplier is obligated to produce only Minimum Run Quantities of
Product upon orders of Finished Product from Purchaser. Supplier hereby agrees to use commercially reasonable efforts to facilitate a smaller minimum run quantity. Purchaser may order Finished Product in quantities other than the Minimum Run
Quantities (each a “Split Batch”) upon payment, in addition to the transfer price set forth in Section 10 herein, to Supplier of any additional costs incurred by Supplier in delivering such Split Batch, including the price
charged to Supplier by a third party manufacturer 

  

 -13- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
for the fill and finish of the Product tablets from its third party vendors related to such Split Batch (such costs not to exceed $[*] for each Split Batch
ordered) provided, however, that no additional costs shall be payable with respect to any changeover between commercial pack and sample pack. On or before the [*] day preceding the commencement of each calendar month, Purchaser shall issue a
purchase order, in the format attached hereto as Exhibit B (each a “Purchase Order”), for the Products to be manufactured and shipped to it on a date (the “Required Delivery Date”) not less than
[*] ([*]) days from the first day of the calendar month immediately following the date that the purchase order is submitted; provided that, Purchaser has delivered all camera ready art for the final packaging of the Product as set forth in
Section 3.2(a) herein. The quantities of Products ordered in each such purchase order shall be firm and binding on Purchaser and shall not be subject to reduction by Purchaser. All purchase orders shall be sent by Purchaser to the attention of
the employee of Supplier as may from time to time be designated by Supplier. To the extent the terms of any purchase order or acknowledgment thereof are inconsistent with, or additional to, the terms of this Agreement, such terms are of no force and
effect. Notwithstanding anything to the contrary contained herein, the terms and conditions of this Agreement shall prevail over any terms and conditions contained on the Purchase Order and any and all terms and conditions contained in a Purchase
Order shall be null and void. 
 4.3 Terms of Delivery. Supplier shall execute all accepted purchase orders consistent with this
Agreement and deliver Finished Product to Purchaser’s designated carrier at Supplier’s facility, to be delivered on the delivery date specified in Purchaser’s purchase orders, and in no event more than five (5) days before the
delivery date specified in Purchaser’s purchase orders, in accordance with Section 4.2; provided that, if Supplier shall engage a new third party vendor to package Finished Products and such vendor shall require additional time to complete
orders due to Purchaser’s packaging requirements, the Parties shall in good faith mutually agree to extend each Required Delivery Date for such order only by a reasonable amount of time to accommodate Supplier’s arrangements with its new
Finished Product packager. Purchaser shall be responsible for arranging, at its expense, all shipping, freight and insurance for its orders of Finished Product. Title and risk of loss will pass to Purchaser when each order of Finished Product is
delivered to Purchaser’s designated carrier at Supplier’s facility. If Purchaser does not timely indicate in writing its selection of a carrier to Supplier, Supplier shall be entitled to select an appropriate carrier. Supplier shall
package each order of Finished Product for shipment in accordance with its customary practices therefor, unless otherwise reasonably specified in writing by Purchaser. 
 4.4 Accompanying Documentation. With each shipment of Finished Product, Supplier shall provide Purchaser with commercially appropriate shipping documentation (including Purchaser’s purchase
order number and the quantity of the Finished Product) and with a Certificate of Analysis and Compliance identifying the applicable lot and batch numbers and indicating conformance of the shipment with the Specifications. 
 4.5 Retention of Samples. Supplier shall properly store and retain appropriate samples (identified by lot and batch number) of Finished Product that
it supplies to Purchaser in conditions and for times consistent with all applicable Law and to permit appropriate or required internal and regulatory checks and references (collectively, the “Shipment Samples”). 
  

 -14- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 4.6 Shortage and Safety Stock. Supplier shall maintain (a) [*] months of safety stock inventory
of Finished Product for Product to be sold to wholesalers, pharmacies or hospitals, and (b) [*] month of safety stock inventory of Finished Product for Professional Samples, determined pursuant to written notice to be delivered by Purchaser to
Supplier on a monthly basis concurrently with the delivery of its Forecast (the “Safety Stock Inventory”); provided, however, that (i) Safety Stock Inventory shall be depleted on a first in first out basis to satisfy Purchase
Orders submitted by Purchaser, (ii) pursuant to Section 16.6(f) below and subject to the terms thereof, Purchaser shall purchase all Safety Stock Inventory at the price determined pursuant to the terms of Section 10 below and
(iii) specific terms and condition regarding the logistics, delivery and warehousing requirements and inventory management costs relating to such Safety Stock Inventory shall be agreed to by the Parties in good faith within thirty
(30) days of the date hereof. In the event that Finished Product is in short supply, Supplier shall notify Purchaser of such shortage as soon as possible and firstly use Safety Stock Inventory to fill Purchaser’s orders and once depleted,
secondly allocate to Purchaser a prorated share of same available to Supplier taking into consideration Purchaser’s relative sales volume in relation to Supplier and Supplier’s other customers. Supplier shall take commercially reasonable
efforts to eliminate, cure or overcome such shortage and to resume performance of its obligations hereunder as soon as reasonably possible. The Safety Stock Inventory shall, subject to Section to 4.7 below, have a shelf life of no less than twenty
four (24) months from the date of delivery of Product from such Safety Stock Inventory. The Parties agree that on the second anniversary of the date hereof, they shall, in good faith, discuss the financial obligations and logistics relating to
the Safety Stock Inventory. 
 4.7 Shelf Life. All Products Manufactured by Supplier shall have a shelf life of no less than thirty-six
(36) months from the date of Manufacturing and no less than twenty four (24) months from the date of delivery. Notwithstanding the foregoing, Purchaser shall accept Product with more than [*] months of shelf life but less than twenty four
(24) months of shelf life (the “Risk-Dated Product”). Purchaser’s obligation to accept Risk-Dated Product, however, shall not exceed more than [*] Product tablets per Minimum Run Quantity; provided that, Supplier shall be
obligated to repurchase from Purchaser [*]% of any Risk-Dated Product that has less than [*] months of shelf-life at the price paid by Purchaser and credit Purchaser for the difference between the Actual Transfer Price paid and/or calculated for
such Risk-Dated Product and Supplier’s cost for the other [*]%. 
  

	5.	OPTION TO MANUFACTURE FINISHED PRODUCT. 

 5.1 Supplier hereby
grants to Purchaser the option, subject to Sections 5.2 to 5.5 below, to be exercised by notice in writing (the “Purchaser’s Option Notice”) to Supplier to acquire the right to Manufacture Products, including an option to acquire a
sublicense to the Patents to the extent necessary to Manufacture Products, whether in the Territory or outside the Territory solely for the purpose of Commercialization in the Territory (the “Manufacturing License”), to be exercised solely
in the event that (x) Regulatory Approval is obtained by another drug manufacturer to market a Generic in the Territory, (y) an interruption in the supply of the Products continues for more than [*] days beyond the ninety (90) day
delivery schedule, or (z) the Actual Transfer Price calculated for any applicable month is less than $[*] per tablet for more than six (6) consecutive months due to changes in the Monthly Average Exchange Rate. 
  

 -15- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 5.2 Purchaser hereby acknowledges that the Manufacturing License may require the prior written approval of LG Life
Sciences, Ltd. and that the grant by Supplier of such Manufacturing License is subject to Supplier’s receipt of written consent from and the rights of LG Life Sciences, Ltd. Consequently, in the event Purchaser exercises its option under
Section 5.1, (i) Supplier shall grant to Purchaser any and all rights it may lawfully have regarding the Manufacture of Products in accordance with Section 5.1 above, and (ii) Supplier shall provide to Purchaser such commercially
reasonable efforts as may be necessary to obtain from LG Life Sciences, Ltd., or its successor-in-title, if applicable, all other required rights necessary for the Manufacture of Products in accordance with this Section 5; provided that,
Supplier shall not be required to make any payments or agree to any material undertakings in connection therewith. 
 5.3 Upon the grant of the
Manufacturing License, Purchaser shall, at its expense, obtain all Regulatory Approvals necessary to Manufacture the Product in accordance with the Specifications and Supplier shall subject to any restrictions pursuant to the rights secured from LG
Life Sciences, Ltd. pursuant to Section 5.2(ii), promptly provide all Product information in its possession required to be provided by Purchaser to any Regulatory Authority in order to obtain such Regulatory Approvals. 
 5.4 The obligations under Sections 3 and 4 shall terminate when Purchaser is capable and lawfully authorized to Manufacture the Products. 
 5.5 Royalty. As consideration for the Manufacturing License, prior to Purchaser receiving the rights set forth under Section 5.1 above,
Purchaser and Supplier shall enter into good faith negotiations regarding the terms and conditions of such Manufacturing License and further agree to negotiate a royalty that is fair and reasonable to both Parties and consistent with all applicable
Laws and the economics of the transactions contemplated hereunder. 
 5.6 Relationship. The Parties hereto agree that any royalty
determined pursuant to Section 5.5 above shall not constitute a sharing of profits between Purchaser and Supplier. The collection, holding and remittance of any such royalty by Purchaser shall in no way constitute Supplier as an agent or
partner of Purchaser and the Parties hereto specifically renounce any intent to form a partnership or joint venture that may be inferred in connection with such royalty. Neither Party hereto has any authority to assume or create any obligation or
liability, express or implied, on behalf of or in the name of the other Party in connection with the collection, holding and remittance of such royalty. 
 5.7 Changes to Specifications. Subject to such restrictions as may be imposed by LG Life Sciences, Ltd., at any time after Purchaser commences Manufacture of the Product pursuant to the rights set forth in this
Section 5, the Purchaser may, at its sole risk and expense, make changes to the Specifications, subject, however, to the following: 
 (a) no change shall be made unless sixty (60) days’ prior written notice thereof is given to Supplier, together with any and all information requested from time to time by Supplier in order to assess, review, validate and approve
same; 
 (b) any and all such changes must be evaluated and approved by Supplier; 
  

 -16- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (c) any regulatory filings required due to any changes approved by Supplier shall be the sole
responsibility of Purchaser; and 
 (d) all changes to the Specifications, as between the Parties, shall be deemed to be part of the
Specifications for the purpose of this Agreement and Supplier shall acquire and maintain all proprietary rights in respect thereto without any reservation of, or compensation to, Purchaser. 
 5.8 Save and except as modified by this Section 5, the obligations and rights as set forth herein shall continue in full force and effect in accordance with
the provisions hereof. 
  

	6.	INSPECTION AND DEFECTIVE PRODUCTS 

 6.1 Receipt of
Finished Product by Purchaser. Purchaser shall be entitled to reject any portion or all of any shipment of Finished Product that does not conform to the Certificate of Analysis and Compliance or otherwise fails to comply with the warranties
set forth in Article 13 of this Agreement (unless such non-conformity was attributable to an act or omission of Purchaser, Abbott Canada or the common carrier once the Finished Product was delivered by Supplier to such common carrier); provided,
that (i) Purchaser shall notify Supplier within [*] days after receipt of such shipment if it is rejecting a shipment due to physical damage, packaging defect or quantity discrepancies that are evident upon visual inspection of the packaged
Finished Product as shipped by Supplier and (ii) in the case of Finished Product having defects not reasonably susceptible to discovery upon customary inspection upon receipt of Finished Product, Purchaser shall notify Supplier within [*] days
after discovery of such defect (but in no event after expiration of the Product). If no notice is provided by Purchaser within the relevant time periods, then Purchaser shall be deemed to have accepted the shipment. Any notice of rejection by
Purchaser shall be accompanied by a reasonably detailed statement of its reasons for rejection and a report of any pertinent analysis performed by Purchaser on the allegedly nonconforming Finished Product, together with the methods and procedures
used. Supplier shall notify Purchaser as promptly as reasonably possible, but in any event within [*] Business Days after receipt of such notice of rejection, whether it accepts Purchaser’s assertions of nonconformity. 
 6.2 Replacement Finished Product. Whether or not Supplier accepts Purchaser’s assertion of nonconformity, promptly upon receipt of a notice of
rejection, unless otherwise specified by Purchaser, Supplier shall use its commercially reasonable efforts to provide replacement Finished Product for those rejected by Purchaser in the original shipment. If the Finished Product rejected by
Purchaser from such original shipment ultimately is found to be nonconforming (whether pursuant to Section 6.3 or if Supplier so acknowledges in writing), Supplier shall bear all expenses for such replacement Finished Product (including all
transportation and/or disposal charges and cost of manufacture for such nonconforming Finished Product) to the extent Purchaser previously paid for any corresponding nonconforming Finished Product. If it is determined subsequently that such Finished
Product was in fact conforming (whether pursuant to Section 6.3 or if Purchaser so acknowledges in writing), then Purchaser shall be responsible not only for the purchase price of the allegedly nonconforming Finished Product (including all
transportation charges), but also, upon receipt and acceptance by Purchaser in accordance with the procedures (and at the same price charged in the original shipment) set forth above, the replacement Finished Product. Replacement shipments shall
also be subject to the procedures contained in Section 4. 
  

 -17- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 6.3 Independent Laboratory Analysis. If Supplier disagrees with any alleged nonconformity timely
notified to Supplier under Section 6.1, then an independent laboratory (or other expert) of recognized repute reasonably acceptable to Supplier and Purchaser (the “Independent Laboratory”) shall analyze (i) a sample from the
relevant shipment provided by Purchaser and (ii) a Shipment Sample as retained by Supplier in accordance with Section 4.5, as may be necessary to substantiate whether the shipment rejected by Purchaser conformed in all material respects to
the Certificate of Analysis and Compliance and any other pertinent Specifications or otherwise failed to comply with the warranties set forth in Article 13 of this Agreement at the time of delivery to the common carrier. At the same time each of
Supplier and Purchaser furnishes to the Independent Laboratory its sample, such party shall also furnish to the other party a split sample of such sample. In conducting its analysis hereunder, the Independent Laboratory shall use the same analytical
methodology used by Supplier. Supplier shall provide a reasonably detailed description of such analytical methodology to the Independent Laboratory. Both Supplier and Purchaser agree to cooperate with the Independent Laboratory’s reasonable
requests for assistance in connection with its analysis hereunder. The Independent Laboratory’s results of analysis, absent manifest error, shall be deemed final as to any dispute over compliance of the Finished Product in all material respects
with the Certificate of Analysis and Compliance and/or any other pertinent Specifications and/or the warranties set forth in Article 13 of this Agreement. If the analysis of the Independent Laboratory shows that the Finished Product did not at the
material time(s) conform in all material respects to the Certificate of Analysis and Compliance or any other pertinent Specifications or the warranties set forth in Article 13 of this Agreement at the time of delivery to the common carrier, the
costs of such analysis shall be paid by Supplier. If the analysis of the Independent Laboratory shows that the Finished Product did at the material time(s) conform in all material respects to the Certificate of Analysis and Compliance and any other
pertinent Specifications and the warranties set forth in Article 13 of this Agreement at the time of delivery to the common carrier, the costs of such analysis shall be paid by Purchaser. 
 6.4 Disposition of Non-Conforming Finished Product. If Supplier acknowledges an alleged nonconformity (or if the Independent Laboratory concludes
that the Finished Product was nonconforming in accordance with Section 6.3), Supplier promptly (and in any case within thirty (30) days thereafter) shall make arrangements for the return, reworking or disposal, at Supplier’s option,
of the nonconforming Finished Product. If Supplier requests that Purchaser dispose of such nonconforming Finished Product, Supplier shall give Purchaser written instructions as to how Purchaser or its agent shall, at Supplier’s expense,
lawfully dispose of any non-conforming Finished Product, and Purchaser shall provide Supplier with written certification of such destruction. Supplier shall pay, or reimburse Purchaser, for any reasonable return shipping charges or out-of-pocket
costs incurred by Purchaser for such return shipment or lawful disposal of such nonconforming Finished Product in accordance with Supplier’s instructions. 
  

 -18- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	7.	DEVELOPMENT OF PRODUCTS 

 7.1 Regulatory Approval of Supplier. 
 (a) Notwithstanding any other provision in this Agreement, any
regulatory filings during the Term for a notice of compliance or drug identification number relating to Product shall be filed on behalf of Supplier, and any notice of compliance or drug identification number issued by HC for Product shall be issued
in the name of Supplier. For greater certainty, this means that during the Term, Purchaser and Abbott Canada shall not make any regulatory filings for a notice of compliance or drug identification number relating to Product unless the notice of
compliance or drug identification number will be issued in the name of Supplier. 
 (b) In connection with Purchaser’s anticipation of
granting rights to Abbott Canada pursuant to Section 2.2 above, Abbott Canada shall use Diligent Efforts in, and be responsible for, all activities relating to obtaining and/or maintaining Regulatory Approvals, listing on public and private
formularies and patent lists (as defined under Patented Medicines (Notice of Compliance) Regulations, relating to Product, including without limitation, using Diligent Efforts to secure [*] and [*] indications for the Product. Abbott Canada agrees
(i) to inform Supplier of all activities, including providing all correspondence, applications, or other documentation or information submitted to or received from Regulatory Authorities and drafts of any documents, filings, data or other
correspondence pertaining to Regulatory Approvals, formulary listings and patent lists in Supplier’s name, and Supplier shall review and approve or otherwise provide comments to Abbott Canada (which shall be incorporated into the filings) with
respect to the substance of such filings no more than ten (10) Business Days after receipt (unless the nature and circumstances of such filing reasonably necessitate a longer review period by Oscient); (ii) to give reasonable prior notice
to Supplier in order to allow Supplier to attend all material meetings with Regulatory Authorities; (iii) to conduct all regulatory and Development activities in accordance with applicable Laws; and (iv) that Supplier shall have the
ability, in a collaborative manner with Abbott Canada, to contact and correspond directly with Regulatory Authorities with respect to Regulatory Approvals in Supplier’s name and issues related to same, upon providing reasonable notice to Abbott
Canada. All activities relating to Development under this Agreement shall be undertaken at Abbott Canada’s and/or Purchaser’s sole cost and expense. 
 (c) Abbott Canada agrees not to request from HC any confidential Drug Master File information relating to Product. 
 (d) In the event that changes are to be made to the Product, including changes relating to the Product’s indications, Improvements or other claims, labeling or manufacture, Abbott Canada shall be responsible for preparing and filing,
as applicable, on behalf of Supplier and in Supplier’s name, any required supplements to new drug submissions, notifiable changes or notices of changes (all as defined under the Law). Supplier shall use reasonable efforts to provide Abbott
Canada at least ten (10) Business Days before an application and/or a response is due to a Regulatory Authority with all necessary technical data, information and other assistance in support of such supplements to new drug submissions,
notifiable changes or notices of changes. Changes to be made to the Product include, without limitation, changing the site of manufacture of the Product from [*] to [*], adding an indication for [*] and/or [*], and adding additional indications
beyond [*], [*] or [*] (subject to Section 7.6 below). 
 (e) Any information which Abbott Canada receives from Supplier pursuant to
this provision, including clinical data and U.S. regulatory filings, shall be used by Abbott Canada solely for the purpose of this Agreement and shall be subject to the terms and conditions of this Agreement, and such information shall be treated as
Confidential Information. 
  

 -19- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 7.2 Regulatory Approval of Abbott Canada. In connection with Purchaser’s anticipation of
granting rights to Abbott Canada pursuant to Section 2.2 above, Abbott Canada shall use Diligent Efforts in, and be responsible for, all activities relating to obtaining and/or maintaining the establishment/product license on behalf of Abbott
Canada required to distribute and import into Canada the Product. However, in the event HC requires a dissolution assay or similar testing as a condition precedent to granting the establishment/product license, then Supplier shall use Diligent
Efforts to forthwith complete and remit to HC, through Abbott Canada, the results thereof and other information relating thereto required by HC. 
 7.3
Regulatory Authorities. Abbott Canada shall be responsible for communications with the Regulatory Authorities with respect to the Product. Supplier shall use reasonable efforts (i) to assist Abbott Canada in responding to any
queries from a Regulatory Authority, (ii) to provide Abbott Canada with all necessary documents, data and information which Supplier has assembled and is in its possession that will assist Abbott Canada in preparing the regulatory documents for
the Territory, and (iii) to provide at least ten (10) Business Days before a response is due to such Regulatory Authority all the necessary documents, data, and information which Supplier has assembled and is in its possession that will
assist Abbott Canada in preparing for such response. Abbott Canada shall advise Supplier of material developments and events relating to regulatory issues in writing within two (2) Business Days after notice of such material developments and
events. Abbott Canada shall take the steps necessary to ensure that information submitted to Regulatory Authorities is kept confidential. 
 7.4
Clinical Trials. Neither Purchaser nor Abbott Canada shall conduct any clinical study or any other study or trial with respect to the Product or any product containing the Compound without Supplier’s prior written consent.

 7.5 Inspections, Inquiries and Complaints 
 (a) Purchaser and/or Abbott Canada shall advise Supplier of any Regulatory Authority visit to, or written or oral inquiry about, any facilities or
procedures relating to the Commercialization of the Product, promptly (but in no event later than one (1) Business Day) after notice of such visit or inquiry. Purchaser and/or Abbott Canada shall, within two (2) business days of receipt or
submission, furnish to Supplier any report or correspondence issued by or provided to the Regulatory Authority in connection with such visit or inquiry. 
 (b) Supplier shall advise Purchaser of any Regulatory Authority visit to, or written or oral inquiry about, any facilities or procedures relating to the manufacture of the Product, promptly (but in no event later than
one (1) Business Day) after notice of such visit or inquiry. 
 (c) Each of Purchaser and Abbott Canada shall advise Supplier within
twenty four (24) hours of any investigation, complaint, claim or potential claim, whether from a Regulatory Authority or not, about Product relating to a safety issue, and shall also advise Supplier within two (2) Business Days of any
issue that may give rise to a potential recall. 
  

 -20- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 7.6 Additional Development. Notwithstanding anything else in this Agreement, all Development activities in
the Territory will, at the time of such activities, be consistent with the U.S. label in regard to duration of therapy, dose, or indication, unless otherwise approved in writing by Supplier; provided that, the Parties agree that (i) the
regulatory filing for [*] in the Territory will be based on 5-day duration of therapy and (ii) Abbott Canada may pursue a regulatory filing for [*] based on 5-day duration of therapy in the Territory. 
  

	8.	COMMERCIALIZATION OF PRODUCT 

 8.1 Responsibility.
From and after the Effective Date, Purchaser or Abbott Canada shall have full control and authority over the Commercialization of Products in the Territory, and shall exercise Diligent Efforts in Commercializing the Products in the Territory,
including diligently seeking formulary listings. All activities relating to Commercialization under this Agreement shall be undertaken at Purchaser’s or Abbott Canada’s sole cost and expense. 
 8.2 Marketing Plan. Abbott Canada shall submit, no later than ninety (90) days from the Effective Date, to the Steering Committee for approval a
marketing plan (the “Marketing Plan”), for Commercialization of the Product in the Territory, which will include, among other things, the annual number of Details to be performed and aggregate amount of Commercializing expenses to be
incurred for the first year after the First Commercial Sale. At least sixty (60) days prior to each Contract Year commencing with the Contract year commencing December 1, 2007, Abbott Canada shall submit the Marketing Plan for such
Contract Year. Purchaser shall ensure that Abbott Canada will have agreed in writing to the Marketing Plan prior to its implementation. 
 8.3 Joint
Steering Committee. 
 (a) Within thirty (30) days of the date of this Agreement, a joint steering committee, comprised of equal
representation by Supplier and Purchaser (the “Steering Committee”), shall be established to perform such functions as appropriate to further the purposes of this Agreement. Accordingly, Purchaser shall keep Supplier informed of the
following matters through the Steering Committee: 
  

	 	(i)	Plans and updates relating to the Commercialization or Development of the Product, including updates on achievement of objectives set forth in the Marketing Plan, progress towards
sales goals, and related sales and marketing and regulatory activities; and 

  

	 	(ii)	Summary and analysis of any Adverse Event information, other medical inquires, complaints, or other issues further defined in the Quality Agreement. 

 (b) Purchaser must ensure that it keeps itself informed of the matters in Section 8.3 above, and to the extent it is not informed, it must seek such
information from Abbott Canada. 
  

 -21- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (c) Supplier or Purchaser may change or replace its representatives on the Steering Committee as it deems
appropriate, by notice to the other. The Steering Committee shall hold meetings at such times and places as shall be determined by the co-chairpersons. The meetings shall be held no less frequently than once every six (6) months during the
first twenty-four (24) months of the Agreement and a minimum of once every twelve (12) months thereafter. Steering Committee meetings may be held in person or by telephone or video conference. 
 (d) The Steering Committee shall only have such powers as are expressly delegated to it in this Agreement. The Steering Committee is not a substitute for
the rights or obligations of the Parties and shall not have the authority to amend this Agreement. 
 (e) Each of Supplier and Purchaser will
designate one of its members of the Steering Committee to act as a co-chairperson to facilitate the performance of its rights and satisfaction of its obligations hereunder. 
 8.4 Standards and Sales Activities Purchaser and Abbott Canada shall, at their sole expense, Commercialize the Product in accordance with good commercial practice with respect to regulated
pharmaceutical products, including applicable Laws. Purchaser and Abbott Canada shall avoid using any practice that would prejudice Supplier’s name, the Trademarks, and the quality of the Products. Purchaser and Abbott Canada shall market
(including price) Product in a manner that maximizes the goodwill and the value over the long term of Product. 
 8.5 Training.
Purchaser shall ensure that each of its and its Sub-Distributors’ sales force and employees are fully trained with respect to the Product and Supplier’s policies and procedures regarding sale, distribution and use of the Product and
reporting of Event information. 
 8.6 Sales Outside the Territory. Purchaser and Abbott Canada shall not: (a) establish any
branch, sales offices, warehouse or other facilities outside of the Territory with respect to the Product, (b) adopt a policy of selling the Product outside the Territory nor undertake the sale or promotion of sales of the Product outside the
Territory, (c) seek customers or solicit orders from any prospective customer whose principal address or place of business is located outside the Territory, and/or (d) provide any price quotations for the Product to any prospective
customer whose principal address or place of business is located outside the Territory. Purchaser and its Sub-Distributors shall, to the extent permitted by Law, use Diligent Efforts not to directly or indirectly knowingly sell to any person
(including a pharmacy or wholesaler) that directly or indirectly sells to any person outside of the Territory. If Purchaser or Abbott Canada receives an order from a prospective customer located outside the Territory, Purchaser and Abbott Canada
shall immediately refer that order to Supplier. Without Supplier’s prior consent, Purchaser or Abbott Canada may not deliver or tender, or cause to be delivered or tendered, the Product (or any sample of the Product) outside the Territory.
Neither Purchaser nor Abbott Canada shall sell any Product to any purchaser if (A) it knows, has reason to believe, or has been informed by Supplier that such purchaser intends to remove the Product from the Territory, either directly or
indirectly, or if (B) such purchaser is known to remove pharmaceuticals from the Territory, either directly or indirectly. Notwithstanding anything hereunder to the contrary, in the event that Purchaser or Abbott Canada becomes aware either
through Supplier or through its own market intelligence that any customer of Purchaser or Abbott Canada is purchasing Product for resale outside the Territory, then Purchaser’s sole obligation and restraint with respect thereto shall be 

  

 -22- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
to ensure that Purchaser and/or Abbott Canada conducts such reasonable enquiries consistent with the Law and takes such measures with respect to such
customer that are consistent with the measures adopted and applied by Purchaser and/Abbott Canada with respect to its own products in order to comply, to the extent commercially reasonable and to the extent permitted by Law, with the provisions of
this Section 8.6. 
 8.7 Marketing, Promotional and Educational Materials. Marketing, promotional and educational materials related
to the Product and prepared for use in the Territory by Purchaser or Abbott Canada shall be prepared in a manner consistent with Canadian Law (the “Promotional Materials”). Notwithstanding this, Purchaser and Abbott Canada are responsible
for ensuring compliance with Laws. Upon request of Supplier, Supplier shall be presented and described as the party that developed the Product in all Promotional Materials. All Promotional Materials shall display the Trademarks in a manner that
promotes the Product and each of the Parties in a manner consistent with good commercial practice in dealing with regulated pharmaceutical products, and shall indicate that FACTIVE is a trademark and sublicensed by Supplier and used under license to
the extent permitted by applicable Law and the prominence of such notice shall depend on space and other physical limitations and all other commercially reasonable limitations. Supplier shall have the right to reproduce, distribute and otherwise use
outside the Territory all Promotional Materials with the prior written consent of the Purchaser. Purchaser and Abbott Canada shall provide and distribute to customers and prospective customers marketing, promotional and educational materials
reasonably necessary to promote the Product in the Territory. Purchaser and Abbott Canada shall be responsible for all expenses relating to the advertising, promotion or sales of the Product. Supplier shall provide Purchaser with Product-related
marketing and promotional materials prepared by Supplier, including related logos and graphics, for use by Purchaser in connection with the development of Promotional Materials. 
  

	9.	RECORDS AND REPORTS 

 9.1 Records. Purchaser
and Abbott Canada shall each maintain complete and accurate records of all inventories, Product in storage, movements, shipments, sales and potential problems involving the Product by unit, by batch number and by customer so that all such matters
can be traced quickly and effectively. Upon request, Purchaser and Abbott Canada shall provide copies of such records to Supplier, and shall provide Supplier, or its representatives, with access to the place where the Product is stored and/or
shipped and other facilities used by Purchaser or Abbott Canada in carrying out this Agreement, during normal business hours and upon reasonable notice, for the purpose of inspecting such facilities for compliance with the terms of this Agreement.
Purchaser and Abbott Canada shall maintain all such records for at least three (3) years. 
 9.2 Reports. Purchaser and Abbott Canada
shall provide Supplier with written reports no less frequently than annually during the Term summarizing Purchaser and Abbott Canada’s efforts to Develop and Commercialize Products hereunder. In addition, Purchaser shall provide Supplier with
prompt written notice of the occurrence of the First Commercial Sale of any Product in the Territory. All reports, updates, Adverse Events and other information provided by one Party to another Party under this Agreement shall be considered
Confidential Information of the Disclosing Party, subject to the terms of Section 11 hereof.  
  

 -23- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 9.3 Annual Plan. On or before the First Commercial Sale and not later than each anniversary date of
the First Commercial Sale, Purchaser and Abbott Canada shall submit to Supplier a business and marketing plan for the following year (the “Annual Plan”). The Annual Plan shall be in a form reasonably required by Supplier, and shall
include: (i) a description of the market and marketing, promotional and customer service programs anticipated for the following year and budgets for each, and (ii) such other information concerning the market, the status of customers and
competitors, the business of Purchaser or Abbott Canada or such other matters related to the Product as Supplier may reasonably request. 
 9.4 Adverse
Events. Within a period of sixty (60) days after the Effective Date, the Parties shall agree upon a Safety Data Exchange Agreement, which will set out in detail the handling of post-market Adverse Event information relating to this
Agreement and be on terms consistent with those standard in the industry for transactions similar to this Agreement. The Safety Data Exchange Agreement will include, and be consistent with, the following: 
  

	 	(a)	Abbott Canada shall be responsible for providing to Supplier any Adverse Event information relating to Product that Abbott Canada or Purchaser receives, within two (2) Business
Days of receipt of such information by Abbott Canada or Purchaser. 

  

	 	(b)	To the extent required, Purchaser and Abbott Canada shall seek additional information regarding Adverse Events upon request from Supplier. 

  

	 	(c)	Supplier shall provide to Abbott Canada details of any information relating to the Adverse Events that is in Supplier’s possession that Abbott Canada requires to comply with
Law. 

  

	 	(d)	Abbott Canada shall file with Regulatory Authorities any Adverse Event information required by Law. Filings shall be made in accordance with Law, including with respect to timing of
filings. 

 Each Party shall comply with the Safety Data Exchange Agreement. To the extent there are any inconsistencies or conflicts between
this Agreement and the Safety Data Exchange Agreement, the terms and conditions of this Agreement shall control unless otherwise agreed to in writing by Supplier and Purchaser in the form of an amendment to this Agreement. In the event that the
Safety Data Exchange Agreement contains material provisions that differ from the Law, the Law shall control. 
 9.5 Purchase Information. Upon
request, Purchaser or Abbott Canada shall provide to Supplier copies of any and all reasonably required purchase information regarding the Product, to the extent such information is easily available and in Purchaser’s or Abbott Canada’s
possession. 
  

	10.	PAYMENTS AND FEES 

 10.1 Initial Transfer Price.
Purchaser shall pay Supplier $[*] per tablet for Finished Product (the “Initial Transfer Price”) ordered during the Contract Year ending November 30 in each of 2006, 2007 and 2008. Upon delivery, Supplier shall invoice
Purchaser for the price of the 

  

 -24- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
Finished Products delivered. Each invoice shall specify the purchase order number to which it corresponds and shall reflect the price set forth in this
Section 10.1. All amounts due to Supplier pursuant to this Section 10.1 shall be paid by Purchaser within thirty (30) days following the date of invoice pursuant to Section 10.5 below. 
  

	10.2	Subsequent Transfer Price. 

 (a) For each Contract Year during the remainder of the Term, commencing on December 1, 2008, Purchaser shall pay Supplier an amount per tablet equal to the Estimated Transfer Price. For purposes of clarification, Schedules D and
E are attached hereto to provide hypothetical forecasted examples of the calculation of Estimated Transfer Price and Actual Transfer Price. The Estimated Transfer Price shall be delivered to Supplier at least thirty (30) days prior to each
such Contract Year. Each invoice for Finished Product shall specify the purchase order number to which it corresponds. All amounts due to Supplier pursuant to this Section 10.2(a) shall be paid by Purchaser within thirty (30) days
following the date of invoice pursuant to Sections 10.5 and 10.6 below. 
 (b) Within fifteen (15) days following the end of every
month, Purchaser shall send a Monthly Report to Supplier detailing the adjustment of the Estimated Transfer Price which shall be calculated as follows: (the “Actual Transfer Price”) 
 Actual Transfer Price = [*] 
 (c)
Notwithstanding anything hereunder to the contrary, in no event shall the Estimated Transfer Price or Actual Transfer Price be less than $[*] per tablet or more than $[*] per tablet. 
 (d)(i) If the Actual Transfer Price is greater than the Estimated Transfer Price for the applicable month, then Purchaser shall owe Supplier an amount
equal to the difference between the Actual Transfer Price and the Estimated Transfer Price multiplied by the number of tablets sold in the applicable month to be paid to Supplier pursuant to the provisions of Section 10.2(e) below (the
“Supplier Credited Amount”). 
 (ii) If the Estimated Transfer Price is greater than the Actual Transfer Price for
the applicable month, then Supplier shall owe to Purchaser an amount equal to the difference between the Estimated Transfer Price and the Actual Transfer Price multiplied by the number of tablets ordered in the applicable to be paid to Purchaser
pursuant to the provisions of Section 10.2(e) below (the “Purchaser Credited Amount”). 
 (e)(i) If the sum of
the Supplier Credited Amount for each of the three months in the applicable Contract Year quarter is greater than the sum of the Purchaser Credited Amount for each of the three months in such Contract Year quarter, then Purchaser shall pay to
Supplier an amount equal to the difference between the sum of the Supplier Credited Amounts and the sum of the Purchaser Credited Amounts within thirty (30) days following the end of such quarter. 
  

 -25- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (ii) If the sum of the Purchaser Credited Amount for each of the three months in the
applicable Contract Year quarter is greater than the sum of the Supplier Credited Amount for each of the three months in such Contract Year quarter, then Supplier shall pay to Purchaser an amount equal to the difference between the sum of the
Purchaser Credited Amounts and the sum of the Supplier Credited Amounts within thirty (30) days following the end of such quarter. 
 (f) In the event of any investigations or orders by any Regulatory Authority relating to pricing of Product that causes Purchaser to retroactively adjust any prices or to otherwise make payments relating to any improperly charged prices or
discounts relating to Product, any payments already calculated and paid to Supplier under this Article 10 shall be adjusted. 
 (g) In the
event the Actual Transfer Price calculated for any Contract Year quarter is less than $[*] per tablet (without regard to the limits set forth in Section 10.2(c)) due to changes in the Monthly Average Exchange Rate, the Supplier may notify the
Purchaser in writing that it wishes to negotiate in good faith a new minimum floor price which is mutually acceptable to both Parties. In establishing such new minimum floor price, the Parties shall take into consideration all relevant factors,
including, without limitation, changes in manufacturing costs and costs of raw materials and packaging materials resulting from fluctuation in the United States currency. In the event that, within three (3) months of such notice, the Parties
are unable to establish a new minimum floor price for the Product, then the matter shall be referred to the most senior officers of each of the Parties who shall for an additional thirty (30) days negotiate in good faith to establish a new
minimum floor price for the Product. At any time during the negotiations, Purchaser may elect to exercise its rights under Section 5. In the event (i) the most senior officers of the Parties fail to agree on a new minimum floor price for
the Product, and (ii) pursuant to the terms of Section 5 above, Purchaser has not been granted the right to Manufacture the Product, then Supplier shall have the right to terminate the Agreement upon one (1) year prior written notice
to Purchaser and the Actual Transfer Price during such one (1) year’s period shall be $[*]. 
 (h) In the event the
Actual Transfer Price calculated for any Contract Year quarter is greater than $[*] per tablet (without regard to the limits set forth in Section 10.2(c)) due to changes in the Monthly Average Exchange Rate, either Party may notify the other in
writing that it wishes to negotiate in good faith a new maximum ceiling price which is mutually acceptable to both Parties. In establishing such new maximum ceiling price, the Parties shall take into consideration all relevant factors, including,
without limitation, changes in manufacturing costs and costs of raw materials and packaging materials as well as changes in Supplier’s overall rate of return (relative to such Actual Transfer Price) resulting from fluctuation in the United
States currency. In the event that, within three (3) months of such notice, the Parties are unable to establish a new maximum ceiling price for the Product, then the matter shall be referred to the most senior officers of each of the Parties
who shall for an additional thirty (30) days negotiate in good faith to establish a new maximum ceiling price for the Product and pending resolution of such matter, the maximum ceiling price for the Product shall remain at $[*] per tablet.

  

 -26- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	10.3	License Fees 

 (a) Approval License
Fees. In further consideration of the rights granted hereunder and subject to the other terms and conditions of this Agreement, Purchaser shall make the following non-refundable, non-creditable payments to Supplier within thirty (30) days
of the occurrence of each of the following events by Purchaser or Abbott Canada: 
  

			
	 Milestone
	  	Payment
	 Regulatory Approval of [*] as the manufacturer of the Product
	  	[*] Dollars ($[*])
	 Regulatory Approval for the Product in the Territory for either [*] or [*]
	  	[*] Dollars ($[*])
	 Regulatory Approval for a Product in any indication other than [*] or [*]
	  	[*] Dollars ($[*])

 provided that, Purchaser shall forthwith upon signing this Agreement pay to Supplier [*] dollars ($[*]) to be
credited as an advance against the first payment for the licensee fees payable upon occurrence of the first milestone. 
 (b) Sales
License Fees. In further consideration of the rights granted hereunder and subject to the other terms and conditions of this Agreement, Purchaser shall make the following non-refundable, non-creditable payments to Supplier within thirty
(30) days of the initial occurrence of each of the following milestones by Purchaser or Abbott Canada: 
  

			
	 Milestone
	  	Payment
	 Annual Net Sales of the Product in the Territory of greater than $[*] dollars (calculated based on Canadian Dollars)
	  	[*] Dollars ($[*])
	 Annual Net Sales of the Product in the Territory of greater than $[*] dollars (calculated based on Canadian Dollars)
	  	[*] Dollars ($[*])
	 Annual Net Sales of the Product in the Territory of greater than $[*] dollars (calculated based on Canadian Dollars)
	  	[*] Dollars ($[*])

 (c) Determination that Payments are Due. Purchaser shall promptly (and in any event within
ten (10) Business Days) provide Supplier with written notice upon its achievement of each of the milestones set forth in Sections (a) and (b). In the event that Supplier believes any license fee is due pursuant to Sections (a) and
(b) in spite of not having received notice from Purchaser, it shall so notify Purchaser and shall provide to Purchaser the data and 

  

 -27- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
information supporting its belief that the conditions for payment have been achieved. If Purchaser does not provide adequate evidence that such milestone has
not been achieved within thirty (30) days of receipt of the data and information from Supplier, the conditions for payment shall be deemed to have been achieved. 
 (d) License Fees Terms. Unless otherwise expressly provided, Purchaser shall make any payment owed to Supplier as license fees hereunder in arrears, within thirty (30) days from the achievement of such
milestone. 
 10.4 Reimbursement of Marketing Support. Within forty-five (45) days after Regulatory Approval in the Territory is
obtained for either [*] or [*], Supplier shall pay to Purchaser the sum of [*] dollars ($[*]), as Supplier’s contribution to the expenses to be incurred by Purchaser and Abbott Canada in obtaining Regulatory Approvals and Commercializing the
Product. 
 10.5 Payment Terms. All sums shall be payable in the United States in United States dollars by bank wire transfer in immediately
available funds to the following account unless Purchaser is otherwise notified in writing by Supplier: 
  

					
	Bank Account:	  	Citizens Bank	  	
		  	28 State Street	  	
		  	Boston, MA 02109	  	
		  	USA	  	
		  	1-877-471-1961	  	
			
	Account Number:	  	1135568364	  	
			
	Bank ABA Number:	  	011500120	  	

 10.6 Overdue Payments. Subject to the other terms of this Agreement, any payments not paid within
the time period set forth in this Section 10 shall bear interest at a rate of LIBOR plus [*] percent ([*]%) for the applicable month from the due date until paid in full, provided that in no event shall said annual rate exceed the maximum
interest rate permitted by law in regard to such payments. Such payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of Supplier to any other
remedy, legal or equitable, to which it may be entitled because of the delinquency of the payment. 
 10.7 Tax Withholding; Restrictions on
Payment. It is the Parties’ understanding that no withholding taxes shall be assessed on the payment made to Supplier pursuant to this Section 10. Any payments payable by either the Supplier or Purchaser (the “Withholding
Party”) to the other under this Agreement may be reduced by the amount required to be paid or withheld pursuant to any applicable Law (“Withholding Taxes”); provided however, that Withholding Party shall withhold taxes at the lowest
tax rate allowed in the applicable tax treaties. The Withholding Party shall submit to the other Party a copy of an original receipt received by the Withholding Party showing payment thereof, or if such receipt is not available, other reasonable
proof of payment of any Withholding Taxes paid or withheld, together with an accounting of the 

  

 -28- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
calculations of such taxes, as promptly as practicable but in no case later than thirty (30) days after such Withholding Taxes are remitted to the
proper governmental authority. Supplier and Purchaser will cooperate reasonably in completing and filing documents required under the provisions of any applicable tax law or under any other Applicable Law in connection with the making of any
required tax payment or withholding payment, or in connection with any claim to a refund of or credit for any such payment. 
 10.8 Records Retention;
Review 
 (a) Records. Commencing as of the date of First Commercial Sale of the Product hereunder, Purchaser and
Sub-Distributor shall keep for at least three (3) years from the end of the calendar year to which they pertain complete and accurate records of sales by Purchaser or Sub-Distributor, as the case may be, of the Product, in sufficient detail to
allow the accuracy of the payments hereunder to be confirmed. 
 (b) Review. Subject to the other terms of this Section 10.8, at
the request of Supplier, which shall not be made more frequently than once per calendar year during the Term, upon at least thirty (30) days’ prior written notice from Supplier, and at the expense of Supplier (except as otherwise provided
herein), Purchaser shall permit independent accountants (who may be certified public accountants or chartered accountants) reasonably selected by Supplier to inspect (during regular business hours) the relevant records required to be maintained by
Purchaser under this Section 10.8. Results of any such review shall be binding on all Parties absent manifest error. Each Party agrees to treat the results of any such accountant’s review of another Party’s records under this
Section 10.8 as Confidential Information of such other Party subject to the terms of Article 11. If any review reveals a deficiency in the calculation and/or payment of royalties by Purchaser, then (a) Purchaser shall promptly pay Supplier
the amount remaining to be paid, and (b) if such underpayment is by ten percent (10%) or more, Purchaser shall pay the reasonable out-of-pocket costs and expenses incurred by Supplier in connection with the review. 
 (c) Other Parties. Purchaser shall include in any agreement with each Sub-Distributor terms requiring such party to retain records as required in
this Section 10.8 and to permit Supplier to inspect such records as required by this Section 10.8. 
  

	11.	TREATMENT OF CONFIDENTIAL INFORMATION 

 11.1
Confidential Obligations. Supplier, Purchaser and Abbott Canada each recognize that another Party’s Confidential Information constitutes highly valuable and proprietary confidential information. Supplier, Purchaser and Abbott
Canada each agree that during the Term and for seven (7) years thereafter, it will keep confidential, and will cause its employees, consultants and Affiliates to keep confidential, all Confidential Information of another party. Neither
Supplier, Purchaser or Abbott Canada, nor any of their respective employees, consultants or Affiliates shall use Confidential Information of another party for any purpose whatsoever other than exercising any rights granted to it or reserved by it
hereunder. Without limiting the foregoing, each of Supplier, Purchaser and Abbott Canada may disclose information to the extent such disclosure is reasonably necessary to (a) file and prosecute patent applications and/or maintain patents which
are filed or prosecuted in accordance with the provisions of this Agreement, or (b)

  

 -29- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
file, prosecute or defend litigation in accordance with the provisions of this Agreement or (c) comply with applicable laws, regulations or court
orders; provided, however, that if a Party is required to make any such disclosure of another Party’s Confidential Information in connection with any of the foregoing, it will give reasonable advance notice to such other Party of
such disclosure requirement and will use reasonable efforts to assist such other Party in efforts to secure confidential treatment of such information required to be disclosed. 
 11.2 Limited Disclosure and Use. Supplier, Purchaser and Abbott Canada each agree that any disclosure of any one Party’s Confidential Information to any officer, employee, consultant or agent
of another Party or any of its Affiliates shall be made only if and to the extent necessary to carry out its rights and responsibilities under this Agreement, shall be limited to the maximum extent possible consistent with such rights and
responsibilities and shall only be made to the extent any such persons are bound by written confidentiality obligations to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this
Agreement. Supplier, Purchaser and Abbott Canada each further agree not to disclose or transfer another Party’s Confidential Information to any third parties under any circumstance without the prior written approval from such other Party (such
approval not to be unreasonably withheld), except as otherwise required by law, and except as otherwise expressly permitted by this Agreement. Supplier, Purchaser and Abbott Canada each shall take such action, and shall cause its Affiliates to take
such action, to preserve the confidentiality of each other’s Confidential Information as it would customarily take to preserve the confidentiality of its own Confidential Information, using, in all such circumstances, not less than reasonable
care. Each of Supplier, Purchaser and Abbott Canada, upon the request of another party, will return all the Confidential Information disclosed or transferred to it by such other party pursuant to this Agreement, including all copies and extracts of
documents and all manifestations in whatever form, within sixty (60) days of such request or, if earlier, the termination or expiration of this Agreement; provided however, that a Party may retain (a) any Confidential Information of
an other Party relating to any license which expressly survives such termination and (b) one (1) copy of all other Confidential Information in inactive archives solely for the purpose of establishing the contents thereof. 
 11.3 Publicity. Neither Supplier, Purchaser nor Abbott Canada may publicly disclose the existence or terms or any other matter of fact regarding
this Agreement without the prior written consent of the other Parties, which consent shall not be unreasonably withheld or delayed; provided, however, that any Party may make such a disclosure (a) to the extent required by law or
by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded, or (b) to any investors, prospective investors, lenders and other
potential financing sources who are obligated to keep such information confidential. In the event that such disclosure is, in the opinion of the disclosing Party’s counsel, required as aforesaid, the disclosing Party shall submit the proposed
disclosure in writing to the other Party at least five (5) days prior to the date of disclosure for an opportunity to comment thereon and the Parties shall coordinate with the other Parties with respect to the wording and timing of any such
disclosure. The Parties, upon the execution of this Agreement, will mutually agree to a press release with respect to this transaction for publication. Once such press release or any other written statement is approved for disclosure by the Parties,
any Party may make subsequent public disclosure of the contents of such statement without the further approval of the other Parties. 
  

 -30- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 11.4 Use of Name. No Party shall employ or use the name of another Party in any promotional
materials or advertising relating to this Agreement without the prior express written permission of the other party or as specifically set out in this Agreement. 
 11.5 Access to Information. If Purchaser or Abbott Canada receives an access to information or freedom of information request relating to Product, it shall notify Supplier within two days of such request, and provide a
copy of its proposed response to such request to Supplier at least five days before the deadline for responding. If Supplier suggests that the proposed response should be amended to keep additional information confidential, Purchaser or Abbott
Canada, as applicable, shall amend the proposed response accordingly. 
  

	12.	INTELLECTUAL PROPERTY RIGHTS 

 12.1 Patent Filing,
Prosecution and Maintenance. Supplier shall be responsible for preparing, filing, prosecuting, obtaining and maintaining, at its sole cost, expense and discretion, all Patent Rights in the Territory. Supplier will keep Purchaser
reasonably informed of the status of such filing, prosecution and maintenance. 
 12.2 Trademark Filing, Prosecution and Maintenance.
Supplier may seek and maintain (or cause to be sought and maintained, in the case of trademarks used under license) such registrations as it deems advisable in respect of the Trademarks in the Territory, and will keep Purchaser reasonably informed
of the status of such registrations and applications therefore. Supplier (or the trademark owner, in the case of trademarks used under license) may from time to time add to, modify or delete any Trademarks. 
 12.3 Notice of Infringement. If, during the Term, any Party learns of any actual, alleged or threatened infringement by a Third Party of any of the
Intellectual Property, including without limitation if a Notice of Allegation pursuant to the Patented Medicines (Notice of Compliance) Regulations is received, such Party shall promptly notify the other Parties and shall provide the other
Parties with available evidence of such infringement. 
 12.4 Violation of Intellectual Property. Purchaser shall have the first right
(but not the obligation), at its own expense and with legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement or other violation of the Intellectual Property in
the Territory. Supplier shall have the right, at its own expense, to be independently represented in any such action by Purchaser by counsel of Supplier’s own choice; provided, however, that under no circumstances shall the
foregoing affect the right of Purchaser to control the suit as described in the first sentence of this Section 12.4. If Purchaser does not notify Supplier of its decision as to whether it intends to file an action or proceeding against a
material infringement or other violation (including a Notice of Allegation pursuant to the Patented Medicines (Notice of Compliance) Regulations) (the “Notice”) within [*] days after the later of (i) Purchaser’s notice to
Supplier under Section 12.3 above, or (ii) a written request from Supplier to take action with respect to such infringement (the “Notice Date”), then Supplier shall have the right (but not the obligation), at its own expense, to
bring suit (or take other appropriate legal action) against such actual, alleged or threatened infringement, with legal counsel of its own choice. If (a) Purchaser does not actually file any action or proceeding against a material infringement
or other violation within [*] days after the 

  

 -31- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
Notice Date, or (b) Purchaser elects not to pursue any action or proceeding against a material infringement or other violation pursuant to the
Notification, then Supplier shall have the right (but not the obligation), at its own expense, to bring suit (or take other appropriate legal action) against such actual, alleged or threatened infringement, with legal counsel of its own choice .
Purchaser acknowledges that L.G. Life Sciences Ltd (or its successors or assigns thereof), as the person licensing certain of the Intellectual Property to the Supplier, is entitled to be represented in suits or actions involving the Intellectual
Property in the Territory, and to have its costs and expenses incurred in respect of such litigation reimbursed, pro rata with Supplier, from any damages, monetary awards, costs or other amounts recovered through such suits or actions, or settlement
thereof; subject to any deductions required to be made in order to reimburse Supplier’s licensor as aforesaid. Any damages, monetary awards, costs or other amounts recovered, whether by judgment or settlement, pursuant to any suit, proceeding
or other legal action taken under this Section 12.4, shall applied as follows: 
 (a) First, to reimburse the Supplier and Purchaser for
their respective costs and expenses (including reasonable legal fees, expert fees and other disbursements) incurred in prosecuting such enforcement action; 
 (b) Second, to Purchaser for reimbursement for Purchaser’s profits on lost sales associated with Products and to Supplier for reimbursement for Supplier’s profits on lost sales to Purchaser and Quarterly
Payments, royalties and license fees owing hereunder based on such lost sales; 
 (c) Third, any amounts remaining shall be allocated as
follows: (A) if Supplier is the Party bringing such suit or proceeding or taking such other legal action, [*] percent ([*]%) to Supplier, (B) if Purchaser is the Party bringing such suit or proceeding or taking such other legal action, [*]
percent ([*]%) to Purchaser, and (C) if the suit is brought jointly, [*] percent ([*]%) to each of Supplier and Purchaser. 
 If either
of Supplier or Purchaser brings any such action or proceeding hereunder, the other agrees to be joined as party plaintiff if necessary to prosecute such action or proceeding, and to give the Party bringing such action or proceeding reasonable
assistance and authority to file and prosecute the suit; provided, however, that neither Supplier nor Purchaser shall be required to transfer any right, title or interest in or to any property to the other, to Sub-Distributor or any Third Party to
confer standing on a Party hereunder. 
 12.5 Right to Use Intellectual Property. Purchaser acknowledges that it has no interest in, and
agrees that it will not at any time assert or claim any interest in, nor register or attempt to register any form of intellectual property which would infringe or otherwise violate any of Intellectual Property, and will cooperate with Supplier to
secure Supplier’s rights under the Intellectual Property in the Territory. The Intellectual Property (whether owned by Supplier or licensed to Supplier) shall as among the Parties remain the exclusive property of Supplier. All benefit and
goodwill arising from Purchaser’s or Sub-Distributor’s use of the Trademarks shall, as among the Parties, inure to the benefit of Supplier. 
  

 -32- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	13.	REPRESENTATIONS AND WARRANTIES 

 13.1 Supplier
Representations. Supplier represents and warrants to Purchaser that: 
  

	 	(a)	the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate Supplier corporate action;

  

	 	(b)	this Agreement is a legal and valid obligation binding upon Supplier and enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by
the Parties does not conflict with any agreement, instrument or understanding to which Supplier is a party or by which it is bound; 

  

	 	(c)	Supplier has the full right and legal capacity to grant the rights granted to Purchaser hereunder in the Territory without violating the rights of any Third Party;

  

	 	(d)	Supplier is not aware of any Third Party patent, patent application or other intellectual property rights in the Territory that would be infringed (i) by using the Trademark,
or (ii) by making, using, offering for sale, selling or importing Product; 

  

	 	(e)	Supplier is not aware of any information that would render invalid and/or unenforceable claims for the Product in the Patent Rights; and 

  

	 	(f)	Supplier warrants exclusively to Purchaser that all of the Products shipped by Supplier or its third party manufacturer in accordance with this Agreement: (i) shall meet
Supplier’s specifications for the shelf life of such Product when stored and handled in accordance with Supplier’s labeled conditions, (ii) shall be manufactured in accordance with the GMP and the Law in effect at the time of
manufacture, and (iii) shall not be adulterated or misbranded as a result of acts or omissions by Supplier; provided, that, (i) the Parties agree that the warranty set forth in this Section 13.1(f) shall not apply to any Product
Manufactured by Purchaser pursuant to Section 5 above, and (ii) subject to Supplier’s indemnification obligations in the event of a product liability claim, Supplier’s sole obligation and the sole remedy under this warranty is
replacement of any Product or a refund of the purchase price that Supplier reasonably determines to be covered by this warranty. 

 13.2
Purchaser Representations. Purchaser represents and warrants to Supplier that: 
  

	 	(a)	the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate Purchaser corporate action;

  

	 	(b)	 this Agreement is a legal and valid obligation binding upon Purchaser and Abbott Canada and enforceable in accordance with its terms, and the execution, delivery

  

 -33- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	 
and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which Purchaser is a party of or by
which it is bound. 

  

	 	(c)	Purchaser has the capacity to fulfill all the obligations under this Agreement. 

  

	 	(d)	Purchaser warrants that Abbott Canada shall Commercialize and Develop Product in accordance with Laws. 

 13.3 Abbott Canada. Abbott Canada represents and warrants to Supplier that: 
  

	 	(a)	the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate Abbott Canada corporate action;

  

	 	(b)	this Agreement is a legal and valid obligation binding upon Abbot Canada and enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement
by the Parties does not conflict with any agreement, instrument or understanding to which Abbott Canada is a party of or by which it is bound. 

  

	 	(c)	Abbott Canada has the capacity to fulfill all the obligations under this Agreement and all obligations pursuant to its appointment as a Sub-Distributor. 

  

	 	(d)	Abbott Canada warrants that it shall Commercialize and Develop Product in accordance with Laws. 

 13.4 No Warranties 
  

	 	(a)	Nothing in this Agreement is or shall be construed as: 

  

	 	(i)	a warranty or representation by any Party as to the validity or scope of any patent application or patent licensed hereunder; or 

  

	 	(ii)	a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted pursuant to this Agreement is or will be free from infringement of
patents, copyrights, and other rights of third parties. 

  

	 	(b)	Except as expressly set forth in this Agreement, NO PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO
EXPRESS OR IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR OF NON-INFRINGEMENT OF ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES, OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES.

  

 -34- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	14.	PRODUCT RECALL 

 In the event that (i) the Regulatory Authority
or any other governmental agency or authority issues a request or orders that the Product be recalled, (ii) a court of competent jurisdiction in Territory orders that the Product be recalled, or (iii) Supplier reasonably determines, after
consultation with Purchaser, that the Product should be recalled in the Territory or a notice is required relating to restrictions on use of the Product, Purchaser and Abbott Canada shall attend to the same, as determined by the mutual agreement of
Supplier and Purchaser, and the Parties shall take all appropriate corrective action. In the event such action results from: (a) Supplier’s negligence or willful misconduct, Supplier shall be responsible for the expenses thereof,
(b) Purchaser’s and/or Abbott Canada’s negligence or willful misconduct, Purchaser shall be responsible for the expenses thereof; and (c) otherwise, the Supplier and Purchaser shall share equally the expenses of the action. For
purposes of this Agreement, the expenses of the action shall be the expenses of notification and return or destruction (if authorized by Supplier) of the Product, the cost of replacement of the Product, and any costs directly associated with the
distribution of replacement Products. Supplier, Purchaser and Abbott Canada shall cooperate fully with one another in carrying out such action. 
 15.
INDEMNIFICATION 
 15.1 Indemnification 
 (a) Purchaser Indemnity. Purchaser shall indemnify, defend and hold harmless Supplier, its Affiliates and their respective directors, officers, employees, stockholders and agents and their respective successors, heirs and assigns
(the “Supplier Indemnitees”) from and against any liability, damage, loss or expense (including reasonable legal fees and expenses of litigation) incurred by or imposed upon such Supplier Indemnitees, or any of them, in connection with any
Third Party claims, suits, actions, demands or judgments, including, without limitation, personal injury and product liability matters, to the extent arising out of (i) the Development or Commercialization of the Product by Purchaser or
Sub-Distributors including, (A) any actions taken or inactions or omissions by Purchaser, Abbott Canada or its Sub-Distributors related to obtaining or filing for Regulatory Approvals, or (B) any actual or alleged injury to a Person or
property or death resulting from Purchaser’s, Abbott Canada’s or its Sub-Distributors negligence in the storage, handling, transportation, maintenance or other activity related to the Development and/or Commercialization of the Product,
(ii) any material breach of this Agreement by Purchaser or Abbott Canada, (iii) the gross negligence or willful misconduct on the part of Purchaser or Sub-Distributor, or (iv) the Manufacturing of the Product pursuant to
Purchaser’s exercise of its rights under Section 5 above or the packaging of the Product pursuant to Purchaser’s exercise of its rights under Section 3.2(d) above. 
 (b) Supplier Indemnity. Supplier shall indemnify, defend and hold harmless Purchaser, its Affiliates and their respective directors, officers,
employees, and agents, 

  

 -35- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
and their respective successors, heirs and assigns (the “Purchaser Indemnitees”), from and against any liability, damage, loss or expense
(including reasonable legal fees and expenses of litigation) incurred by or imposed upon such Purchaser Indemnitees, or any of them, in connection with (y) any claims, suits, actions, demands or judgments to the extent arising out of
(i) any material breach of this Agreement by Supplier, (ii) the gross negligence or willful misconduct on the part of Supplier, or (iii) any breach or inaccuracy of any representation, warranty, or guarantee given by Supplier
contained in this Agreement or (z) any Third Party product liability claims resulting from the use or consumption in accordance with the product insert by any person of any Product supplied by Supplier under this Agreement, unless (A) the
Third Party damages were caused or materially contributed to by Purchaser’s or Abbott Canada’s storage, handling, transportation, manufacture, maintenance or other activity related to the Development and/or Commercialization of the Product
by Purchaser or Abbott Canada, or (B) such Third Party product liability claim is for reimbursement for the purchase price or disgorgement of Purchaser’s or Abbott Canada’s profits or revenues. 
 (c) In order to provide for just, equitable and conscionable contribution in circumstances in which the indemnification provided for in Sections 15.1(a)
and 15.1(b) both apply in accordance with their respective terms, the Parties agree to the extent mandated by a court of law or as otherwise ordered or agreed to by the Parties to contribute proportionally to the aggregate losses resulting from
demands, claims, actions, causes of action, suits, proceedings, hearings or investigations of Third Parties. 
 15.2 Indemnification
Procedures. In the event that any Indemnitee is seeking indemnification under Section 15.1 above from a Party (the “Indemnifying Party”), the other Party shall notify the Indemnifying Party of such claim with respect to such
Indemnitee as soon as reasonably practicable after the Indemnitee receives notice of the claim, and the Party (on behalf of itself and such Indemnitee) shall permit the Indemnifying Party to assume direction and control of the defense of the claim
(including the right to settle the claim solely for monetary consideration) and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. The indemnification obligations under Article 15 shall not apply to
any harm suffered as a direct result of any delay in notice to the Indemnifying Party hereunder or to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnifying
Party, which consent shall not be withheld or delayed unreasonably. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnifying Party and its legal representatives in the investigation of any claim, demand, action or
other proceeding covered by Section 15.1. 
  

	16.	TERM AND TERMINATION 

 16.1 Term. Unless
earlier terminated in accordance with the terms of this Section 16, the term of this Agreement shall commence on the Effective Date and shall mean the period commencing on the Effective Date and continuing until the expiration of the last Valid
Claim of the Patent Rights in the Territory to the extent necessary for the Manufacture, use or sale of the Product (the “Initial Term”) and shall automatically renew for successive [*] year periods (each, a “Renewal Term”; the
Initial Term and any Renewal Term are hereinafter collectively referred to as the “Term”), unless Purchaser gives written notice of termination to Supplier at least one hundred and eighty (180) days prior to the end of the Initial
Term or Renewal Term, as the case may be. 
  

 -36- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 16.2 Termination Rights for Breach. Subject to the other terms of this Agreement, this Agreement and the
rights and options granted herein may be terminated (i) by Supplier upon any material breach by Purchaser or Abbott Canada, or (ii) by Purchaser upon any material breach by Supplier, of any material obligation or condition, effective ten
(10) days after giving written notice to the breaching Party of such termination in the case of a payment breach and thirty (30) days after giving written notice to the breaching Party of such termination in the case of any other breach,
which notice shall describe such breach in reasonable detail. The foregoing notwithstanding, if such default or breach is cured or remedied or shown to be non-existent within the aforesaid ten (10) or thirty (30) day period, the notice
shall be automatically withdrawn and of no effect. 
 16.3 Termination for Bankruptcy. In the event that either Supplier or Purchaser
files for protection under bankruptcy laws, makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act or has any such
petition filed against it which is not discharged within sixty (60) days of the filing thereof, then the other may terminate this Agreement effective immediately upon written notice to such Party. 
 16.4 Supplier Right to Terminate. Subject to Section 19.8, Supplier shall have the right to terminate this Agreement, if: (i) Purchaser or
Abbott Canada challenges the validity of any of the Intellectual Property related to the Product, (ii) Abbott Canada has not launched the Product in the Territory on or before [*] months from the date of execution of this Agreement,
(iii) Purchaser does not spend at least $[*] million on advertising and promotional expenses for the Product during the first year after First Commercial Sale, (iv) Purchaser does not spend during the second year after First Commercial
Sale, an amount equal to at least [*]% of the actual advertising and promotional expenses incurred by Purchaser during the first year after First Commercial Sale; (v) Purchaser does not spend during the third year after First Commercial Sale,
an amount equal to at least [*]% of the actual advertising and promotional expenses incurred by Purchaser during the first year after First Commercial Sale, or (vi) the annual minimum Detailing thresholds (calculated on a PDE basis) set forth
below is not achieved by Purchaser: 
  

			
	 First Launch Date Year
	  	 Number of Planned Details

	 First year after Launch Date
	  	[*] Planned PDEs
		
	 Second year after Launch Date
	  	[*]% of the number of PDEs actually conducted by Purchaser during the first year after Launch
		
	 Third Year after Launch Date
	  	[*]% of the number of PDEs actually conducted by Purchaser during the first year after Launch

  

 -37- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Calculation of the amounts set out in the table above shall be based on Purchaser’s internal automated call
reporting system reports, and may be verified by Supplier pursuant to Supplier’s audit rights provided herein. 
 16.5 Purchaser Right to
Terminate. Purchaser shall have the right to terminate this Agreement upon ten (10) days notice to the Supplier in the event Regulatory Approval is not obtained for the Product for the [*] indication within [*] months of submission for
such Regulatory Approval.  
 16.6 Effects of Termination. 
  

	 	(a)	Termination for Breach. Upon termination of this Agreement pursuant to this Section 16, as of the effective date of such termination, all relevant licenses and
sublicenses granted by Supplier to Purchaser hereunder shall terminate automatically and Purchaser and Abbott Canada shall cease Commercializing or Developing the Product or using the Trademarks. 

  

	 	(b)	Within ten (10) days of delivery or receipt of a notice of termination by Purchaser pursuant to Section 16.2 or 16.3, Purchaser shall have the option to terminate all
unfilled orders for Products and, if such option is exercised, then all unfilled orders for Products shall be deemed cancelled without any rights or recourses whatsoever against any party hereto. 

  

	 	(c)	Sell-off Period. Notwithstanding the foregoing, Purchaser and Abbott Canada shall have the right, for sixty (60) days or such longer time period (if any) on which the
Parties mutually agree in writing taking into account the Product purchased pursuant to Sections 16.6(d) and 16.6(f), to sell or otherwise dispose of all Products ordered pursuant to this Agreement and then on hand. 

  

	 	(d)	Upon the expiration of the Term or in the event of the termination of this Agreement by Supplier pursuant to Section 16.2 or 16.3, Purchaser agrees to purchase from Supplier a
maximum of [*] tablets of Product having a shelf life of no less than [*] months, at a price per Product tablet equal to Supplier’s actual cost to Manufacturer and package such Product. Notwithstanding the foregoing, Purchaser shall accept
Risk-Dated Product in accordance with the terms set out in Section 4.7 and shall accept Product with more than [*] months of shelf life but less than [*] months of shelf life (the “Liquidation Product”) at the time of delivery
in which case Purchaser will use Diligent Efforts to sell the Liquidation Product in the ordinary course of its business and Supplier shall be obligated to repurchase from Purchaser all of the Liquidation Product the Purchaser is unable to sell and
which has less than [*] months of shelf life at the price paid for such Liquidation Product. 

  

	 	(e)	 Transfer of Documentation. Upon the expiration of the Term or in the event of the termination of this Agreement for any other reason, Purchaser and Abbott
Canada shall immediately deliver to Supplier, or such other person as it may designate, all promotional material, including catalogues, Product price lists, and any other 

  

 -38- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	 
documents or material (including any material delivered in electronic form and Confidential Information) provided by Supplier to Purchaser or Abbott Canada
with respect to the Product or its Commercialization in the Territory. 

  

	 	(f)	Sale of Safety Stock Inventory. Upon the expiration of the Term or in the event of the termination of this Agreement by the Purchaser pursuant to Section 16.5 or by
Supplier pursuant to Section 16.2, 16.3 or 16.4, Purchaser agrees to purchase from Supplier all of the Safety Stock Inventory in accordance with the terms and conditions set forth in Sections 4.6 and 4.7. 

 16.7 Remedies. Except as otherwise expressly set forth in this Agreement, the termination provisions of this Article 16 are in addition to any
other relief and remedies available to the Parties at law. 
 16.8 Surviving Provisions. Notwithstanding any provision herein to the contrary,
the rights and obligations of the Parties set forth in Sections 1, 2.2(d), 2.3, 2.5, 9.1, 10, 11, 13.4, 15, 16, 17, 19 and 20 (solely with respect to guaranty of obligations which survive termination or expiration of the Agreement, as well as
any rights or obligations otherwise accrued hereunder (including any accrued payment obligations), shall survive the expiration or termination of the Term. Without limiting the generality of the foregoing, Purchaser shall have no obligation to make
any milestone or royalty payment to Supplier that has not accrued prior to the effective date of any termination of this Agreement, but shall remain liable for all such payment obligations accruing prior to the effective date of such termination.

  

	17.	DISPUTES 

 17.1 Negotiation. The Parties
recognize that a bona fide dispute as to certain matters may from time to time arise during the term of this Agreement which relates to any Party’s rights and/or obligations hereunder. In the event of the occurrence of such a dispute, any Party
may, by written notice to the other Parties, have such dispute referred to their respective senior officials designated below or their successors, for attempted resolution by good faith negotiations within thirty (30) days after such notice is
received. Said designated senior officials are as follows: 
 For Purchaser: General Manager of Abbott Canada or a delegate with similar
authority to bind Purchaser and Abbott Canada 
 For Supplier: Chief Executive Officer 
 For Abbott Canada: General Manager of Abbott Canada or a delegate with similar authority to bind Purchaser and Abbott Canada 
 In the event the designated senior officials are not able to resolve such dispute within the thirty (30) day period, such dispute shall be referred
to arbitration in accordance with Section 17.2 hereof. 
  

 -39- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 17.2 Arbitration. Subject to Section 17.1, any dispute, controversy or claim initiated by any Party
arising out of, resulting from or relating to this Agreement, or the performance by another Party of its obligations under this Agreement (other than bona fide third party actions or proceedings filed or instituted in an action or proceeding by a
third party against a Party), whether before or after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a Party shall decide to institute arbitration proceedings, it shall give written notice to that effect to
the other Parties. Any such arbitration shall be conducted under the Commercial Arbitration Rules of the American Arbitration Association by a panel of three arbitrators appointed in accordance with such rules. Any such arbitration shall be held in
Boston Massachusetts. The method and manner of discovery in any such arbitration proceeding shall be governed by the laws of the Commonwealth of Massachusetts. The arbitrators shall have the authority to grant injunctions and/or specific
performance and to allocate amongst the Parties the costs of arbitration in such equitable manner as they determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such court for
judicial acceptance of any award and an order of enforcement, as the case may be. In no event shall a demand for arbitration be made after the date when institution of a legal or equitable proceeding based upon such claim, dispute or other matter in
question would be barred by the applicable statute of limitations. Notwithstanding the foregoing, any Party shall have the right, without waiving any right or remedy available to such Party under this Agreement or otherwise, to seek and obtain from
any court of competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such Party, pending the selection of the arbitrators hereunder or pending the arbitrators’ determination
of any dispute, controversy or claim hereunder. 
  

	18.	NON-COMPETITION 

 During the Term, each of Purchaser, Abbott Canada
and any of their respective Affiliates agree for itself and on behalf of their directors, officers and employees that it and they shall not directly or indirectly Commercialize or Develop in the Territory the following products: 
  

	 	(a)	products which are members of the [*]; provided that, Purchaser, Abbott Canada and their respective Affiliates may directly or indirectly Commercialize or Develop products approved
by the Canadian Regulatory Authorities for [*] upon rejection by the Canadian Regulatory Authorities of a supplemental drug application for the Product for the [*] indication; and 

  

	 	(b)	products which are members of the [*] provided, that (i) Supplier files prior to August 1, 2009 a new or supplemental drug application with the Canadian Regulatory
Authorities for the Product in such indication, and (ii) a notice of compliance with respect thereto is obtained within twenty-four (24) months of such submission. 

  

	19.	MISCELLANEOUS 

 19.1 Notification. All notices,
requests and other communications hereunder shall be in writing, shall be addressed to the receiving Party’s address set forth below or to such other address as a Party may designate by notice hereunder, and shall be either (i) delivered
by hand, (ii) made by facsimile transmission (to be followed with written fax confirmation), (iii) sent by private courier service providing evidence of receipt, or (iv) sent by registered or certified mail, 

  

 -40- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
return receipt requested, postage prepaid. The addresses and other contact information for the Parties are as follows: 
  

			
	 If to Supplier:
	  	 Oscient Pharmaceutical Corporation
 1000 Winter Street, Suite 2200
 Waltham, MA 02451
 Attention: Chief Executive Officer

	 With a copy to:
	  	 Oscient Pharmaceutical Corporation
 1000 Winter Street, Suite 2200
 Waltham, MA 02451
 Attention: Legal

	 If to Purchaser:
	  	 Abbott International, LLC
 200
Abbott Park Road
 Dept 64E, AP34-1
 Abbott Park, IL 60064-6194

	 If to Abbott Canada
	  	 Abbott Laboratories, Limited
 8401
Trans-Canada Highway
 St. Laurent, Québec H4S 1Z1
 Attention: The President

	 With a copy to:
	  	 Abbott Laboratories, Limited
 8401
Trans-Canada Highway
 St. Laurent, Québec H4S 1Z1
 Attention: Legal

 All notices, requests and other communications hereunder shall be deemed to have been given either (i) if by
hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by telecopy or facsimile transmission, at the time that receipt thereof has been acknowledged by the recipient,
(iii) if sent by private courier, on the day such notice is delivered to the recipient, or (iv) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made. 
 19.2 Language.
This Agreement has been prepared in the English language and the English language shall control its interpretation. 
 19.3 Governing
Law. This Agreement will be construed, interpreted and applied in accordance with the laws of the State of New York (excluding its body of law controlling conflicts of law). 
 19.4 Entire Agreement. This is the entire Agreement between the Parties with respect to the subject matter hereof and supersedes all prior
representations, understandings and agreements between the Parties with respect to the subject matter hereof. No modification shall be effective unless in writing with specific reference to this Agreement and signed by the Parties. 
  

 -41- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 19.5 Waiver. The terms or conditions of this Agreement may be waived only by a written
instrument executed by the Party waiving compliance. The failure of any Party at any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by any Party of any
condition or term shall be deemed as a continuing waiver of such condition or term or of another condition or term. 
 19.6
Headings. Section and subsection headings are inserted for convenience of reference only and do not form part of this Agreement. 
 19.7 Assignment. Neither this Agreement nor any right or obligation hereunder may be assigned, delegated or otherwise transferred, in whole or part, by any Party without the prior express written consent of the
others; provided, however, that Supplier or Purchaser may without the written consent of the other or of any Sub-Distributor, assign this Agreement and its rights and delegate its obligations hereunder to its Affiliates, or in connection with the
transfer or sale of all or substantially all of such Party’s assets or business, or in the event of its merger, consolidation, change in control or similar transaction. Any permitted assignee shall assume all obligations of its assignor under
this Agreement. Any purported assignment in violation of this Section 19.7 shall be void. The terms and conditions of this Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the Parties.

 19.8 Force Majeure. 
  

	 	(a)	No Party shall be liable for failure of or delay in performing obligations set forth in this Agreement (excluding any payment obligation under this Agreement), and no Party shall be
deemed in breach of its obligations, if such failure or delay is due to natural disasters, labour strikes or any causes beyond the reasonable control of such Party. In event of such force majeure, the Party affected thereby shall given prompt notice
to the other Parties and use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 

  

	 	(b)	It is agreed and understood by the Parties that a product liability claim or clinical trial results sponsored by Supplier that have negative safety results in respect of the Product
which would reasonably be expected to a have material adverse event on the Commercialization of the Product in the Territory shall constitute an event of force majeure and in any such event, the Parties may collaborate with each other and meet in
order to discuss and conclude arrangements in order to minimize the consequences of such force majeure and ensure that the spirit and intent of this Agreement are respected to the extent possible. Such collaborative efforts shall also include, to
the extent necessary, good faith negotiation of the milestones, performance criteria and other terms and conditions of this Agreement to ensure that the rights and entitlements of each Party under this Agreement are not materially affected by the
continuation of such event of force majeure. 

 19.9 Construction. The Parties hereto acknowledge and agree that:
(i) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting
Party shall not be employed in the interpretation of this Agreement; 

  

 -42- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
and (iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party,
regardless of which Party was generally responsible for the preparation of this Agreement. 
 19.10 Severability. If any
provision(s) of this Agreement are or become invalid, are ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the Term hereof, it is the intention of
the Parties that the remainder of this Agreement shall not be affected thereby. The Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof in good faith in order to provide a reasonably acceptable alternative
to the term, covenant or condition of this Agreement or the application thereof that is invalid, illegal or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to be effectuated. 
 19.11 Status. Nothing in this Agreement is intended or shall be deemed to constitute a partner, agency, employer-employee, or joint venture
relationship among the Parties. 
 19.12 Limitation of Liability. EXCEPT FOR ANY BREACH OF ANY CONFIDENTIALITY OBLIGATIONS OR DUE TO A
PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, IN NO EVENT SHALL ANY PARTY BE LIABLE TO THE OTHERS OR ANY OF THEIR AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS, BUSINESS
OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE. 
 19.13 Export Compliance. 
 (a) Purchaser and/
Abbott Canada shall be responsible for the importation of the Product into the Territory, in its name as importer of record, and shall obtain at its expense, all permits and authorizations, and shall comply with all Canadian customs laws,
regulations and official standards applicable to such importation. Supplier agrees to provide a certificate of origin for the Product, as requested by Purchaser for purposes of importing the Product into the Territory. 
 (b) Purchaser and Abbott Canada shall comply with all Canadian and United States laws and regulations controlling the export of certain commodities and
technical data, including without limitation all Export Administration Regulations of the United States Department of Commerce (collectively, “Export Control Laws”). Among other things, these laws and regulations prohibit or require a
license for the export of certain types of commodities and technical data to specified countries. Purchaser hereby gives written assurance that it will comply with, and will cause its Affiliates and Sub-Distributor to comply with, all Export Control
Laws, that it bears sole responsibility for any violation thereof by itself or its Affiliates or Sub-Distributors, and that it will indemnify, defend, and hold Supplier harmless (in accordance with Section 15) for the consequences of any such
violation. 
  

 -43- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 19.14 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further
instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 19.15 Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 19.16 Third Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any third
party, including any creditor of any Party. No such third party shall obtain any right under any provision of this Agreement or shall by reasons of any such provision make any claim in respect of any debt, liability or obligation (or otherwise)
against any Party. 
 19.17 Non-Solicitation Until the one (1) year anniversary of the termination or expiration of this Agreement,
no Party nor its respective Affiliates shall, and shall cause each of its Affiliates not to, directly or indirectly, without the other Parties’ prior written consent, solicit the employment of any employee (or former employee bound by a
non-competition obligation) of the other Parties or their respective Affiliates with whom it has come in contact in conducting activities under this Agreement; provided, however, that the foregoing provisions shall not apply to a general
advertisement or solicitation program that is not specifically targeted at such persons. 
 19.18 United Nations Convention on Sale of
Goods. The United Nations Convention on Sale of Goods is hereby expressly excluded from application to this Agreement. 
  

	20.	PARENT OBLIGATIONS. 

 Abbott Laboratories (“Abbott US”)
hereby guarantees for the benefit of Supplier the performance by Purchaser of Purchaser’s obligations under this Agreement. If Purchaser fails to perform when due any of its obligations to Supplier under this Agreement, upon notice from
Supplier, Abbott U.S. shall promptly assume or cause the performance of such obligation(s). The obligations of Abbott U.S. under this Section 20 are continuing and irrevocable, and Abbott U.S. waives any failure or delay by Supplier in
asserting or enforcing any of its rights or making any claims or demands against Purchaser before demanding performance by Abbott U.S. hereunder. 
 [Remainder of page intentionally left blank] 
  

 -44- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representative in two (2) originals. 
  

									
	ABBOTT INTERNATIONAL, LLC	 		 	OSCIENT PHARMACEUTICALS CORPORATION
					
	By:	 	/s/ Stafford O’Kelly	 		 	 By:
	 	/s/ Steven M. Rauscher
					
	 Title:
	 	 Vice President
	 		 	 Title:
	 	 President and Chief Executive Officer

 ABBOTT LABORATORIES,LTD. (for purposes of Sections 1.1, 2.3, 2.5, 3.2(b), 3.3(c), 7, 8.2, 8.4, 9.4, 11, 13.3,
16, 18 and 19 only) 

			
		
	By:	 	/s/ Marcelo Vizio
		
	 Title:
	 	 General Manager

 ABBOTT LABORATORIES (for the purpose of Section 20 only) 

			
		
	By:	 	/s/ Stafford O’Kelly
		
	 Title:
	 	 Vice President

  

 -45- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Schedule A 
 Specifications 
 [*] [2 pages omitted] 

 Schedule B 
 Trademarks 
 [*] 

 Schedule C 
 Patents 
 FACTIVE® Patent Portfolio in Canada 
 [*] 

 Schedule D 
 Next Year Transfer Price Determination 
 [*] [1 page omitted] 
  

 Schedule E 
 Transfer Price Quarterly Reconciliation 
 [*] [1 page omitted]Revenue Interest Assignment Agreement

 Exhibit 10.2 
 REVENUE INTERESTS ASSIGNMENT AGREEMENT 
 Dated as of July 21, 2006 
 and 
 Restated as of August 18, 2006

 between 
 OSCIENT
PHARMACEUTICALS CORPORATION, 
 GUARDIAN II ACQUISITION CORPORATION 
 and 
 PAUL ROYALTY FUND HOLDINGS II 
  

 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted
version of this exhibit has been filed separately with the Commission. 

 Table of Contents 
  

					
	 	  	 	  	Page
	 ARTICLE I DEFINITIONS
	  	1
			
	 Section 1.01
	  	 Definitions
	  	1
		
	 ARTICLE II ASSIGNMENT OF INTERESTS
	  	15
			
	 Section 2.01
	  	 Assignment
	  	15
			
	 Section 2.02
	  	 Payments by the Assignors
	  	15
			
	 Section 2.03
	  	 Purchase Price
	  	16
			
	 Section 2.04
	  	 No Assumed Obligations
	  	16
		
	 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE ASSIGNORS
	  	16
			
	 Section 3.01
	  	 Organization
	  	16
			
	 Section 3.02
	  	 Corporate Authorization
	  	16
			
	 Section 3.03
	  	 Governmental Authorization
	  	17
			
	 Section 3.04
	  	 Ownership
	  	17
			
	 Section 3.05
	  	 Financial Statements
	  	18
			
	 Section 3.06
	  	 No Undisclosed Liabilities
	  	18
			
	 Section 3.07
	  	 Solvency
	  	18
			
	 Section 3.08
	  	 Litigation
	  	18
			
	 Section 3.09
	  	 Compliance with Laws
	  	18
			
	 Section 3.10
	  	 Conflicts
	  	19
			
	 Section 3.11
	  	 Subordination
	  	19
			
	 Section 3.12
	  	 Intellectual Property
	  	19
			
	 Section 3.13
	  	 Regulatory Approval
	  	22
			
	 Section 3.14
	  	 Material Contracts
	  	23
			
	 Section 3.15
	  	 Place of Business
	  	24
			
	 Section 3.16
	  	 Broker’s Fees
	  	24
			
	 Section 3.17
	  	 Insurance
	  	24
		
	 ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PRF
	  	24
			
	 Section 4.01
	  	 Organization
	  	24
			
	 Section 4.02
	  	 Authorization
	  	24
			
	 Section 4.03
	  	 Broker’s Fees
	  	24
			
	 Section 4.04
	  	 Conflicts
	  	24

  

 -i- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Table of Contents 
 (continued) 
  

					
	 	  	 	  	Page
	 ARTICLE V COVENANTS
	  	25
			
	 Section 5.01
	  	 Consents and Waivers
	  	25
			
	 Section 5.02
	  	 Access; Information
	  	25
			
	 Section 5.03
	  	 Material Contracts
	  	26
			
	 Section 5.04
	  	 Confidentiality; Public Announcement
	  	26
			
	 Section 5.05
	  	 Security Agreement
	  	27
			
	 Section 5.06
	  	 Best Efforts; Further Assurance
	  	27
			
	 Section 5.07
	  	 Call, Put and Buy-Down Options
	  	28
			
	 Section 5.08
	  	 Remittance to Deposit Accounts
	  	29
			
	 Section 5.09
	  	 Out-License Agreements
	  	32
			
	 Section 5.10
	  	 Intellectual Property.
	  	32
			
	 Section 5.11
	  	 Negative Covenants
	  	32
			
	 Section 5.12
	  	 Other Agreements
	  	33
			
	 Section 5.13
	  	 Genesoft Consent/Cash Balance
	  	33
			
	 Section 5.14
	  	 Insurance
	  	34
			
	 Section 5.15
	  	 Notice
	  	34
			
	 Section 5.16
	  	 Use of Proceeds.
	  	34
		
	 ARTICLE VI THE CLOSING; CONDITIONS TO CLOSING
	  	35
			
	 Section 6.01
	  	 Closing
	  	35
			
	 Section 6.02
	  	 Conditions Applicable to PRF
	  	35
			
	 Section 6.03
	  	 Conditions Applicable to the Assignors
	  	37
		
	 ARTICLE VII TERMINATION
	  	38
			
	 Section 7.01
	  	 Termination Date
	  	38
			
	 Section 7.02
	  	 Effect of Termination
	  	38
		
	 ARTICLE VIII MISCELLANEOUS
	  	38
			
	 Section 8.01
	  	 Survival
	  	38
			
	 Section 8.02
	  	 Specific Performance
	  	39
			
	 Section 8.03
	  	 Notices
	  	39
			
	 Section 8.04
	  	 Successors and Assigns
	  	40

  

 -ii- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Table of Contents 
 (continued) 
  

					
	 	  	 	  	Page
			
	 Section 8.05
	  	 Indemnification
	  	40
			
	 Section 8.06
	  	 Independent Nature of Relationship
	  	41
			
	 Section 8.07
	  	 Federal Tax
	  	42
			
	 Section 8.08
	  	 Entire Agreement
	  	42
			
	 Section 8.09
	  	 Amendments; No Waivers
	  	42
			
	 Section 8.10
	  	 Interpretation
	  	43
			
	 Section 8.11
	  	 Headings and Captions
	  	43
			
	 Section 8.12
	  	 Counterparts; Effectiveness
	  	43
			
	 Section 8.13
	  	 Severability
	  	43
			
	 Section 8.14
	  	 Expenses
	  	43
			
	 Section 8.15
	  	 Governing Law; Jurisdiction
	  	43
			
	 Section 8.16
	  	 Waiver of Jury Trial
	  	44

  

 -iii- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXHIBITS 
  

					
	 Exhibit A
	  	–	  	Antara Purchase Agreement
	 Exhibits B-1 and B-2
	  	–	  	Forms of Assignments of Interests
	 Exhibits C-1 and C-2
	  	–	  	Forms of Deposit Agreements
	 Exhibit D
	  	–	  	Form of Security Agreement
	 Exhibit E
	  	–	  	Legal Opinion of Ropes & Gray LLP (transaction opinion)
	 Exhibit F-1
	  	–	  	Legal Opinion of Ropes & Gray LLP (IP opinion-Antara)
	 Exhibit F-2
	  	–	  	Legal Opinion of Hamilton Brook Smith and Reynolds (IP opinion-Factive)
	 Exhibit G
	  	–	  	Stock Purchase Agreement
	 Exhibit H
	  	–	  	Note Purchase Agreement
	 Exhibit I
	  	–	  	Form of Warrant

  

 -iv- 

 REVENUE INTERESTS ASSIGNMENT AGREEMENT 
 This REVENUE INTERESTS ASSIGNMENT AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”)
is made and entered into as of July 21, 2006 by and among Oscient Pharmaceuticals Corporation, a Massachusetts corporation (the “Company”), Guardian II Acquisition Corporation, a wholly-owned Delaware subsidiary of the Company,
and Paul Royalty Fund Holdings II, a California general partnership (“PRF”). 
 WHEREAS, each of the Assignors (as
defined below) wishes to sell, assign, convey and transfer to PRF, and PRF wishes to purchase from the Assignors, the Assigned Interests (as hereinafter defined), upon and subject to the terms and conditions hereinafter set forth. 
 NOW, THEREFORE, in consideration of the mutual covenants, agreements representations and warranties set forth herein, the parties hereto agree as
follows: 
 ARTICLE I 
 DEFINITIONS 
 Section 1.01 Definitions. 
 The following terms, as used herein, shall have the following meanings: 
 “Affiliate” shall mean any Person that controls, is controlled by, or is under common control with another Person. For purposes of this definition, “control” shall mean (i) in
the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (ii) in the case of non-corporate entities, direct or indirect
ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. 
 “Aggregate Deposit Funds” shall mean any and all financial assets, funds, monies, checks or other items deposited into the Joint Accounts. 
 “Agreement” shall have the meaning set forth in the first paragraph hereof. 
 “Antara” shall mean any product used for treating patients with hypercholesterolemia, mixed dyslipidemia or hypertriglyceridemia which
includes: (i) the formulation of fenofibrate, known as 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester; or (ii) any formulation, reformulation or line extension containing fenofibrate as an active ingredient,
or any derivative or closely related analogs of fenofibrate (including but not limited to any stereoisomers, either separated or combined, any hydrates, any polymorphs, any salts, any solvates and any crystal forms) approved by the FDA as
monotherapy or in combination with any other pharmaceutical substance that is made, developed, sold, offered for sale, distributed, marketed or promoted by the Company, its Affiliates or Licensees. 
 “Antara Purchase Agreement” shall mean that certain Asset Purchase Agreement by and among the Company, Guardian and Reliant
Pharmaceuticals, Inc. dated as of the date hereof, including the exhibits specifically listed therein, attached hereto as Exhibit A. 
  

 -1- 

 “applicable Deposit Accounts” shall have the meaning set forth in
Section 5.08(h). 
 “Applicable Percentage” shall mean, as of any date of determination, on a Fiscal
Year-by-Fiscal Year basis (or applicable portion thereof in the first and last Fiscal Years under this Agreement), during the Revenue Interest Period, 
 (a) prior to the date that the cumulative payments received and retained (i.e., not refunded by PRF) by PRF under Sections 2.02, 5.07(c) and 5.08 first exceed [*] percent ([*]%) of the cumulative
payments made by PRF under Section 2.03, the following: 
 (i) with respect to Net Revenues of up to and including
[*]dollars ($[*]),[*] percent ([*]%); 
 (ii) with respect to Net Revenues in excess of [*]dollars ($[*]) but less than and
including [*] dollars ($[*]), [*] percent ([*]%); and 
 (iii) with respect to Net Revenues in excess of [*] dollars
($[*]),[*] percent ([*]%); and 
 (b) from and after the date that the cumulative payments received and retained (i.e., not
refunded by PRF) by PRF under Sections 2.02, 5.07(c) and 5.08 are at least [*] percent ([*]%) of the cumulative payments made by PRF under Section 2.03, [*] percent ([*]%). 
 For the avoidance of doubt, the percentages set forth in this definition of “Applicable Percentage” are subject to reduction by fifty percent
(50%) pursuant to Section 5.07(c). 
 “Assigned Interests” shall mean PRF’s right to receive amounts equal
to the Applicable Percentage of the Net Revenues pursuant to the terms and conditions of this Agreement. 
 “Assignments of
Interests” shall mean those Assignments of Interests dated the Closing Date pursuant to which each of the Assignors shall assign to PRF all of its rights and interests in and to the Assigned Interests purchased hereunder, which Assignments
of Interests shall be substantially in the forms of Exhibit B-1 and Exhibit B-2. 
 “Assignors” shall mean
collectively the Company and Guardian. 
 “Audit Costs” shall mean, with respect to any audit of the books and records of
the Company and its Subsidiaries with respect to amounts payable or paid under this Agreement, the out – of – pocket cost of such audit payable to third parties, including all fees, costs and expenses incurred in connection therewith.

 “Bankruptcy Event” shall mean the occurrence of any of the following: 
 (i) an Assignor shall commence any case, proceeding or other action (A) under any existing or future law of any jurisdiction,
domestic or foreign, relating to bankruptcy, insolvency, reorganization, relief of debtors or the like, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization,
arrangement, adjustment, winding-up, liquidation, dissolution, composition or 

  

 -2- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
other relief with respect to it or its debts, or (B) seeking appointment of a receiver, trustee, custodian or other similar official for it or for all
or any portion of its assets, or an Assignor shall make a general assignment for the benefit of its creditors; 
 (ii) there
shall be commenced against an Assignor any case, proceeding or other action of a nature referred to in clause (i) above which remains undismissed, undischarged or unbonded for a period of sixty (60) Business Days; 
 (iii) there shall be commenced against an Assignor any case, proceeding or other action seeking issuance of a warrant of attachment,
execution, distraint or similar process against (A) all or any substantial portion of its assets and/or (B) the Products or any substantial portion of the Intellectual Property related to the Products, which results in the entry of an
order for any such relief which shall not have been vacated, discharged, stayed, satisfied or bonded pending appeal within sixty (60) Business Days from the entry thereof; 
 (iv) the failure of an Assignor to take action to object to any of the acts set forth in clauses (ii) or (iii) above within ten
(10) days of such Assignor receiving written notice of such act; or 
 (v) an Assignor shall generally not, or shall be
unable to, or shall admit in writing its inability to, pay its respective debts as they become due. 
 “Business Day” shall
mean any day other than a Saturday, a Sunday, any day which is a legal holiday under the laws of the State of New York, or any day on which banking institutions located in the State of New York are required by law or other governmental action to
close. 
 “Call Option” shall have the meaning set forth in Section 5.07(a). 
 “Call Option Closing Date” shall have the meaning set forth in Section 5.07(a). 
 “Change of Control” shall mean: 
 (i) the bona fide acquisition by any Person or group (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934) of beneficial ownership of any capital stock of the Company, if after
such acquisition, such Person or group would be the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of securities of the Company representing more than fifty percent
(50%) of the combined voting power of the Company’s then outstanding securities entitled to vote generally in the election of directors; 
 (ii) the consummation after approval by the Company’s stockholders of a bona fide merger or consolidation of the Company, with any other Person, other than a merger or consolidation which would result in the
Company’s voting securities outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the combined
voting power of the Company’s voting securities or such surviving entity’s voting securities outstanding immediately after such merger or consolidation; 
  

 -3- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (iii) during any period of two (2) consecutive years, individuals who at the
beginning of such period constitute the board of directors of the Company (together with any new directors (other than a director designated by a Person who has entered into an agreement with the Company to effect a transaction described in clause
(i) or (ii) of this definition of “Change of Control”), whose election by such board of directors or nomination for election by the Company’s stockholders, as applicable, was approved by a vote of a majority of the
directors then still in office who either were directors at the beginning of such period or whose election or nomination for election was previously so approved) cease for any reason to constitute at least a majority of the board of directors of the
Company then in office, provided that the circumstances described in this clause (iii) shall not be deemed to be a Change of Control if the directors constituting a majority of the Board of Directors of the Company were elected or appointed in
connection with a merger or consolidation of the Company which is not, pursuant to clause (ii) of this definition, a Change of Control; or 
 (iv) the bona fide sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any of its Subsidiaries of all or substantially all the
assets of the Company and its Subsidiaries taken as a whole or the sale or disposition (whether by merger or otherwise) of one or more Subsidiaries of the Company if substantially all of the assets of the Company and its Subsidiaries taken as a
whole are held by such Subsidiary or Subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned (direct or indirect) Subsidiary of the Company. 
 “Change of Control Notice” shall have the meaning set forth in Section 5.07(b). 
 “Change of Control Period” shall have the meaning set forth in Section 5.07(b). 
 “Closing” shall have the meaning set forth in Section 6.01. 
 “Closing Date” shall have the meaning set forth in Section 6.01. 
 “Collateral” shall mean the property included in the definition of “Collateral” in the Security Agreement. 
 “Company” shall have the meaning set forth in the first paragraph hereof. 
 “Confidential Information” shall mean, as it relates to the Company and its Affiliates and the Products, the Intellectual Property,
confidential business information, financial data and other like information (including ideas, research and development, know-how, formulas, schematics, compositions, technical data, specifications, customer and supplier lists, pricing and cost
information, and business and marketing plans and proposals), inventory, ideas, algorithms, processes, computer software programs or applications (in both source code and object code form), client lists and tangible or intangible proprietary
information or material, or such other information that either party identifies to the other as confidential or the nature of which or the circumstances of the disclosure of which would reasonably indicate that such information is confidential.
Notwithstanding the foregoing definition, Confidential Information shall not include information that (i) is already in the public domain at the time the information is disclosed, (ii) thereafter is obtained from other sources not subject
to confidentiality, or (iii) is required to be disclosed under securities laws, rules and regulations applicable to the Company or its Affiliates or PRF, as the case may be, or pursuant to the rules and regulations of any 

  

 -4- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
securities exchange or trading system or pursuant to any other laws, rules or regulations of any Governmental Authority having jurisdiction over the Company,
its Affiliates or PRF. 
 “Consolidated Cash” shall mean, as of the end of each fiscal month end close, the aggregate
balance of cash and cash equivalents of Assignors on a consolidated basis, less any Restricted Cash. 
 “Daily Amount” shall
have the meaning set forth in Section 2.02(a)(ii). 
 “Debt Condition” shall have the meaning set forth in
Section 6.02(k). 
 “Default” shall mean the occurrence of any event or circumstance that would, with the giving
of notice, lapse of time, or both, be an Event of Default. 
 “Deposit Account (Antara)” shall mean, collectively, any
deposit and segregated deposit accounts established and maintained at the Deposit Bank pursuant to a Deposit Account Control Agreement (Antara) and this Agreement. The Deposit Account (Antara) shall be the account into which all payments made in
respect of the sale or other disposition of Antara are to be remitted. 
 “Deposit Account (Factive)” shall mean,
collectively, any deposit and segregated deposit accounts established and maintained at the Deposit Bank pursuant to a Deposit Account Agreement (Factive) and this Agreement. The Deposit Account (Factive) shall be the account into which all payments
made in respect of the sale or other disposition of Factive are to be remitted. 
 “Deposit Accounts” shall mean,
collectively, the Deposit Account (Antara) and the Deposit Account (Factive). 
 “Deposit Account Control Agreement
(Antara)” shall mean, any agreement entered into by a Deposit Bank, Guardian and PRF as of the Closing Date, substantially, in the form of Exhibit C-1 attached hereto, pursuant to which, among other things, the Deposit Account
(Antara), the Joint Concentration Account (Antara), the PRF Concentration Account (Antara), and Guardian Concentration Account shall be established and maintained. 
 “Deposit Account Agreement (Factive)” shall mean any agreement entered into by a Deposit Bank, the Assignors and PRF as of the Closing Date, substantially in the form of Exhibit C-2 attached
hereto, pursuant to which, among other things, the Deposit Account (Factive), the Joint Concentration Account (Factive), the PRF Concentration Account (Factive), and the Oscient Concentration Account shall be established and maintained. 

“Deposit Agreements” shall mean, collectively, the Deposit Account Control Agreement (Antara) and the Deposit Account Agreement
(Factive). 
 “Deposit Bank” shall mean JPMorgan Chase Bank or such other bank or financial institution approved by each of
PRF and the Company and a party to any Deposit Agreement. 
 “Disputes” shall have the meaning set forth in
Section 3.12(j). 
  

 -5- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 “Drug Approval Application” shall mean an application for Regulatory Approval required
before commercial sale or use of either Product as a drug in a regulatory jurisdiction, including with respect to an NDA or supplemental NDA, or a prior approval supplement to an NDA or any amendments thereto submitted to the FDA. 
 “Equity Condition” shall have the meaning set forth in Section 6.02(k). 
 “Event of Default” shall mean the occurrence of any Put Option Event and any other breach by the Assignors of this Agreement, whether or
not constituting a Put Option Event. 
 “Excluded Liabilities and Obligations” shall have the meaning set forth in
Section 2.04. 
 “Factive” shall mean any orally administered product used for the treatment of bacterial
infections, which includes: (i) the formulation of gemifloxacin mesylate, known as (R,S)-7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]- 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; or (ii) any
formulation, reformulation or line extension containing gemifloxacin mesylate as an active ingredient, or any derivative or closely related analogs of gemifloxacin mesylate (including but not limited to any stereoisomers, either separated or
combined, any hydrates, any polymorphs, any salts, any solvates and any crystal forms) approved by the FDA as monotherapy or in combination with any other pharmaceutical substance that is made, developed, sold, offered for sale, distributed,
marketed or promoted by the Company, its Affiliates or Licensees. 
 “FDA” shall mean the United States Food and Drug
Administration or any successor federal agency thereto. 
 “FDA Approval” shall mean approval by the FDA of the formulation,
manufacture, marketing, sale and distribution of the Products. 
 “Final Payments” shall mean, for any Fiscal Quarter, the
product of the Applicable Percentage and Net Revenues for such quarter. 
 “Financial Statements” shall mean the audited
consolidated balance sheets of the Company and its Subsidiaries at December 31, 2003, December 31, 2004, and December 31, 2005 and the related audited consolidated statements of operations and cash flows and the related audited
consolidated statements of shareholders’ equity and comprehensive income of the Company and its Subsidiaries for the fiscal years ended December 31, 2003, December 31, 2004, and December 31, 2005, and the unaudited
consolidated balance sheet of the Company and its Subsidiaries at March 31, 2006 and the related unaudited consolidated statements of operations and cash flows and the related unaudited consolidated statement of shareholders’ equity and
comprehensive income of the Company and its Subsidiaries for the fiscal quarter ended March 31, 2006 and in each case, the accompanying footnotes thereto. 
 “Fiscal Quarter” shall mean a calendar quarter. 
 “Fiscal Year” shall mean
a calendar year. 
 “Full Buy-Down Option” shall have the meaning set forth in Section 5.07(d). 
  

 -6- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 “Full Buy-Down Option Closing Date” shall have the meaning set forth in
Section 5.07(d). 
 “Full Buy-Down Price” shall mean an amount, when taken together with Payments made prior to
the payment of the Full Buy-Down Price, that would generate an internal rate of return (utilizing the same methodology utilized by the IRR function in Microsoft Excel 2003) to PRF of [*] percent ([*]%) in respect of the PRF Payments. 
 “GAAP” shall mean generally accepted accounting principles in the United States in effect from time to time. 
 “Genesoft Consent” shall have the meaning set forth in Section 5.13. 
 “Genesoft Note Purchase Agreement” shall mean Note Amendment and Exchange Agreement among Genesoft Pharmaceuticals, Inc., Genome
Therapeutics Corp. and the Genesoft Noteholders listed on schedules A and B thereto, dated as of November 17, 2003. 
 “Genesoft
Noteholder” shall mean the noteholders listed on schedules A and B to the Genesoft Note Purchase Agreement. 
 “Governmental
Authority” shall mean any government, court, regulatory or administrative agency or commission, or other governmental authority, agency or instrumentality, whether foreign, federal, state or local (domestic or foreign), including the United
States Patent and Trademark Office, the FDA, the United States National Institutes of Health, or any other government authority in any country. 
 “Gross Product Revenues” with respect to the Products means, for any period of determination, the sum of the following for such period: (i) the amounts invoiced by the Assignors or any of their Affiliates or licensees
or sublicensees to a Third Party with respect to the sale of Products in the Territory by the Assignors or any of their Affiliates or licensees or sublicensees, respectively, and (ii) collections in respect of write-offs or allowances for bad
debts in respect of items described in the preceding clause (i). For the avoidance of doubt, Gross Product Revenues shall not include (x) any amounts invoiced by the Assignors or any of their Affiliates to a Third Party in connection with any
marketing, royalty, co-promotion, development, manufacturing, equity investment, cost sharing or other strategic investment arrangement, or (y) any revenues, investments or service fees in connection with a rights transfer with respect to
either Product permitted hereunder. For purposes of prevention of duplication, “Gross Product Revenue” shall not include amounts invoiced by distributors, wholesalers or other Persons acting in similar capacities. 
 “Guardian” shall mean Guardian II Acquisition Corporation, a Delaware corporation. 
 “Guardian Concentration Account” shall mean a segregated account established and maintained at the Deposit Bank pursuant to the terms of
the Deposit Account Control Agreement (Antara) and this Agreement. The Guardian Concentration Account shall be the account into which the funds remaining in the Joint Concentration Account (Antara) after payment therefrom of the amounts payable to
PRF pursuant to this Agreement are swept in accordance with the terms of this Agreement and the Deposit Account Control Agreement (Antara). 
  

 -7- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 “In-License Agreement” shall have the meaning set forth in the definition of
“Material Contract”. 
 “Intellectual Property” shall mean (i) all proprietary information; trade secrets;
know-how; confidential information; inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a pending patent application) and improvements thereto; registered or unregistered trademarks, trade names,
service marks, including all goodwill associated therewith; registered and unregistered copyrights and all applications thereof; in each case that are owned, controlled by, issued to, licensed to, licensed by or hereafter acquired by or licensed by
the Company or its Subsidiaries, in each case directly relating to a Product, and (ii) the Patents. 
 “Interim Applicable
Percentage” shall mean, as of any date of determination, on a Fiscal Year-by-Fiscal Year basis (or applicable portion thereof in the first and last Fiscal Years under this Agreement), during the Revenue Interest Period, 
 (a) prior to the date that the cumulative payments received and retained (i.e., not refunded by PRF) by PRF under Sections 2.02,
5.07(c) and 5.08 are less than [*] percent ([*]%) the cumulative payments made by PRF under Section 2.03, the following: 
 (i) with respect to Aggregate Deposit Funds in each fiscal year of up to and including [*] dollars ($[*]),[*] percent ([*]%); 
 (ii) with respect to Aggregate Deposit Funds in each fiscal year in excess of [*] dollars ($[*]) but less than and including [*] dollars
($[*]),[*] percent ([*]%); and 
 (iii) with respect to Aggregate Deposit Funds in each fiscal year in excess of [*] dollars
($[*]), [*] percent ([*]%); and 
 (b) from and after the date that the cumulative payments received and retained (i.e., not
refunded by PRF) by PRF under Sections 2.02, 5.07(c) and 5.08 are at least [*] percent ([*]%) the cumulative payments made by PRF under Section 2.03, [*] percent ([*]%). 
 For the avoidance of doubt, the percentages set forth in this definition of “Interim Applicable Percentage” are subject to reduction by fifty percent
(50%) as and to the extent provided in Section 5.07(c) and subject to adjustment pursuant to Section 5.08(f). 
 “Interim Payments” shall mean for any Fiscal Quarter, the product of the Interim Applicable Percentage and the Aggregate Deposit Funds received in such quarter. 
 “Joint Accounts” shall mean, collectively, the Joint Concentration Account (Antara) and the Joint Concentration Account (Factive).

 “Joint Concentration Account (Antara)” shall mean a segregated account, subject to a control agreement in favor of PRF,
established for the benefit of the Company and PRF and maintained at the Deposit Bank pursuant to the terms of the Deposit Control Agreement (Antara) and this Agreement. The Joint Concentration Account (Antara) shall be the account into which the
Deposit Bank sweeps the funds held in the Deposit Account (Antara). 
  

 -8- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 “Joint Concentration Account (Factive)” shall mean a segregated account established for
the benefit of the Company and PRF and maintained at the Deposit Bank pursuant to the terms of the Deposit Account Agreement (Factive) and this Agreement. The Joint Concentration Account (Factive) shall be the account into which the Deposit Bank
sweeps the funds held in the Deposit Account (Factive). 
 “Knowledge” shall mean the actual knowledge of an officer or
employee of the Company or any Affiliates thereof relating to a particular matter. Notwithstanding the foregoing, an officer or employee of the Company or any Affiliate thereof charged with responsibility for the aspect of the business relevant or
related to the matter at issue shall be deemed to have knowledge of a particular matter if, in the prudent exercise of his or her duties and responsibilities in the ordinary course of business, such officer or employee should have known of such
matter. 
 “Licensees” shall mean, collectively, the licensees, sublicensees or distributors under the Out-License
Agreements; each a “Licensee”. 
 “Liens” shall mean any mortgage, deed of trust, pledge, hypothecation,
assignment, security interest, lien (whether statutory or otherwise), charge, claim or encumbrance, or preference, priority or other security agreement or preferential arrangement held or asserted in respect of any asset of any kind or nature
whatsoever including, without limitation, any conditional sale or other title retention agreement, any lease having substantially the same economic effect as any of the foregoing, and the filing of, or agreement to give, any financing statement
under the UCC except: 
 (a) Liens for taxes, assessments or governmental charges not then due and delinquent; 
 (b) Liens incidental to the conduct of business or the ownership of properties and assets (including landlords’, lessors’, carriers’,
warehousemen’s, mechanics’, materialmen’s and encumbrances in the nature of leases, subleases, zoning restrictions, easements, right of way and other rights and restrictions of record on the use of real property and defects in title
arising or incurred in the ordinary course of business, which, individually and in the aggregate, do not materially impair the use or value of the property or assets subject thereto or which relate only to assets that in the aggregate are not
material) and Liens to secure the performance of bids, tenders, lease or trade contracts, or to secure statutory obligations (including obligations under workers compensation, unemployment insurance and other social security legislation), surety or
appeal bonds or other Liens of like general nature incurred in the ordinary course of business and not in connection with the borrowing of money; 
 (c) Any attachment or judgment Lien, unless the judgment it secures has not, within 60 days after the entry thereof, been discharged or execution thereof stayed pending appeal, or has not been discharged within 60 days after the expiration
of any such stay; and 
 (d) Liens securing the Transaction Documents. 
 “Losses” shall mean collectively, any and all claims, damages, losses, judgments, liabilities, costs and expenses (including reasonable
expenses of investigation and reasonable attorneys’ fees and expenses in connection with any action, suit or proceeding). 
  

 -9- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 “Material Adverse Effect” shall mean (i) a material adverse change in the business,
operations, assets or business or financial condition of any of the Company or its Subsidiaries, (ii) a material adverse effect on the validity or enforceability of any of the Transaction Documents, (iii) a material adverse effect on the
ability of an Assignor to perform any of its obligations under any of the Transaction Documents, (iv) a material adverse effect on the rights or remedies of PRF under any of the Transaction Documents, (v) a material adverse effect on the
right of PRF to receive the Assigned Interests or any payment due to PRF hereunder and (vi) a material adverse effect on the Products or the ability of the Company to distribute, market and/or sell the Products; provided, however
the Material Adverse Effect shall exclude any effect resulting from (a) changes to general economic conditions or any occurrence or condition affecting the pharmaceutical industry generally, (b) war, hostilities, military actions or acts
of terrorism or (c) any decision or commitment by the FDA (or any FDA advisory committee) with respect to any of the Company’s pending supplemental NDAs with respect to Factive. 
 “Material Contract” shall mean any contract, agreement or other arrangement to which either the Company or any of its Subsidiaries is a
party or any of the Company’s or its Subsidiaries’ respective assets or properties are bound or committed (other than the Transaction Documents) pursuant to which an Assignor is granted a license to Intellectual Property covering the
Products (each an “In-License Agreement”) or pursuant to which the Product is manufactured or packaged. 
 “NDA”
shall mean a new drug application and all amendments and supplements thereto, submitted to the FDA with respect to the Products. 
 “Net Revenues” with respect to the Products shall mean, for any period of determination, the difference of 
 (a)
Gross Product Revenues for such period, less 
 (b) the sum, with respect to the items described in clause (i) of the definition of
Gross Product Revenues, of 
 (i) cash, trade discounts and wholesaler fee-for service amounts, 
 (ii) Medicaid and Medicare and managed market rebates and chargebacks, 
 (iii) accruals related to ordinary course of business consumer cash vouchers, sample coupon cards and similar types of revenue reserves,

 (iv) allowances and adjustments actually credited to customers for Products that are spoiled, damaged, outdated, obsolete,
returned or otherwise recalled, but only if and to the extent the same are in accordance with sound business practices and not in excess of customary industry standards, 
 (v) charges for freight, postage, shipping, delivery, service and insurance charges, to the extent invoiced, 
 (vi) taxes, duties or other governmental charges to the extent invoiced, and 
  

 -10- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (vii) write-offs or allowances for bad debts. 
 Net Revenues shall be determined in accordance with GAAP as applied by the Company on the date of this Agreement. 
 “Note Purchase Agreement” shall have the meaning set forth in Section 6.02(l). 
 “Note” shall have the meaning set forth in the Note Purchase Agreement. 
 “Obligations” shall mean any and all obligations of the Assignors under the Transaction Documents. 
 “Oscient Concentration Account” shall mean a segregated account established and maintained at the Deposit Bank pursuant to the terms of
the Deposit Account Agreement (Factive) and this Agreement. The Oscient Concentration Account shall be the account into which the funds remaining in the Joint Concentration Account (Factive) after payment therefrom of the amounts payable to PRF
pursuant to this Agreement are swept in accordance with the terms of this Agreement and the Deposit Account Agreement (Factive). 
 “Oscient Indemnified Party” shall have the meaning set forth in Section 8.05(b). 
 “Out-License Agreement” shall mean any existing or future license, development, commercialization, co-promotion, collaboration, distribution, manufacturing, marketing or partnering agreement entered into by an Assignor or
any of its Affiliates relating to either of the Products pursuant to which the Assignors or any of their Affiliates grant a license to distribute or sell either of the Products in the Territory. 
 “Partial Buy-Down Option” shall have the meaning set forth in Section 5.07(c). 
 “Partial Buy-Down Option Closing Date” shall have the meaning set forth in Section 5.07(c). 
 “Partial Buy-Down Price” shall mean an amount, when taken together with fifty percent (50%) of the Payments made prior to the
payment of the Partial Buy-Down Price, that would generate an internal rate of return (utilizing the same methodology utilized by the IRR function in Microsoft Excel 2003) to PRF of [*] percent ([*]%) in respect of fifty percent (50%) of the
PRF Payments. 
 “Patent Office” shall mean the respective patent office, including the United States Patent and Trademark
Office and any comparable foreign patent office, for any Patents. 
 “Patents” shall mean all patents, patent rights, patent
applications, patent disclosures and invention disclosures issued or filed, together with all reissues, divisions, continuations, continuations-in-part, revisions, extensions, and reexaminations thereof relating to the Product, composition of
matter, formulation, or methods of manufacture or use thereof that are issued or filed as of the date hereof or during the Revenue Interest Period, including, without limitation, those identified in Schedule 3.12 in each case, which are owned,
controlled by, issued to, licensed to or licensed by the Company or any of its Affiliates. 
  

 -11- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 “Payments” shall mean cumulative payments made by the Assignors to and received and
retained by PRF pursuant to Sections 2.02, 5.07(c) and 5.08, as applicable. Payments made pursuant to Sections 2.02 and 5.08 shall be deemed to have been received by PRF on the 45th day of the Fiscal Quarter in which such
payments were made. Payments made pursuant to Section 5.07(c) shall be deemed to have been received by PRF on the date such payments were made. 
 “Person” shall mean an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, but not including a government or political subdivision or
any agency or instrumentality of such government or political subdivision. 
 “PRF” shall have the meaning set forth in the
first paragraph hereof. 
 “PRF Concentration Account (Antara)” shall mean a segregated account established for the benefit
of PRF and maintained at the Deposit Bank pursuant to the terms of the Deposit Account Control Agreement (Antara) and this Agreement. The PRF Concentration Account (Antara) shall be the account into which the funds held in the Joint Concentration
Account (Antara) which are payable to PRF pursuant to this Agreement are swept by the Deposit Bank in accordance with the terms of this Agreement and the Deposit Account Control Agreement (Antara). 
 “PRF Concentration Account (Factive)” shall mean a segregated account established for the benefit of PRF and maintained at the Deposit
Bank pursuant to the terms of the Deposit Account Agreement (Factive) and this Agreement. The PRF Concentration Account (Factive) shall be the account into which the funds held in the Joint Concentration Account (Factive) which are payable to PRF
pursuant to this Agreement are swept by the Deposit Bank in accordance with the terms of this Agreement and the Deposit Account Agreement (Factive). 
 “PRF Indemnified Party” shall have the meaning set forth in Section 8.05(a). 
 “PRF Payments” shall mean cumulative payments made by PRF pursuant to Section 2.03. 
 “Products” shall mean Antara and Factive; individually, each a “Product”. 
 “Put/Call
Price” shall mean the greater of: 
 (a) (i) if the Partial Buy-Down Option has not been exercised, an amount, when
taken together with Payments made prior to the payment of the Put/Call Price, that would generate an internal rate of return (utilizing the same methodology utilized by the IRR function in Microsoft Excel 2003) to PRF of [*] percent ([*]%) in
respect of the PRF Payments, or 
 (ii) if the Partial Buy-Down Option has been exercised and the Partial Buy-Down Price has
been paid, an amount, when taken together with fifty percent (50%) of the Payments (exclusive of payments made under Section 5.07(c)) made prior to the payment of the Put/Call Price, that would generate an internal rate of return
(utilizing the same methodology utilized by the IRR function in Microsoft Excel 2003) to PRF of [*] percent ([*]%) in respect of [*] percent ([*]%) of the PRF Payments. 
  

 -12- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (b) if the date of exercise of the Call Option or Put Option, as applicable, is

 (i) on or before December 31, 2007, an amount equal to [*] percent ([*]%) of the PRF Payments as of such date, less an
amount equal to the Payments prior to the payment of the Put/Call Price, or 
 (ii) after December 31, 2007, an amount
equal to [*] percent ([*]%) of the PRF Payments as of such date, less an amount equal to the Payments made prior to the payment of the Put/Call Price. 
 “Put Option” shall have the meaning set forth in Section 5.07(b). 
 “Put Option Closing Date” shall have the meaning set forth in Section 5.07(b). 
 “Put Option
Event” shall mean any one of the following events: 
 (i) any Change of Control; 
 (ii) any Bankruptcy Event; 
 (iii) any Transfer by the Company or any of its Subsidiaries of all or substantially all of either Product; 
 (iv) any breach by an Assignor in any material respect of any of its covenants in Section 2.02(a)(ii) (unless such breach results from any action or omission by any Person other than an Assignor),
Section 5.08(c) (unless such breach results from any action or omission by any Person other than an Assignor) or Section 5.08(g), which breach in each case, is not cured within sixty (60) days following delivery by PRF
to the Assignors of written notice of such breach; 
 (v) any (A) breach by an Assignor in any material respect of any of
its covenants in Sections 5.03, 5.05, 5.08(d), 5.09, 5.10, 5.11, 5.13 or 5.16, or (B) representation made by an Assignor in any of Sections 3.04, 3.10, 3.12,
3.13(b) or 3.14 proves after the Closing Date, based on facts or circumstances which PRF was not aware of on or prior to the Closing Date, to have been false or incorrect in any material respect when made; in each case if and only if
such breach or falseness or incorrectness (x) is not cured (if such breach or falseness or incorrectness is capable of being cured) within seventy (70) days following delivery by PRF to the Assignors of written notice thereof, and
(y) results in a Material Adverse Effect; or 
 (vi)(A) any permanent injunction issued by a Governmental Authority as a
result of a lawsuit instituted by [*] or their successors, assignees or affiliates (each individually, a “Potential Plaintiff” and collectively, the “Potential Plaintiffs”) that suspends the sale of Antara and remains in effect
and not stayed for more than 60 days, (B) any preliminary or temporary injunction issued by a Governmental Authority as a result of a lawsuit instituted by a Potential Plaintiff that suspends the sale of Antara and remains in effect and not
stayed for more than 90 days, or (C) a voluntary withdrawal by an Assignor of Antara from the market that suspends sales of Antara for more than 30 days as a result of a Dispute involving a Potential Plaintiff and an Assignor. 
  

 -13- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 “Quarterly Report” shall mean, with respect to the relevant Fiscal Quarter of the
Company, (i) a report showing all payments made by the Assignors to PRF under this Agreement during such quarter and showing in reasonable detail the basis for the calculation of such payments, (ii) a reconciliation of such report referred
to in clause (i) above to all information and data deliverable to the Company, PRF or their Affiliates by the parties to any Out-License Agreement, together with relevant supporting documentation, and (iii) such additional information as
PRF may reasonably request. 
 “Regulatory Agency” shall mean a Governmental Authority with responsibility for the approval
of the marketing and sale of pharmaceuticals in the United States or other regulation of pharmaceuticals. 
 “Regulatory
Approval” shall mean all approvals (including, without limitation, where applicable, pricing and reimbursement approval and schedule classifications), product and/or establishment licenses, registrations or authorizations of any
Governmental Authority of a Drug Approval Application necessary for the manufacture, use, storage, import, export, transport, offer for sale, or sale of the Products in a regulatory jurisdiction. 
 “Restricted Cash” shall mean any cash required under GAAP to be reflected on the consolidated balance sheet of the Company (or the notes
thereto) as restricted cash. 
 “Revenue Interest Period” shall mean the period from and including the date hereof through
and including December 31, 2016, unless earlier terminated upon a full repurchase of the Assigned Interests by the Company pursuant to Section 5.07 or otherwise in accordance with the terms of this Agreement. 
 “Revenue Interests” shall mean (A) with respect to any Out-License Agreement, all of the Company’s and its Affiliates’
rights under such Out-License Agreement, including, without limitation, rights to receive payments in respect of sale of the Products in the Territory and (B) otherwise, all of the Company’s and its Affiliates’ rights, however
derived, to receive payments in respect of sales of the Products in the Territory. 
 “Security Agreement” shall mean the
Security Agreement dated the Closing Date by and between Guardian and PRF providing for, among other things, the grant by Guardian in favor of PRF of a valid continuing, perfected lien on and security interest in, certain of the Assigned Interests
and the other Collateral described therein, which Security Agreement shall be substantially in the form of Exhibit D. 
 “Stock Purchase Agreement” shall have the meaning set forth in Section 6.02(k). 
 “Subsidiary” or “Subsidiaries” shall mean with respect to any Person (i) any corporation of which the outstanding capital stock having at least a majority of votes entitled to be cast in the election
of directors under ordinary circumstances shall at the time owned, directly or indirectly, by such Person or (ii) any other Person of which at least a majority voting interest under ordinary circumstances is at the time, directly or indirectly,
owned by such Person. 
 “Term” shall mean the term of this Agreement, as provided in Section 7.01 hereof.

  

 -14- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 “Territory” shall mean, with respect to Factive, the United States, and, with respect to
Antara, the “Territory”, as defined in the Antara Purchase Agreement. 
 “Third Party” shall mean any Person other
than the Company, Guardian or PRF or their respective Affiliates. 
 “Transaction Documents” shall mean, collectively, this
Agreement, the Assignments of Interests, the Security Agreement and the Deposit Agreements. 
 “Transfer” or
“Transferred” shall mean any sale, conveyance, assignment, disposition, pledge, hypothecation or transfer (other than a transfer to an Affiliate to which PRF has consented, which consent shall not be unreasonably withheld, delayed
or conditioned). 
 “True-Up Statement” shall have the meaning set forth in Section 5.08(g)(i). 
 “UCC” shall mean the Uniform Commercial Code (or any similar or equivalent legislation) as in effect in any applicable jurisdiction.

 “United States” shall mean the United States of America, its territories and possessions, including, without limitation,
Puerto Rico. 
 “Waived Consent” shall have the meaning set forth in Section 6.02 (n). 
 “Year-to-Date Net Revenues” shall have the meaning set forth in Section 5.08(g)(i). 
 ARTICLE II 
 ASSIGNMENT OF INTERESTS

 Section 2.01 Assignment. 
 Upon the terms and subject to the conditions set forth in this Agreement, each of the Assignors agrees to sell, assign, transfer and convey to PRF, and PRF agrees to purchase from the Assignors, free and clear of all
Liens (except those Liens created in favor of PRF pursuant to the Security Agreement and any other Transaction Document and those Liens of the Company set forth on Schedule 2.01) and subject to the conditions set forth in Article VI, all of
the Assignors’ rights and interests in and to the Assigned Interests on the Closing Date. PRF’s ownership interest in the Assigned Interests so acquired shall vest immediately upon the Assignors’ receipt of payment for such Assigned
Interests pursuant to Section 2.03. 
 Section 2.02 Payments by the Assignors. 
 (a) Payments in Respect of the Assigned Interests. 
 (i) PRF shall be entitled to receive the Applicable Percentage in respect of Net Revenues made during the Revenue Interest Period. 
 (ii) Commencing on the date hereof, the Interim Applicable Percentage of the Aggregate Deposit Funds in each Fiscal Year shall be swept
from the Joint Accounts into the PRF Concentration Account (Antara) and the PRF Concentration Account (Factive), as applicable, on a daily basis (the “Daily Amount”) pursuant to Section 5.08. 
  

 -15- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (b) Payment Procedure. Other than payments made pursuant to the Deposit Agreements, any payments
to be made by the Assignors to PRF hereunder or under any other Transaction Document shall be made by wire transfer of immediately available funds. 
 Section 2.03 Purchase Price. 
 (a) Assigned Interests. In full consideration for the assignment by the
Assignors of the Assigned Interests, and subject to the terms and conditions set forth herein, PRF shall pay to the Assignors forty million dollars ($40,000,000) by wire transfer of immediately available funds at the time of Closing to an account
designated in writing by the Assignors. 
 (b) Payment Procedure. The payment to be made by PRF under this Section 2.03
shall be paid by wire transfer of immediately available funds to the account(s) designated by the Assignors. 
 Section 2.04 No Assumed
Obligations. 
 Notwithstanding any provision in this Agreement or any other writing to the contrary, PRF is acquiring only the
Assigned Interests and is not assuming any liability or obligation of the Company or any of its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter, whether under any Transaction Document or otherwise. All
such liabilities and obligations shall be retained by and remain obligations and liabilities of the Company or its Affiliates (the “Excluded Liabilities and Obligations”). 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES OF THE ASSIGNORS 

The Assignors hereby jointly and severally represent and warrant to PRF the following as of the date of this Agreement: 
 Section 3.01 Organization. 
 Each Assignor is a corporation duly incorporated, validly existing and in good standing under the laws of its state of organization, and has all corporate powers and all licenses, authorizations, consents and approvals required to carry on
its business as now conducted and as proposed to be conducted in connection with the transactions contemplated by the Transaction Documents. Each Assignor is duly qualified to do business as a foreign corporation and is in good standing in every
jurisdiction in which the failure to do so would have a Material Adverse Effect. 
 Section 3.02 Corporate Authorization.

 Each Assignor has all necessary power and authority to enter into, execute and deliver the Transaction Documents and to perform all of
the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder. The 

  

 -16- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
Transaction Documents have been duly authorized, executed and delivered by each Assignor and each Transaction Document constitutes the valid and binding
obligation of such Assignor, enforceable against it in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally
or general equitable principles. 
 Section 3.03 Governmental Authorization. 
 Except as set forth on Schedule 3.03, the execution and delivery by the Assignors of the Transaction Documents, and the performance by them of
their obligations hereunder and thereunder, does not require any notice to, action or consent by, or in respect of, or filing with, any Governmental Authority, except for the filing of financing statements under the UCC. 
 Section 3.04 Ownership. The Assignors hereby jointly and severally represent and warrant to PRF the following (provided, however, with
respect to Antara, only after giving effect to the closing of the transaction contemplated by the Antara Purchase Agreement): 
 (a) Except
as set forth on Schedule 3.04(a), the Assignors own, or hold a valid license under, all of the Intellectual Property and the Regulatory Approvals with respect to the Products free and clear of all Liens, and no license or covenant not to sue
under any Intellectual Property or Regulatory Approvals has been granted to any Third Party. 
 (b) Except as set forth on Schedule
3.04(b), the Assignors, immediately prior to the assignment of the Assigned Interests, own, and are the sole holders of, all the Revenue Interests; and the Assignors own, and are the sole holders of, and/or have and hold a valid, enforceable and
subsisting license to, all of those other assets that are required to produce or receive any payments from any Licensee or payor under and pursuant to, and subject to the terms of any Out-License Agreement, in each case free and clear of any and all
Liens, except those Liens created in favor of PRF pursuant to the Security Agreement or any other Transaction Document, and those Liens of the Company set forth on Schedule 2.01. Except as set forth on Schedule 3.04(b), neither
Assignor has transferred, sold, or otherwise disposed of, or agreed to transfer, sell, or otherwise dispose of any portion of the Revenue Interests other than as contemplated by this Agreement. No Person other than the Assignors has any right to
receive the payments payable under any Out-License Agreement, other than PRF’s rights with respect to the Assigned Interests, from and after the Closing Date. Each Assignor has the full right to sell, transfer, convey and assign to PRF all of
its rights and interests in and to the Assigned Interests being sold, transferred, conveyed and assigned to PRF pursuant to this Agreement without any requirement to obtain the consent of any Person. By the delivery to PRF of the executed
Assignments of Interests, each Assignor shall transfer, convey and assign to PRF all of its rights and interests in and to the Assigned Interests being sold, transferred, conveyed and assigned to PRF pursuant to this Agreement, free and clear of any
Liens, except those Liens created in favor of PRF pursuant to the Security Agreement and any other Transaction Document and the Liens of the Company set forth on Schedule 2.01. At the Closing, and upon the delivery of the Assignments of
Interests to PRF by the Assignors, PRF shall have acquired good and valid rights and interests of the Assignors in and to the Assigned Interests being sold, transferred, conveyed and assigned to PRF pursuant to this Agreement, free and clear of any
and all Liens, except those Liens created in favor of PRF pursuant to the Security Agreement and any other Transaction Document and the Liens of the Company set forth on Schedule 2.01. 
  

 -17- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Section 3.05 Financial Statements. 
 The Financial Statements are complete and accurate in all material respects, were prepared in conformity with GAAP and present fairly in all material
respects the financial position and the financial results of the Company and its Subsidiaries as of the dates and for the periods covered thereby. 
 Section 3.06 No Undisclosed Liabilities. 
 Except as disclosed in the Financial Statements, the Company or its
Subsidiaries does not have any material liabilities, except: (a) liabilities incurred since the date of the most recent balance sheet in the ordinary course of business, (b) liabilities with respect to matters disclosed in this Agreement
(including matters disclosed in the schedules hereto), (c) liabilities under the agreements listed as Exhibits in the Company’s Annual Report on Form 10-K for the year ending December 31, 2005 or its Quarterly Report on Form 10-Q for
the quarter ending March 31, 2006, (d) liabilities under the Antara Purchase Agreement and (e) liabilities under, or incurred in connection with, this Agreement. 
 Section 3.07 Solvency. 
 Neither Assignor is insolvent as defined in any statute of the United States Bankruptcy Code or in the fraudulent conveyance or fraudulent transfer statutes of the Commonwealth of Massachusetts or the States of New York or Delaware.
Assuming consummation of the transactions contemplated by the Transaction Documents, (i) the present fair saleable value of each Assignor’s assets is greater than the amount required to pay its debts as they become due, (ii) neither
Assignor has unreasonably small capital with which to engage in its business, and (iii) neither Assignor has incurred, nor does it have present plans to or intend to incur, debts or liabilities beyond its ability to pay such debts or
liabilities as they become absolute and matured. 
 Section 3.08 Litigation. 
 There is no (i) action, suit, arbitration proceeding, claim, investigation or other proceeding pending or, to the Knowledge of the Company,
threatened against the Company or its Subsidiaries or (ii) any governmental inquiry pending or, to the Knowledge of the Company, threatened against the Company or its Subsidiaries, in each case with respect to clauses (i) and
(ii) above, which, if adversely determined, would question the validity of, or would adversely affect the transactions contemplated by any of the Transaction Documents or would reasonably be expected to have a Material Adverse Effect. There is
no action, suit, claim, proceeding or investigation pending or, to the Knowledge of the Company, threatened against the Company, its Subsidiaries or any other Person relating to the Products, the Intellectual Property, the Regulatory Approvals, the
Revenue Interests or the Assigned Interests. 
 Section 3.09 Compliance with Laws. 
 None of the Company and its Subsidiaries (i) is in violation of, has not violated, or to the Knowledge of the Company, is not under investigation
with respect to, and (ii) to the Company’s Knowledge has not been threatened to be charged with or been given notice of any violation of any law, rule, ordinance or regulation of, or any judgment, order, writ, decree, permit or license

  

 -18- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
entered by any Governmental Authority applicable to the Company, the Assigned Interests or the Revenue Interests which would reasonably be expected to have a
Material Adverse Effect. 
 Section 3.10 Conflicts. 
 (a) Neither the execution and delivery of any of the Transaction Documents nor the performance or consummation of the transactions contemplated hereby
and thereby will: (i) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of: (A) any law, rule, ordinance or
regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which the Company or any of its Subsidiaries or any of their respective assets or properties may be subject or bound;
or (B) any contract, agreement, commitment or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries or any of their respective assets or properties is bound or committed;
(ii) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the certificate of incorporation or by-laws (or other organizational or constitutional
documents) of the Company or any of its Subsidiaries; (iii) except for the filing of the UCC-1 financing statements required hereunder and filings with the United States Patent and Trademark Office, require any notification to, filing with, or
consent of, any Person or Governmental Authority; (iv) give rise to any right of termination, cancellation or acceleration of any right or obligation of the Company or any of its Subsidiaries or any other Person or to a loss of any benefit
relating to the Revenue Interests or the Assigned Interests; or (v) result in the creation or imposition of any Lien on (A) the assets or properties of the Company or any of its Subsidiaries or (B) the Assigned Interests, the Revenue
Interests, or any other Collateral, other than, with respect to clause (v) above, pursuant to the Security Agreement. 
 (b) None of the
Company and its Subsidiaries has granted, nor does there exist, any Lien on the Revenue Interests, the Assigned Interests or any other Collateral other than pursuant to the Security Agreement or as set forth on Schedule 2.01. 
 Section 3.11 Subordination. The claims and rights of PRF created by any Transaction Document in and to the Assigned Interests
and the Revenue Interests of the Company are not subordinated to any creditor of the Company; and the claims and rights of PRF created by any Transaction Document in and to the Assigned Interests, the Revenue Interests and any other Collateral of
Guardian are not subordinated to any creditor of Guardian other than, in each case, as set forth on Schedule 2.01. 
 Section 3.12
Intellectual Property. The Assignors hereby jointly and severally represent and warrant to PRF the following (provided, however, with respect to Antara, only after giving effect to the closing of the transaction contemplated by the Antara
Purchase Agreement): 
 (a) For each Product, Schedule 3.12(a) sets forth an accurate, true and complete list (by category and family)
of all (1) Patents and utility models, (2) trade names, common law trademarks, common law service marks, registered trademarks, registered service marks, and applications for trademark registration or service mark registration (in each
case used in connection with a Product), (3) registered and unregistered copyrights and (4) domain name 

  

 -19- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
registrations and websites, in each case with respect to clauses (1), (2), (3) and (4) above in this subsection (a) that are necessary to
make, have made, use, sell, have sold, offer for sale, import, develop, promote, market, distribute, manufacture, commercialize or otherwise exploit each Product for FDA approved indications in the Territory by the Assignors, their Affiliates,
manufacturers, suppliers, or distributors. For each item of intellectual property listed on Schedule 3.12(a), the Assignors have identified (i) the record owner, (ii) the application number, (iii) the patent number,
(v) the expiration date, as applicable, including any applicable term extensions, if applicable, (vi) the earliest relied upon priority filing date used to calculate the expiration date, and (vii) the due date(s) for any applicable
maintenance, annuity or renewal fee. Except as disclosed therein, each listed Intellectual Property item on Schedule 3.12(a) is not invalid and not unenforceable and no listed Intellectual Property item has lapsed, expired, been cancelled or
become abandoned. To the Company’s Knowledge, the Patent applications listed in Schedule 3.12(a) have been and continue to be prosecuted by competent patent counsel in a diligent manner. 
 (b) Schedule 3.12(b) sets forth an accurate, true and complete list of all agreements, whether oral or written, express or implied, including,
without limitation, assignments, licenses, options, franchise, distribution, marketing and manufacturing agreements, sponsorships, project agreements, collaboration agreements, joint development agreements, agreements not to enforce, consents,
settlements, security interests, liens and other encumbrances or mortgages, and any amendments(s) renewal(s), novation(s) and termination(s) pertaining thereto, pursuant to which the Company has the legal right to exploit Intellectual Property that
is owned by another Person or a Third Party. To the Assignors’ Knowledge, there are no unpaid fees or royalties under any agreement listed on Schedule 3.12(b) that have become due, or are expected to become overdue, as of the Closing
Date, except as disclosed on Schedule 3.12(b). 
 (c) Each agreement listed in Schedule 3.12(b) is legal, valid, binding,
enforceable, and in full force and effect. The Assignors are not in breach of such listed agreements and, no circumstances or grounds exist that would give rise to a claim of breach or right of rescission, termination, revision, or amendment of any
of the agreements specified in Schedule 3.12(b), including, without limitation, the execution, delivery and performance of this Agreement and the other Transaction Documents, except as disclosed on Schedule 3.12(c). 
 (d) Except for Intellectual Property licensed to the Company or Guardian, as the case may be, pursuant to any agreement listed on Schedule 3.12(b)
and Intellectual Property owned by the Company or Guardian, as the case may be, no other Intellectual Property is necessary to make, have made, offer to sell, sell, have sold, use, import, make public, reproduce, transmit, extract, distribute,
commercialize or market the Product for FDA approved indications. The Assignors have the full, legal right to make, have made, use, sell, have sold, offer for sale, import, develop, distribute, manufacture, commercialize, or market the Products in
the Territory, without infringing any valid and enforceable intellectual property right that is owned by another Person or a Third Party. 
 (e) The Assignors possess sole, exclusive, valid, marketable and unencumbered title to the Intellectual Property for which it is listed as the owner on Schedule 3.12(a), and is a party to the agreements listed on Schedule
3.12(b); all assignments from each inventor, as the case may be, to the Assignors or to a predecessor in interest of the Assignors, have been executed and recorded for each of the Patents; there are no Liens, mortgages or encumbrances on or to
any Intellectual Property listed on Schedule 3.12(a) that it owns or agreement listed on Schedule 3.12(b), except as disclosed on Schedule 3.12(e). 
  

 -20- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (f) There are no unpaid fees currently overdue for any of the Intellectual Property listed on Schedule
3.12(a), nor have any applications or registrations therefor lapsed or become abandoned, been cancelled or expired. 
 (g) To the
Assignors’ Knowledge and except as set forth on Schedule 3.12(g), each owner and inventor of each Patent and the Assignors (to the extent that either Assignor is an applicant or is otherwise involved in the patent prosecution of any
Patent) have complied in all material respects with all applicable duties of candor and good faith in dealing with the U.S. Patent Office, including the duty to disclose all information known to be material to patentability. 
 (h) To the Assignors’ Knowledge, no payments by the Assignors are, or at any time in the future expected to, become due to any other Person in
respect of the Product or the Intellectual Property, except as disclosed on Schedule 3.12(h). 
 (i) Neither the Assignors nor to the
Assignors’ Knowledge any Person, has undertaken or omitted to undertake any acts, and to the Assignors’ Knowledge, no circumstance or grounds exist, that would invalidate, reduce or eliminate, in whole or in part, the enforceability or
scope of (i) any Intellectual Property or, in the case of Intellectual Property owned or licensed by either of the Assignors, the Assignors’ entitlement to exclusively exploit such Intellectual Property, or (ii) the Company’s
right to enjoy payments made in respect of sales of the Product or other revenues from any Intellectual Property. 
 (j) Except as disclosed
on Schedule 3.12(j), there is, and has been, no pending, decided or settled opposition, interference proceeding, reexamination proceeding, cancellation proceeding, injunction, claim, lawsuit, proceeding, hearing, investigation, complaint,
arbitration, mediation, demand, International Trade Commission investigation, decree, or any other dispute, disagreement, or claim (collectively referred to hereinafter as “Disputes”), nor, to the Assignors’ Knowledge, has any such
Dispute been threatened, challenging the legality, validity, enforceability or ownership of any Intellectual Property or which would give rise to a credit against the revenues of Assignors as a result of the manufacture, sale offer for sale, use,
importation or exportation of the Product or the exploitation of the licensed Intellectual Property and, to the Company’s Knowledge, no circumstances or grounds exist that would give rise to such a Dispute. There are no Disputes by any Person
or Third Party against the Company, and to the Assignors’ Knowledge, its licensors. The Assignors have not received any written notice or claim of any such Dispute, and, to the Assignors’ Knowledge, there exists no circumstances or grounds
upon which any such claim could be asserted, as pertaining to the Product. Neither the Assignors, nor to the Assignors’ Knowledge its licensor, have sent any notice of any Dispute to a Third Party, and to the Assignors’ Knowledge, there
exists no circumstance or grounds upon which the Assignors or their licensor could assert any such Dispute, as pertaining to the Product. No Intellectual Property or the Product is subject to any outstanding injunction, judgment, order, decree,
ruling charge, settlement or other disposition of Dispute, and the Assignors have fully complied with, paid and otherwise satisfied all such obligations, except as disclosed on Schedule 3.12 (j). 
  

 -21- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (k) There is no pending or, to the Assignors’ Knowledge, threatened action, suit, or proceeding, or
any investigation or claim by any Governmental Authority to which either Assignor is a party (1) that would be the subject of a claim for indemnification by any Person or Third Party under any Out-License Agreement or In-License Agreement, or
(2) that the marketing, sale or distribution of the Product in the United States by the Assignors pursuant to the related License Agreement, as applicable, does or will infringe on any valid and enforceable patent or other intellectual property
rights of any other Person, and, to the Assignors’ Knowledge, there is no basis for any such action, suit, proceeding, investigation or claim of the type described in clause (1) or (2) above. To the Assignors’ Knowledge, there
are no pending published or unpublished United States, international or foreign patent applications owned by any other Person, which, if issued, would be valid and enforceable, and would limit or prohibit the manufacture, use, sale or importation of
the Products for FDA approved indications or the licensed Intellectual Property relating to the Products. 
 (l) The Assignors have taken,
and will continue to take, all commercially reasonable measures and precautions necessary to protect and maintain (1) the confidentiality of all Intellectual Property (except such Intellectual Property whose value would be unimpaired by public
disclosure) that it owns and (2) the value of all Intellectual Property and assets related to the Product. 
 (m) No material trade
secret of the Assignors relating to the Product has been published or disclosed to any Person except pursuant to a written agreement requiring such Person to keep such trade secret confidential. 
 (n) Assignors have previously provided to PRF, pursuant to a Joint Defense/Common Interest Agreement, copies of all written opinions of counsel with
respect to any Third Party intellectual property rights relating to the Products, including all freedom-to-operate, product clearance or right-to-use opinions and assessments. 
 Section 3.13 Regulatory Approval. The Assignors hereby jointly and severally represent and warrant to PRF the following (provided,
however, with respect to Antara, only after giving effect to the closing of the transaction contemplated by the Antara Purchase Agreement): 
 (a) The Company and its Subsidiaries have made available to PRF all of the following documents that the Company and its Subsidiaries have possession of in any form from any contract party to any Out-License Agreement or In-License Agreement
that have been requested by PRF: 
 all correspondence with a Regulatory Agency, including, without limitation, written notes
in respect of telephone communications, electronic communications, copies of all submissions to any active regulatory files regarding preclinical, clinical, manufacturing, adverse events, any notices and forms received by a contract party from
appropriate Regulatory Agencies relating to compliance, developmental (including safety, efficacy and potency), marketing, promotion or manufacturing activities concerning the Intellectual Property or Products; 
 correspondence or reports from both internal corporate employees and non-governmental consultants relating to any of the regulatory and/or
product liability exposures, marketing and reimbursement strategies, manufacturing (i.e., annual audit reports), preclinical and clinical data issues concerning the Products; and 
  

 -22- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 any information or communication that would indicate that any Regulatory Agency
(A) is not likely to approve any application with respect to the Products, (B) is likely to revise or revoke any current approval granted by any Regulatory Agency with respect to the Products, or (C) is likely to pursue compliance
actions against the Company, its Subsidiaries or any contract party relating to an In-License Agreement or Out-License Agreement. 
 (b) The
Company and its Subsidiaries are in material compliance with, and have materially complied with, all applicable federal, state, local and foreign laws, rules, regulations, standards, orders and decrees governing its business, including all
regulations promulgated by each Regulatory Agency, the failure of compliance with which would reasonably be expected to result in a Material Adverse Effect; the Company and its Subsidiaries have not received any notice citing action or inaction by
any of them that would constitute any material non-compliance with any applicable federal, state, local and foreign laws, rules, regulations, or standards, which could reasonably be expected to result in a Material Adverse Effect; and to the
Company’s Knowledge, no prospective change in any applicable federal, state, local or foreign laws, rules, regulations or standards has been adopted which, when made effective, would reasonably be expected to result in a Material Adverse
Effect. 
 (c) To the Knowledge of the Assignors, the studies, tests and preclinical and clinical trials conducted relating to the Products
by or on behalf of the Company or its Subsidiaries were and, if still pending, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and
scientific standards; the descriptions of the results of such studies, tests and trials provided to PRF are accurate in all material respects; and the Company and its Subsidiaries have not received any notices or correspondence from any Regulatory
Agency or comparable authority requiring the termination, suspension, or material modification or clinical hold of any such studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or its Subsidiaries, which
termination, suspension, material modification or clinical hold would reasonably be expected to result in a Material Adverse Effect. 
 Section 3.14 Material Contracts. 
 Neither the Company nor any of its Subsidiaries is in breach of or in default
under any Material Contract or any Out-License Agreement, which default, individually or in the aggregate, would result in a Material Adverse Effect. Except as disclosed on Schedule 3.14 to the Knowledge of the Company, nothing has occurred and no
condition exists that would permit any other party thereto to terminate any Material Contract with respect to the Products in the Territory. Neither the Company nor any of its Subsidiaries has received any notice or, to the Knowledge of the Company,
any threat of termination of any such Material Contract. To the Knowledge of the Company, no other party to a Material Contract is in breach of or in default under such Material Contract. All Material Contracts are valid and binding on the Company
and its Subsidiaries and, to the Knowledge of the Company, on each other party thereto, and are in full force and effect. 
  

 -23- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Section 3.15 Place of Business. 
 The Company’s principal place of business and chief executive office are set forth on Schedule 3.15. 
 Section 3.16 Broker’s Fees. 
 The Company and its Subsidiaries have not taken any action that would entitle any Person to any commission or broker’s fee in connection with the transactions contemplated by the Transaction Documents. 
 Section 3.17 Insurance. 
 The Company and its Subsidiaries maintain the insurance policies listed on Schedule 3.17 which policies are in full force and effect. 
 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF PRF 
 PRF represents and warrants to the Assignors the following: 
 Section 4.01 Organization. 
 PRF is a general partnership duly formed and validly
existing under the laws of the State of California. 
 Section 4.02 Authorization. 
 PRF has all necessary power and authority to enter into, execute and deliver the Transaction Documents and to perform all of the obligations to be
performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder. The Transaction Documents have been duly authorized, executed and delivered by PRF and each Transaction Document constitutes the valid
and binding obligation of PRF, enforceable against PRF in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights
generally or general equitable principles. 
 Section 4.03 Broker’s Fees. 
 PRF has not taken any action that would entitle any Person to any commission or broker’s fee in connection with the transactions contemplated by the
Transaction Documents. 
 Section 4.04 Conflicts. 
 Neither the execution and delivery of this Agreement or any other Transaction Document nor the performance or consummation of the transactions
contemplated hereby or thereby will: (i) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of: (A) any law, rule or
regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which PRF or any of its assets or properties may be 

  

 -24- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
subject or bound; or (B) any contract, agreement, commitment or instrument to which PRF is a party or by which PRF or any of its assets or properties is
bound or committed; (ii) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the organizational or constitutional documents of PRF; or
(iii) require any notification to, filing with, or consent of, any Person or Governmental Authority. 
 ARTICLE V 
 COVENANTS 
 During the Term, the
following covenants shall apply: 
 Section 5.01 Consents and Waivers. 
 Each Assignor shall use its commercially reasonable efforts to obtain and maintain any required consents, acknowledgements, certificates or waivers so
that the transactions contemplated by this Agreement or any other Transaction Document may be consummated and shall not result in any default or breach or termination of any of the Material Contracts or any Out-License Agreements, if any.

 Section 5.02 Access; Information. 
 (a) Promptly after receipt by an Assignor of notice of any action, claim, investigation, proceeding (commenced or threatened), certificate, offer, proposal, material correspondence or other material written
communication (in each case other than that received in the ordinary course of business) relating to the transactions contemplated by this Agreement, any other Transaction Document, the Revenue Interests, Material Contracts or any Out-License
Agreement, then, the Assignor shall inform PRF of the receipt of such notice and the substance of such action, claim, investigation, proceeding, certificate, offer, proposal, correspondence or other written communication and, if in writing shall
furnish PRF with a copy of such notice and any related materials with respect to such action, claim, investigation, proceeding, certificate, offer, proposal, correspondence or other written communication. 
 (b) The Assignors shall keep and maintain, or cause to be kept and maintained, at all times accurate and complete books and records. The Assignors shall
keep and maintain, or cause to be kept and maintained, at all times full and accurate books of account and records adequate to correctly reflect all payments paid and/or payable with respect to Revenue Interests and Assigned Interests and all
deposits made into the applicable Deposit Accounts. 
 (c) PRF and any of PRF’s representatives shall have the right, once a year (and
at any other time a Default or Event of Default shall have occurred or be continuing), to visit the Company and its Subsidiaries’ offices and properties where the Company and its Subsidiaries keep and maintain its books and records relating or
pertaining to the Revenue Interests, the Assigned Interests and the other Collateral for purposes of conducting an audit of such books and records, and to inspect, copy and audit such books and records, during normal business hours, and, upon five
(5) Business Days’ written notice given by PRF to the Company (provided one (1) Business Day’s notice shall be required if a Default or Event of Default shall have occurred and be continuing), the Company will provide PRF and any
of PRF’s representatives reasonable 

  

 -25- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
access to such books and records, and shall permit PRF and any of PRF’s representatives to discuss the business, operations, properties and financial
and other condition of the Company or any of its Affiliates including, but not limited to, matters relating or pertaining to the Revenue Interests, the Assigned Interests and the other Collateral with officers of such parties, and with their
independent certified public accountants (to the extent such independent certified accountants agree to discuss such matters with PRF). 
 (d) In the event any audit of the books and records of the Company and its Subsidiaries relating to the Revenue Interests, Assigned Interests, and the other Collateral by PRF and/or any of PRF’s representatives reveals that the amounts
paid to PRF hereunder for the period of such audit have been understated by more than five percent (5%) of the amounts determined to be due for the period subject to such audit, then the Audit Costs in respect of such audit shall be borne by
the Company; and in all other cases, such Audit Costs shall be borne by PRF. 
 (e) The Company shall, promptly after the end of each Fiscal
Quarter (but in no event later than forty-five (45) days following the end of such Fiscal Quarter), produce and deliver to PRF a Quarterly Report for such quarter, together with a certificate of the Company, certifying that to the knowledge of
the Company (i) such Quarterly Report is a true and complete copy and (ii) any statements and any data and information therein prepared by the Company are true, correct and accurate in all material respects. 
 (f) The Company shall maintain a system of accounting established and administered in accordance with sound business practices to permit preparation of
financial statements in conformity with GAAP. 
 (g) The Company shall deliver to PRF the following financial statements: Within forty-five
(45) calendar days after the end of each Fiscal Quarter, copies of the unaudited consolidated financial statements of the Company and its Subsidiaries for such Fiscal Quarter; and 
 Within ninety (90) calendar days after the end of each Fiscal Year, copies of the audited consolidated financial statements of the Company and its
Subsidiaries for such Fiscal Year. 
 Section 5.03 Material Contracts. 
 The Assignors shall comply with all material terms and conditions of and fulfill all of its obligations under all the Material Contracts. The Assignors
shall not amend any Material Contract or issue any consents or other approvals under any Material Contract (other than consents or approvals given in the ordinary course of business) without the prior written consent of PRF not to be unreasonably
withheld, delayed or conditioned. 
 Section 5.04 Confidentiality; Public Announcement. 
 (a) All information furnished by PRF to the Company or by the Company to PRF, including the Confidential Information, in connection with this Agreement
and any other Transaction Document and the transactions contemplated hereby and thereby, as well as the 

  

 -26- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
terms, conditions and provisions of this Agreement and any other Transaction Document, shall be kept confidential by the Company and PRF, and shall be used
by the Company and PRF only in connection with this Agreement and any other Transaction Document and the transactions contemplated hereby and thereby. Notwithstanding the foregoing, the Company and PRF may disclose such information to their
partners, directors, employees, managers, officers, investors, bankers, advisors, trustees and representatives, provided that such Persons shall be informed of the confidential nature of such information and shall be obligated to keep such
information confidential pursuant to the terms of this Section 5.04(a). The Company will consult with PRF, and PRF will consult the Company, on the form, content and timing of any such disclosures of Confidential Information including,
without limitation, any disclosures made pursuant to applicable securities laws or made to investment or other analysts. 
 (b) Except as
required by law or the rules and regulations of any securities exchange or trading system or the FDA or any Governmental Authority with similar regulatory authority, or except with the prior written consent of the other party (which consent shall
not be unreasonably withheld), no party shall issue any press release or make any other public disclosure with respect to the transactions contemplated by this Agreement or any other Transaction Document; provided, however, that the
Company and PRF may jointly prepare a press release for dissemination promptly following the date hereof and the Closing Date. 
 Section 5.05 Security Agreement. 
 Guardian shall, at all times until the Obligations are paid and performed in
full, grant in favor of PRF a valid, continuing, first perfected lien on and security interest in the Revenue Interests and the Assigned Interests relating to it and the other Collateral described in the Security Agreement. 
 Section 5.06 Best Efforts; Further Assurance. 
 (a) Subject to the terms and conditions of this Agreement, each of PRF and the Assignors will use their best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary
under applicable laws and regulations to consummate the transactions contemplated by this Agreement and any other Transaction Document. PRF and the Assignors agree to execute and deliver such other documents, certificates, agreements and other
writings (including any financing statement filings requested by PRF) and to take such other actions as may be reasonably necessary in order to consummate or implement expeditiously the transactions contemplated by this Agreement and any other
Transaction Document and to vest in PRF good, valid and marketable rights and interests in and to the Assigned Interests free and clear of all Liens, except those Liens created in favor of PRF pursuant to the Security Agreement and any other
Transaction Document and those Liens set forth on Schedule 2.01. 
 (b) PRF and the Assignors shall execute and deliver such
additional documents, certificates and instruments, and perform such additional acts, as may be reasonably requested and necessary or appropriate to carry out and effectuate all of the provisions of this Agreement and any other Transaction Document
and to consummate all of the transactions contemplated by this Agreement and any other Transaction Document. 
  

 -27- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (c) PRF and the Assignors shall cooperate and provide assistance as reasonably requested by the other
respective party in connection with any litigation, arbitration or other proceeding (whether threatened, existing, initiated, or contemplated prior to, on or after the date hereof) to which any party hereto or any of its officers, directors,
shareholders, agents or employees is or may become a party or is or may become otherwise directly or indirectly affected or as to which any such Persons have a direct or indirect interests, in each case relating to this Agreement, any other
Transaction Document, the Assigned Interests or any other Collateral, or the transactions described herein or therein. 
 Section 5.07 Call, Put and Buy-Down Options. 
 (a) Call Option. In the event that a Change of Control
shall occur during the Term, the Assignors shall have the right, but not the obligation (the “Call Option”), to repurchase the Assigned Interests from PRF for a repurchase price in cash equal to the Put/Call Price. In order to
exercise the Call Option, the Company shall deliver written notice to PRF of its election to so repurchase the Assigned Interests on the closing date of the Change of Control (the “Call Option Closing Date”); provided, that
such notice shall be delivered no later than ten (10) Business Days prior to the Call Option Closing Date. On the Call Option Closing Date, the Assignors shall repurchase from PRF the Assigned Interests at the Put/Call Price in cash, the
payment of which shall be made by wire transfer of immediately available funds to the account designated by PRF. 
 (b) Put Option. In
the event that a Put Option Event shall occur during the Term, PRF shall have the right, but not the obligation (the “Put Option”), to require the Assignors to repurchase from PRF the Assigned Interests at the Put/Call Price in
cash. In order to exercise the Put Option, PRF shall deliver written notice to the Assignors of PRF’s election within one hundred eighty (180) days following the receipt of written notice from Assignors of the occurrence of a Put Option
Event (other than a Put Option Event arising as a result of a Change of Control) or within thirty (30) days (the “Change of Control Period”) following PRF’s receipt of written notice from the Assignors of a bona fide offer from a
Third Party that would result in a Change of Control (the “Change of Control Notice”). In the event PRF elects to exercise its Put Option, PRF shall deliver written notice to the Company specifying the closing date (the “Put Option
Closing Date”), which date shall (i) in the event of a Change of Control, be the date of consummation of such Change of Control, and (ii) otherwise, not be earlier than thirty (30) days nor later than forty-five
(45) days after the occurrence of the Put Option Event. On the Put Option Closing Date, the Assignors shall repurchase from PRF the Assigned Interests at the Put/Call Price in cash, the payment of which shall be made by wire transfer of
immediately available funds to the account designated by PRF. Notwithstanding anything to the contrary contained herein, immediately upon the occurrence of a Bankruptcy Event, PRF shall be deemed to have automatically and simultaneously elected to
have the Assignors repurchase from PRF the Assigned Interests for the Put/Call Price in cash and the Put/Call Price shall be immediately due and payable without any further action or notice by any party. The Change of Control Notice shall describe
in reasonable detail the terms of the proposed Change of Control transaction, including the identity of the other party or parties to such transaction. The Company shall supplement the Change of Control Notice during the Change of Control Period as
necessary to reflect changes in terms of the proposed transaction. If following receipt of PRF’s determination of whether or not to elect to exercise its Put Option with respect to the transaction described in the Change of Control Notice, the
terms of the proposed transaction change materially, the Company shall provide PRF a new Change of Control Notice. 
  

 -28- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (c) Partial Buy-Down Option. During the first two Fiscal Years immediately following the Fiscal
Year in which annual Net Revenues were equal to or greater than [*] dollars ($[*]), the Assignors shall have the right, but not the obligation (the “Partial Buy-Down Option”), to cause a reduction hereunder of each of the
percentages set forth in the definitions of “Applicable Percentage” and the “Interim Applicable Percentage” by fifty percent (50%) (thereby reducing by fifty percent (50%) the amounts payable by the Assignors under
Section 2.03) by paying to PRF an amount of cash equal to the Partial Buy-Down Price. In order to exercise the Partial Buy-Down Option, the Company shall deliver written notice to PRF to such effect indicating the closing date (the
“Partial Buy-Down Option Closing Date”); provided, that such notice shall be delivered no later than twenty (20) Business Days prior to the Partial Buy-Down Option Closing Date. On the Partial Buy-Down Option Closing
Date, the Assignors shall pay to PRF the Partial Buy-Down Price in cash by wire transfer of immediately available funds to the account designated by PRF, and the percentages set forth in the definitions of “Applicable Percentage” and
“Interim Applicable Percentage” shall automatically be reduced hereunder without further action to [*] percent ([*]%) of the amounts set forth in their respective definitions hereunder. 
 (d) Full Buy-Down Option. During the first two Fiscal Years immediately following the Fiscal Year in which annual Net Revenues were equal to or
greater than [*] dollars ($[*]), the Assignors shall have the right, but not the obligation (the “Full Buy-Down Option”), to repurchase the Assigned Interests from PRF for a repurchase price in cash equal to the Full Buy-Down Price.
In order to exercise the Full Buy-Down Option, the Company shall deliver written notice to PRF to such effect indicating the closing date (the “Full Buy-Down Option Closing Date”); provided, that such notice shall be
delivered no later than twenty (20) Business Days prior to the Full Buy-Down Option Closing Date. On the Full Buy-Down Option Closing Date, the Assignors shall repurchase from PRF the Assigned Interests at the Full Buy-Down Price in cash, the
payment of which shall be made by wire transfer of immediately available funds to the account designated by PRF. 
 (e) Further
Assurance. In connection with the consummation of a repurchase of the Assigned Interests pursuant to the Call Option, the Put Option or the Full Buy-Down Option, PRF agrees that it will (i) promptly execute and deliver to Guardian such UCC
termination statements and other documents as may be necessary to release PRF’s Lien on the Collateral and otherwise give effect to such repurchase and (ii) take such other actions or provide such other assistance as may be necessary to
give effect to such repurchase. 
 Section 5.08 Remittance to Deposit Accounts. 
 (a) On or before the Closing Date, the parties hereto shall enter into the Deposit Account Control Agreement (Antara) and the Deposit Account Agreement
(Factive) in form and substance reasonably satisfactory to the parties hereto and the Deposit Bank, which Deposit Agreements will provide for, among other things, the establishment and maintenance of a Deposit Account (Antara), Deposit Account
(Factive), a Joint Concentration Account (Antara), a Joint Concentration Account (Factive), an Oscient Concentration Account, an Guardian Concentration Account and a PRF Concentration Account (Antara) and a PRF Concentration Account (Factive) in
accordance with the terms herein and therein. The PRF Concentration Account (Antara) shall be held solely for the benefit of PRF, but shall be subject to the terms and conditions of this Agreement, the Security Agreement and the other Transaction
Documents. 

  

 -29- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
Funds deposited into the Deposit Accounts shall be swept by the Deposit Bank on a daily basis into the Joint Concentration Account (Antara) or the Joint
Concentration Account (Factive), as applicable, and subsequent thereto, the Daily Amount shall be swept into the PRF Concentration Account (Antara) or the PRF Concentration Account (Factive), as applicable. PRF shall have immediate and full access
to any funds held in the PRF Concentration Account (Antara) or the PRF Concentration Account (Factive) and such funds shall not be subject to any conditions or restrictions whatsoever. After the Daily Amount is swept into the PRF Concentration
Account (Antara) or the PRF Concentration Account (Factive), as applicable, the amounts remaining in the Joint Concentration Account (Antara) or the Joint Concentration Account (Factive) shall then be swept, at the direction of the Company, into the
Oscient Concentration Account or the Guardian Concentration Account, as applicable. The Assignors shall have immediate and full access to any funds held in the Oscient Concentration Account and the Guardian Concentration Account, as applicable, and
such funds shall not be subject to any conditions or restrictions whatsoever other than those of the Deposit Bank; provided, however, that nothing herein shall (i) affect or reduce the Assignors’ obligations to pay in full all amounts due
to PRF under this Agreement, or (ii) in any manner limit the recourse of PRF to the Collateral to satisfy the Assignors’ Obligations. 
 (b) The Company shall pay for all fees, expenses and charges of the Deposit Bank. 
 (c) Each Out-License Agreement, if any, shall,
within twenty (20) Business Days after the date of Closing, be amended to contain a provision providing for all payments in respect of sales of the Products and in respect of royalties received from Licensees to be remitted directly by the
applicable party into the applicable Deposit Account and the Assignors shall cause such payments to be remitted directly by the applicable party into such Deposit Account. The Assignors shall cause all other payments in respect of sales of the
Products to be remitted directly by the applicable party into the applicable Deposit Account. Without in any way limiting the foregoing, commencing on the Closing Date and thereafter, any and all payments in respect of sales of the Products received
by the Company or its Subsidiaries shall be deposited into the applicable Deposit Account within three (3) Business Days of the Company or its Subsidiaries’ receipt thereof. 
 (d) With respect to any Out-License Agreement entered into by the Company or any of its Subsidiaries from and after the date hereof, the Company shall,
or shall cause its Subsidiaries to, (i) at the time of the execution and delivery of such agreement, instruct any party thereto under such agreement to remit to the applicable Deposit Account when due all applicable payments in respect of sales
and licensing revenue in respect of the Products and in respect of royalties received from Licensees that are due and payable to the Company and its Subsidiaries in respect of or derived from such agreement during the Term and (ii) deliver to
PRF evidence of such instruction and of such applicable party’s agreement thereto. 
 (e) The Assignors shall not have any right to
terminate the Deposit Bank without PRF’s prior written consent. Any such consent, which PRF may grant or withhold in its sole and absolute discretion, shall be subject to the satisfaction of each of the following conditions to the satisfaction
of PRF: 
 (i) the successor Deposit Bank shall be acceptable to PRF; 
  

 -30- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (ii) PRF, the Assignors and the successor Deposit Bank shall have entered into deposit
agreements substantially in the form of the Deposit Agreements initially entered into; 
 (iii) all funds and items in the
accounts subject to the Deposit Agreements to be terminated shall be transferred to the new accounts held at the successor Deposit Bank prior to the termination of the then existing Deposit Bank; and 
 (iv) PRF shall have received evidence that all of the applicable parties making payments in respect of sales of the Products have been
instructed to remit all future payments in respect of sales of the Products to the new accounts held at the successor Deposit Bank. 
 (f)
Interim Applicable Percentage Adjustment. Each of PRF and the Company shall, following June 30 of each year during the Term (commencing June 30, 2007), agree to adjust the Interim Applicable Percentage such that the Interim Payments
more accurately reflect the Final Payments. The adjustment shall be made based on the Interim Payments and Final Payments made in the twelve month period proceeding each June 30th and shall be adjusted to minimize in future quarters the
difference between Interim Payments made in such quarter and the Final Payments in such quarter. Each such adjustment shall become effective September 1 of each year during the Term (Commencing September 1, 2007). 
 (g) True-Up. 
 (i)
Following the end of each Fiscal Quarter, as soon as the Company shall have determined the Net Revenues for such Fiscal Quarter and for each other Fiscal Quarter in the Fiscal Year in which the then most recently ended Fiscal Quarter occurred (the
“Year-to-Date Net Revenues”) and in any event no later than forty-five (45) days after the end of such Fiscal Quarter (unless such Fiscal Quarter is the last Fiscal Quarter of a Fiscal Year in which case no later than ninety
(90) days after the end of such Fiscal Quarter), the Company shall present PRF a certificate, in reasonable detail with supporting calculations and information, detailing the Year-to-Date Net Revenues (the “True-Up Statement”).

 (ii) If PRF has received on or prior to the last day of the most recently ended Fiscal Quarter payments from the Company
under Section 2.02 or this Section 5.08 in respect of the Fiscal Year for which Year-to-Date Net Revenues is calculated under clause (i) above which are in excess of the Applicable Percentage of Year-to-Date Net
Revenues, PRF shall pay such excess to the Company within twenty (20) days of receipt by PRF of the True-Up Statement. 
 (iii) If the Applicable Percentage of Year-to-Date Net Revenues is in excess of the amounts PRF has received on or prior to the last day of the most recently ended Fiscal Quarter in respect of the Fiscal Year for which Year-to-Date Net
Revenues is calculated under clause (i) above under Section 2.02 or this Section 5.08, the Company shall pay such excess to PRF within twenty (20) days of the receipt by PRF of the True-Up Statement. 
 (h) As used herein “applicable Deposit Accounts” shall mean the Deposit Account (Antara) (with respect to Deposit Funds and Net Revenues
in respect of Antara) and the Deposit Account (Factive) (with respect to Deposit Funds and Net Revenues in respect of Factive), as applicable. 
  

 -31- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Section 5.09 Out-License Agreements. 
 Each Assignor shall use its commercially reasonable efforts to duly perform and observe all of its covenants and obligations under each Out-License
Agreement in all material respects. Upon the occurrence of a material breach of any of the Out-License Agreements by any other party thereto, which is not cured as provided therein, each Assignor thereto shall use its commercially reasonable efforts
to seek to enforce its rights and remedies thereunder. 
 Section 5.10 Intellectual Property. 
 (a) Except with respect to the patents set forth on Schedule 5.10, each Assignor shall, at its sole expense, either directly or by causing any
Licensee or licensor to do so, take any and all actions (including taking legal action to specifically enforce the applicable terms of any License Agreement) and prepare, execute, deliver and file any and all agreements, documents or instruments
which are necessary or desirable to (A) diligently maintain the applicable Intellectual Property and the Patents and (B) diligently defend or assert such Intellectual Property and such Patents against infringement or interference by any
other Persons, and against any claims of invalidity or unenforceability, in any jurisdiction (including, without limitation, by bringing any legal action for infringement or defending any counterclaim of invalidity or action of a Third Party for
declaratory judgment of non-infringement or non-interference). Except with respect to the patents set forth on Schedule 5.10, neither Assignor shall, and shall use its commercially reasonable efforts to cause any Licensee or licensor not to,
disclaim or abandon, or fail to take any action necessary or desirable to prevent the disclaimer or abandonment of, the applicable Patents or other Intellectual Property; provided however, this Section shall not apply to abandonment of any Patents
made in the ordinary course of prosecution (e.g., abandonment of a pending application in favor of a continuation application). 
 (b) In the
event that the Assignors become aware that any Product infringes or violates any valid and enforceable intellectual property of a Third Party in the Territory, the Assignors shall promptly use commercially reasonable efforts to attempt to secure the
right to use such intellectual property on behalf of itself and shall pay all costs and amounts associated with obtaining any such right to use, without any reduction in the Assigned Interests. 
 (c) Each Assignor shall directly, or through a Licensee, take any and all actions and prepare, execute, deliver and file any and all agreements,
documents or instruments that are necessary or commercially reasonable or desirable to secure and maintain all Regulatory Approvals. Neither Assignor shall withdraw or abandon, or fail to take any action necessary to prevent the withdrawal or
abandonment of, any Regulatory Approval once obtained. 
 Section 5.11 Negative Covenants. 
 Until the earlier of (i) the end of the Term, (ii) the exercise of the Company of the Full Buy-Down Option and payment in full of the Full Buy
Down Option Price, or (iii) receipt by PRF of cumulative payments under Sections 2.02, 5.07(c) and 5.08 of at least [*] percent ([*]%) of the amounts paid by PRF under Section 2.03, the Company shall not, nor
shall it permit any of its Subsidiaries to, without the prior written consent of PRF: 
 (a) with respect to the Company, borrow money in
order to acquire the right to distribute or sell any pharmaceutical product other than within a Subsidiary of the Company, which Subsidiary maintains a separateness on a basis similar to Guardian under the Note Purchase Agreement; 
  

 -32- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (b) with respect to the Company or any Subsidiary, guarantee in any manner any obligation of any such
Subsidiary referred to in clause (a) above unless all of the Obligations of Guardian are equally and ratably guaranteed by the Company; 
 (c) fail to maintain the separate corporate existence of Guardian or any Subsidiary referred to in clause (a) above, or with respect to the Company, consolidate or merge with Guardian or any Subsidiary referred to in clause
(a) above or permit Guardian or any such Subsidiary to convey, transfer, sell or lease all or substantially all of its assets in a single transaction or series of transactions to the Company or any Third Party; 
 (d) other than in the ordinary course of business, forgive, release or compromise any amount owed to the Company or its Subsidiaries and relating to the
Assigned Interests; 
 (e) other than in the ordinary course of business, waive, amend, cancel or terminate, exercise or fail to exercise,
any of its material rights constituting or relating to the Revenue Interests; 
 (f) amend, modify, restate, cancel, supplement, terminate or
waive any material provision of any Out-License Agreement or In-License Agreement, or grant any consent thereunder, or agree to do any of the foregoing, including, without limitation, entering into any agreement with any Licensee or licensor, as
applicable under the provisions of such Out-License Agreement or In-License Agreement; or 
 (g) create, incur, assume or suffer to exist any
Lien, or exercise any right of rescission, offset, counterclaim or defense, upon or with respect to the Assigned Interests, the Revenue Interests or the other Collateral, or agree to do or suffer to exist any of the foregoing, except for any Lien or
agreements in favor of PRF granted under or pursuant to this Agreement, the other Transaction Documents, or that certain Note Purchase Agreement by and between Guardian and PRF and the transactions contemplated thereby. 
 Section 5.12 Other Agreements. 
 The Company shall not enter into, nor shall it permit any of its Subsidiaries to enter into, any agreement that would be reasonably expected to have a Material Adverse Effect without PRF’s prior written consent, which consent shall not
to be unreasonably withheld, delayed or conditioned. 
 Section 5.13 Genesoft Consent/Cash Balance. 
 (a) The Company shall use commercially reasonable efforts (which shall not require the Company to make any payments or agree to any material
undertakings) to obtain, within one hundred eighty (180) days following the Closing Date, Genesoft Noteholder consent under the Genesoft Note Purchase Agreement (the “Genesoft Consent”) to permit a grant in favor of PRF, of a
valid continuing, perfected lien on and security in all of the Company’s assets securing Guardian’s obligations under the Note Purchase Agreement and this Agreement. In addition, to the extent the indebtedness under the Genesoft Note
Purchase Agreement is refinanced or 

  

 -33- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
replaced and the replacement or refinancing indebtedness is secured, the obligations of the Company hereunder shall be equally and ratably secured unless and
until (i) the Waived Consent referenced in 6.02(n) has been obtained, or (ii) the Company markets Antara that uses a formulation of fenofibrate that is not micronized. 
 (b) Until such time as the Company obtains the Genesoft Consent, at least [*] percent ([*]%) of Consolidated Cash shall be in a deposit account in the
name of Guardian, provided that in no event shall the amount of consolidated cash in a Guardian deposit account be required to exceed the sum of the outstanding principal amount of and the unpaid interest on the Note. 
 Section 5.14 Insurance. 
 The Company shall (i) maintain the current insurance policies with its current insurance company or with companies having at least the same rating from A.M. Best Company, Inc., including product liability insurance and directors and
officers insurance and insurance against litigation, liability, subject only to such exclusions and deductible items as are usual and customary in insurance policies of such type, and (ii) maintain PRF as an additional insured party with
respect to its general liability and product liability insurance policies. From time to time (with reasonable frequency) the Company will revise its insurance policy so as to maintain coverage in amounts customary for companies of comparable size
and condition similarly situated in the same industry as the Company. 
 Section 5.15 Notice. 
 The Company shall provide PRF with written notice as promptly as practicable (and in any event within three (3) Business Days) after becoming aware
of any of the following: 
 (a) the occurrence of a Bankruptcy Event; 
 (b) any material breach or default by an Assignor of any covenant, agreement or other provision of this Agreement or any other Transaction Document;

 (c) any representation or warranty made or deemed made by an Assignor in any of the Transaction Documents or in any certificate delivered
to PRF pursuant hereto shall prove to be untrue, inaccurate or incomplete in any material respect on the date as of which made or deemed made; 
 (d) the occurrence of a Change of Control; 
 (e) the occurrence of a Put Option Event; or 
 (f) any sublicense by a Licensee of any rights licensed pursuant to any Out-License Agreement. 
 Section 5.16 Use of Proceeds. 
 The Assignors shall use all proceeds received from PRF pursuant to Section 2.03 to fund the purchase price of and related transaction expenses in connection with the transactions contemplated by the Antara Purchase Agreement.
The Assignors shall not use any such proceeds for any other purpose. 
  

 -34- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Section 5.17 Antara Products. 
 In the event the Assignors acquire rights to additional products which are included within the definition of “Antara”, such rights shall be
acquired by Guardian unless otherwise agreed by PRF. 
 ARTICLE VI 
 THE CLOSING; CONDITIONS TO CLOSING 
 Section 6.01 Closing.

 Subject to the closing conditions set forth in Sections 6.02 and 6.03, the closing of the assignment of the Assigned
Interests (the “Closing”) shall take place at the offices of Ropes & Gray LLP, Boston, Massachusetts at 10:00 a.m. (Eastern Time) on the second (2nd) Business Day following the satisfaction or waiver of the conditions
precedent specified in this Article VI (other than the conditions to be satisfied on the Closing Date, but subject to the waiver or satisfaction of such conditions), or at such other time and place as the parties hereto may mutually agree.
The date on which the Closing shall occur is referred to herein as the “Closing Date”. 
 Section 6.02 Conditions
Applicable to PRF. 
 The obligation of PRF to effect the Closing shall be subject to the satisfaction of each of the following
conditions, any of which may be waived by PRF in its sole discretion: 
 (a) Accuracy of Representations and Warranties. The
representations and warranties of the Assignors set forth in the Transaction Documents shall be true, correct and complete in all material respects as of the Closing Date. 
 (b) No Adverse Circumstances. There shall not have occurred or be continuing any event or circumstance (including any development with respect to
the efficacy of the Products or the Intellectual Property or the use or expected future use of the same as opposed to competing products) that could reasonably be expected to have a Material Adverse Effect. 
 (c) Litigation. No action, suit, litigation, proceeding or investigation shall have been instituted, be pending or threatened (i) challenging
or seeking to make illegal, to delay or otherwise directly or indirectly to restrain or prohibit the consummation of the transactions contemplated by this Agreement, or seeking to obtain damages in connection with the transactions contemplated by
this Agreement, or (ii) seeking to restrain or prohibit PRF’s acquisition or future receipt of the Assigned Interests. 
 (d)
Consents. All notices to, consents, approvals, authorizations and waivers from Third Parties and Government Authorities that are required for the consummation of the transactions contemplated by this Agreement or any of the Transaction
Documents shall have been obtained or provided for and shall remain in effect. 
  

 -35- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (e) Deposit Agreements. The Deposit Agreements (together with any necessary account control
agreements) shall have been executed and delivered by the Assignors, PRF and the Deposit Bank, and PRF shall have received the same. 
 (f)
Assignments of Interests. The Assignments of Interests shall have been executed and delivered by each Assignor to PRF, and PRF shall have received the same. 
 (g) Security Agreement. The Security Agreement shall have been duly executed and delivered by all the parties thereto, together with proper financing statements (including Form UCC-1s) for filing under the UCC
and/or any other applicable law, rule, statute or regulation relating to the perfection of a security interest in filing offices in the jurisdictions listed on Schedule 6.02(g), and such agreements shall be in full force and effect.

 (h) Legal Opinions. 
 (i) PRF shall have received the opinion of Ropes & Gray LLP, transaction counsel to the Company, to the effect set forth in Exhibit E. 
 (ii) PRF shall have received opinions of Ropes & Gray LLP, intellectual property counsel to the Company, and Hamilton Brook Smith
and Reynolds, intellectual property counsel to the Company, to the effect set forth in Exhibits F-1 and F-2 respectively. 
 (i) Corporate Documents of the Assignors. PRF shall have received on the Closing Date, certificates, dated as of the Closing Date, of an executive officer of each Assignor (the statements made in which shall be true and correct on
and as of the Closing Date): (i) attaching copies, certified by such officer as true and complete, of each Assignor’s certificate of incorporation or other organizational documents (together with any and all amendments thereto) certified
by the appropriate Governmental Authority as being true, correct and complete copies; (ii) attaching copies, certified by such officer as true and complete, of resolutions of the board of directors of each Assignor authorizing and approving the
execution, delivery and performance by such Assignor of the Transaction Documents and the transactions contemplated herein and therein; (iii) setting forth the incumbency of the officer or officers of such Assignor who have executed and
delivered the Transaction Documents including therein a signature specimen of each such officer or officers; and (iv) attaching copies, certified by such officer as true and complete, of a certificate of the appropriate Governmental Authority
of each Assignor’s jurisdiction of incorporation, stating that such Assignor is in good standing under the laws of its incorporation. 
 (j) Covenants. Each Assignor shall have complied in all material respects with its covenants set forth in the Transaction Documents. 
 (k) Closing of Equity Financing. The Company shall have consummated the transactions contemplated by that certain Common Stock and Warrant Purchase Agreement dated the date hereof by and between PRF and the
Company (the “Stock Purchase Agreement”), attached hereto as Exhibit G (the “Equity Condition”). 
  

 -36- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (l) Closing of Debt Financing. Guardian shall have consummated the transactions contemplated by
that certain Note Purchase Agreement dated the date hereof by and between Guardian and PRF (the “Note Purchase Agreement”), attached hereto as Exhibit H (the “Debt Condition”). 
 (m) Issuance of Warrant. The Company shall have issued that certain Warrant to Purchase Common Stock of the Company, in the form attached hereto
as Exhibit I. 
 (n) Closing of Acquisition. The transactions contemplated by the Antara Purchase Agreement shall have been
consummated or shall be consummated substantially simultaneously with the Closing; provided that PRF acknowledges that the parties to the Antara Purchase Agreement have waived receipt of one of the Required Consents (as defined in the Antara
Purchase Agreement) (the “Waived Consent”). 
 Section 6.03 Conditions Applicable to the Assignors.

 The obligation of the Assignors to effect the Closing shall be subject to the satisfaction of each of the following conditions, any of
which may be waived by the Assignors in their sole discretion: 
 (a) Accuracy of Representations and Warranties. The representations
and warranties of PRF set forth in this Agreement shall be true, correct and complete in all material respects as of the Closing Date. 
 (b)
Litigation. No action, suit, litigation, proceeding or investigation shall have been instituted, be pending or threatened (i) challenging or seeking to make illegal, to delay or otherwise directly or indirectly to restrain or prohibit
the consummation of the transactions contemplated by this Agreement, or seeking to obtain damages in connection with the transactions contemplated by this Agreement, or (ii) seeking to restrain or prohibit PRF’s acquisition or future
receipt of the Assigned Interests. 
 (c) Closing Certificate. The Company shall have received at the Closing a certificate of an
authorized representative of PRF certifying that the conditions set forth in Sections 6.03(a) and (b) have been satisfied in all material respects as of the Closing Date. 
 (d) Other Financing. The Equity Condition and the Debt Condition shall have been satisfied. 
 (e) Closing of Acquisition. The transactions contemplated by the Antara Purchase Agreement shall have been consummated or shall be consummated
substantially simultaneously with the Closing. 
  

 -37- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 ARTICLE VII 
 TERMINATION 
 Section 7.01 Termination Date. 
 Except as otherwise provided in this Section 7.01 and in Sections 7.02 and 8.01, this Agreement shall terminate upon expiration
of the Revenue Interest Period. If any payments are required to be made by one of the parties hereunder after that date, this Agreement shall remain in full force and effect until any and all such payments have been made in full, and (except as
provided in Section 7.02) solely for that purpose. In addition, this Agreement shall sooner terminate if the Company shall have exercised the Call Option or the Full Buy-Down Option or if PRF shall have exercised the Put Option, in each
case pursuant to Section 5.07, with the termination date in that event being the date on which the Company completes the repurchase of the Assigned Interests with payment in full to PRF. 
 Section 7.02 Effect of Termination. 
 In the event of the termination of this Agreement pursuant to Section 7.01, this Agreement shall forthwith become void and have no effect without any liability on the part of any party hereto or its Affiliates, directors,
officers, stockholders, partners, managers or members other than the provisions of this Section 7.02 and Sections 5.04, 5.05, 8.01, and 8.05 hereof, which shall survive any termination as set forth in
Section 8.01. Nothing contained in this Section 7.02 shall relieve any party from liability for any breach of this Agreement. 
 ARTICLE VIII 
 MISCELLANEOUS 
 Section 8.01 Survival. 
 (a)
All representations and warranties made herein and in any other Transaction Document, any certificates or in any other writing delivered pursuant hereto or in connection herewith shall survive the execution and delivery of this Agreement and the
Closing and shall continue to survive until the termination of this Agreement in accordance with Article VII. Notwithstanding anything in this Agreement or implied by law to the contrary, all the agreements contained in Sections 5.04,
5.05, 8.01, shall survive indefinitely following the execution and delivery of this Agreement and the Closing and the termination of this Agreement. 
 (b) Any investigation or other examination that may have been made or may be made at any time by or on behalf of the party to whom representations and warranties are made shall not limit, diminish or in any way affect
the representations and warranties in the Transaction Documents, and the parties may rely on the representations and warranties in the Transaction Documents irrespective of any information obtained by them by any investigation, examination or
otherwise. 
  

 -38- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Section 8.02 Specific Performance. 
 Each of the parties hereto acknowledges that the other party will have no adequate remedy at law if it fails to perform any of its obligations under any
of the Transaction Documents. In such event, each of the parties agrees that the other party shall have the right, in addition to any other rights it may have (whether at law or in equity), to specific performance of this Agreement. 
 Section 8.03 Notices. 
 All
notices, consents, waivers and communications hereunder given by any party to the other shall be in writing (including facsimile transmission) and delivered personally, by telegraph, telecopy, telex or facsimile, by a recognized overnight courier,
or by dispatching the same by certified or registered mail, return receipt requested, with postage prepaid, in each case addressed: 
 If to
PRF to: 
 Paul Royalty Fund Holdings II 
 c/o Paul Capital Partners 
 140 East 45th Street, 44th Floor 
 New York, NY 10017 
 Attention: Gregory B.
Brown, MD 
 Facsimile No.: (646) 264-1101 
 with a copy to: 
 McDermott Will & Emery LLP 
 227 West Monroe Street 
 Chicago, IL
60606-5096 
 Attention: Timothy R.M. Bryant 
 Facsimile No.: (312) 984-7700 
 If to the Company or any of its Subsidiaries to: 
 Oscient Pharmaceuticals Corporation 
 1000
Winter Street, Suite 2200 
 Waltham, MA 02451 
 Attention: Legal Department 
 Facsimile No.: 781-398-2530 
 with a copy to: 
 Ropes & Gray LLP

 One International Place 
 Boston, MA 02110 
 Attention: Patrick O’Brien 
 Facsimile No.: (617) 951-7050 
  

 -39- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 or to such other address or addresses as PRF or the Company or its Subsidiaries may from time to time designate by notice
as provided herein, except that notices of changes of address shall be effective only upon receipt. All such notices, consents, waivers and communications shall: (a) when posted by certified or registered mail, postage prepaid, return receipt
requested, be effective three (3) Business Days after dispatch, unless such communication is sent trans-Atlantic, in which case they shall be deemed effective three (3) Business Days after dispatch, (b) when telegraphed, telecopied,
telexed or facsimiled, be effective upon receipt by the transmitting party of confirmation of complete transmission, or (c) when delivered by a recognized overnight courier or in person, be effective upon receipt when hand delivered.

 Section 8.04 Successors and Assigns. 
 The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. Neither Company nor Guardian shall be entitled to assign any of its
obligations and rights under the Transaction Documents without the prior written consent of PRF. Upon advanced written notice to the Company, PRF may assign without consent of the Company or Guardian any of its obligations and rights under the
Transaction Documents without restriction; provided, however, that PRF, notwithstanding such assignment, will remain liable under Sections 5.08(g) (to the extent of any amounts subject thereto during the Fiscal Quarter as of the
date of such assignment) and 8.05 hereunder. 
 Section 8.05 Indemnification. 
 (a) The Assignors hereby indemnify and hold PRF and its Affiliates and any of their respective partners, directors, managers, members, officers,
employees and agents (each a “PRF Indemnified Party”) harmless from and against any and all Losses (including all Losses in connection with any product liability claims or claims of infringement or misappropriation of any
intellectual property rights of any Third Parties) incurred or suffered by any PRF Indemnified Party arising out of (i) any breach of any representation, warranty or certification made by the Assignors in any of the Transaction Documents or
certificates given by either Assignor in writing pursuant hereto or thereto or any breach of or default under any covenant or agreement by either Assignor pursuant to any Transaction Document, including any failure by any Assignor to satisfy any of
the Excluded Liabilities and Obligations; or (ii) any claim or action instituted by the Potential Plaintiffs thereof against a PRF Indemnified Party which is related to Antara. 
 (b) PRF hereby indemnifies and holds the Company, its Affiliates and any of their respective partners, directors, managers, officers, employees and
agents (each an “Oscient Indemnified Party”) harmless from and against any and all Losses incurred or suffered by an Oscient Indemnified Party arising out of any breach of any representation, warranty or certification made by PRF in
any of the Transaction Documents or certificates given by PRF in writing pursuant hereto or thereto or any breach of or default under any covenant or agreement by PRF pursuant to any Transaction Document. 
 (c) If any claim, demand, action or proceeding (including any investigation by any Governmental Authority) shall be brought or alleged against an
indemnified party in respect of which indemnity is to be sought against an indemnifying party pursuant to the preceding paragraphs, the indemnified party shall, promptly after receipt of notice of the commencement of 

  

 -40- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
any such claim, demand, action or proceeding, notify the indemnifying party in writing of the commencement of such claim, demand, action or proceeding,
enclosing a copy of all papers served, if any; provided, that the omission to so notify such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under the foregoing
provisions of this Section 8.05 unless, and only to the extent that, such omission results in the forfeiture of, or has an adverse effect on the exercise or prosecution of, substantive rights or defenses by the indemnifying party. In
case any such action is brought against an indemnified party and it notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may wish, jointly with any
other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who may be counsel to the indemnifying party unless such counsel determines it would be inappropriate due to
conflict of interest), and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this Section 8.05
for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation. In any such proceeding, an indemnified party shall have the right to retain its own
counsel, but the reasonable fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel,
(ii) the indemnifying party has assumed the defense of such proceeding and has failed within a reasonable time to retain counsel reasonably satisfactory to such indemnified party or (iii) the named parties to any such proceeding (including
any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between them based on the advice of
such counsel. It is agreed that the indemnifying party shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate law firm (in addition to
local counsel where necessary) for all such indemnified parties. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment
for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified
party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an
unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. 
 Section
8.06 Independent Nature of Relationship. 
 (a) The relationship between the Company and its Subsidiaries, on the one hand, and
PRF, on the other hand, is solely that of seller and purchaser, and neither PRF, on the one hand, nor the Company or its Subsidiaries, on the other hand, has any fiduciary or other special relationship with the other or any of their respective
Affiliates. Nothing contained herein or in any other Transaction Document shall be deemed to constitute the Company and its Subsidiaries and PRF as a partnership, an association, a joint venture or other kind of entity or legal form. 
  

 -41- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (b) No officer or employee of PRF will be located at the premises of the Company or any of its
Affiliates, except in connection with an audit performed pursuant to Section 5.02. No officer, manager or employee of PRF shall engage in any commercial activity with the Company or any of its Affiliates other than as contemplated herein
and in the other Transaction Documents. 
 (c) The Company and/or any of its Affiliates shall not at any time obligate PRF, or impose on PRF
any obligation, in any manner or respect to any Person not a party hereto. 
 Section 8.07 Federal Tax. 
 Notwithstanding the accounting treatment thereof, for United States federal, state and local tax purposes, the Assignors and PRF shall treat the
transactions contemplated by the Transaction Documents as debt for United States tax purposes. The parties hereto agree not to take any position that is inconsistent with the provisions of this Section 8.07 on any tax return or in any
audit or other administrative or judicial proceeding unless (i) the other party to this Agreement has consented to such actions, which consent shall not be unreasonably withheld, or (ii) the party that contemplates taking such an
inconsistent position has been advised by counsel in writing that it is more likely than not (x) that there is no “reasonable basis” (within the meaning of Treasury Regulation Section 1.6662-3(b)(3)) for the position specified in
this Section 8.07 or (y) that taking such a position would otherwise subject the party to penalties under the Internal Revenue Code of 1986, as amended. 
 Section 8.08 Entire Agreement. 
 This Agreement, together with the Exhibits and Schedules
hereto (which are incorporated herein by reference), and the other Transaction Documents constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements (including the Term Sheet for
Purchase of Revenue Interest, Debt and Equity from Oscient Pharmaceuticals Corporation dated June 29, 2006 between Paul Capital Advisors, LLC and the Company), understandings and negotiations, both written and oral, between the parties with
respect to the subject matter of this Agreement; provided, however, the terms of that certain Confidential Disclosure Agreement by and between the Company and Paul Capital Advisors, LLC dated as of June 8, 2006 shall continue in
effect. No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits, Schedules or other Transaction Documents) has been made or relied upon by either party hereto. None of this Agreement, nor
any provision hereof, is intended to confer upon any Person other than the parties hereto any rights or remedies hereunder. 
 Section 8.09 Amendments; No Waivers. 
 (a) This Agreement or any term or provision hereof may not be amended,
changed or modified except with the written consent of the parties hereto. No waiver of any right hereunder shall be effective unless such waiver is signed in writing by the party against whom such waiver is sought to be enforced. 
 (b) No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or
partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.

  

 -42- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Section 8.10 Interpretation. 
 When a reference is made in this Agreement to Articles, Sections, Schedules or Exhibits, such reference shall be to an Article, Section, Schedule or
Exhibit to this Agreement unless otherwise indicated. The words “include”, “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation”. Neither
party hereto shall be or be deemed to be the drafter of this Agreement for the purposes of construing this Agreement against one party or the other. 
 Section 8.11 Headings and Captions. 
 The headings and captions in this Agreement
are for convenience and reference purposes only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement. 
 Section 8.12 Counterparts; Effectiveness. 
 This Agreement may be executed in two or more
counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other
parties hereto. Any counterpart may be executed by facsimile or pdf signature and such facsimile or pdf signature shall be deemed an original. 
 Section 8.13 Severability. 
 If any provision of this Agreement is held to be invalid or unenforceable, the
remaining provisions shall nevertheless be given full force and effect. 
 Section 8.14 Expenses. 
 Each party hereto will pay all of its own fees and expenses in connection with entering into and consummating the transactions contemplated by this
Agreement; provided, that the Company agrees to reimburse PRF for fifty percent (50%) of PRF’s actual, reasonable and documented out-of-pocket expenses to cover due diligence and other, including legal, expenses associated with the
transactions contemplated hereby; and provided, further, that the Company agrees to reimburse and indemnify PRF for any expenses (including reasonable fees and expenses of legal counsel) incurred by PRF in connection with asserting or
enforcing of PRF’s rights hereunder, including, without limitation, in connection with any insolvency, bankruptcy or similar proceeding involving the Company. 
 Section 8.15 Governing Law; Jurisdiction. 
 (a) This Agreement shall be governed by, and
construed, interpreted and enforced in accordance with, the laws of the state of New York, without giving effect to the principles of conflicts of law thereof. 
  

 -43- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (b) Any legal action or proceeding with respect to this Agreement or any other Transaction Document may
be brought in any state or federal court of competent jurisdiction in the state, county and city of New York. By execution and delivery of this Agreement, each party hereto hereby irrevocably consents to and accepts, for itself and in respect of its
property, generally and unconditionally the non-exclusive jurisdiction of such courts. Each party hereto hereby further irrevocably waives any objection, including any objection to the laying of venue or based on the grounds of forum non
conveniens, which it may now or hereafter have to the bringing of any action or proceeding in such jurisdiction in respect of any Transaction Document. 
 (c) Each party hereto hereby irrevocably consents to the service of process out of any of the courts referred to in subsection (b) above of this Section 8.15 in any such suit, action or proceeding by
the mailing of copies thereof by registered or certified mail, postage prepaid, to it at its address set forth in this Agreement. Each party hereto hereby irrevocably waives any objection to such service of process and further irrevocably waives and
agrees not to plead or claim in any suit, action or proceeding commenced hereunder or under any other Transaction Document that service of process was in any way invalid or ineffective. Nothing herein shall affect the right of a party to serve
process on the other party in any other manner permitted by law. 
 Section 8.16 Waiver of Jury Trial. 
 Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any action, proceeding, claim or
counterclaim arising out of or relating to any Transaction Document or the transactions contemplated under any Transaction Document. This waiver shall apply to any subsequent amendments, renewals, supplements or modifications to any Transaction
Document. 
 Section 8.17 Restatement 
 This restated Revenue Interests Assignment Agreement amends, restates in its entirety and replaces, without novation, the Revenue Interests Assignment Agreement, dated July 21, 2006; provided, however, that the
execution and delivery of this restated Revenue Interests Assignment Agreement shall not (a) operate as a waiver of any right, power or remedy of PRF or the Assignors under the Revenue Interests Assignment Agreement, dated as of July 21,
2006 or (b) extinguish or impair any obligations of the Assignors or PRF under the Revenue Interests Assignment Agreement, dated as of July 21, 2006. Notwithstanding the foregoing, for all purposes of the Transaction Documents and the Note
Purchase Agreement Schedule 3.12 attached hereto shall be deemed to be Schedule 3.12 attached to the Revenue Interest Assignment Agreement dated as of July 21, 2006. 
 [SIGNATURE PAGE FOLLOWS] 
  

 -44- 
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 IN WITNESS WHEREOF, the parties hereto have caused this Amended and Restated Revenue Interests
Assignment Agreement to be duly executed by their respective authorized officers as of the date first above written. 
  

			
	OSCIENT PHARMACEUTICALS CORPORATION
		
	By:	 	/s/ Dominick C. Colangelo
	Name:	 	Dominick C. Colangelo
	Title:	 	Executive Vice President
	
	GUARDIAN II ACQUISITION CORPORATION
		
	By:	 	/s/ Dominick C. Colangelo
	Name:	 	Dominick C. Colangelo
	Title:	 	Vice President
	
	PAUL ROYALTY FUND HOLDINGS II
		
	By:	 	Paul Royalty Fund II, LP, its Managing Partner
		
	By:	 	Paul Capital Royalty Management, LLC, its General Partner
		
	By:	 	Paul Capital Advisors, LLC, its Manager
		
	By:	 	/s/ Gregory B. Brown
	Name:	 	Gregory B. Brown, MD
	Title:	 	Member

  

 -45-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]